1 |
Acyldepsipeptide 4 (ADEP4)
|
Acyldepsipeptide |
2013 |
Preclinical |
2 |
FY-901
|
Aminoglycoside |
2012 |
Preclinical |
4 |
Plazomicin (Zemdri)
|
Aminoglycoside |
2012 |
Approved |
6 |
AVP-21D9 (Thravixa)
|
Antibody |
2011 |
Phase 1 (NCT01202695) |
7 |
MEDI3902
|
Antibody |
2014 |
Phase 2 (NCT04631016) |
8 |
Suvratoxumab, MEDI4893, LC-10
|
Antibody |
2012 |
Phase 3 (NCT05331885) |
9 |
OH-CATH30
|
Antimicrobial peptide |
2012 |
Preclinical |
10 |
AA-139 (Arenicin)
|
Antimicrobial peptide |
2013 |
Preclinical |
11 |
Anuran Trypsin Inhibitory Peptide SLF1
|
Experimental |
2015 |
Preclinical |
12 |
Anuran Trypsin Inhibitory Peptide SLF2
|
Antimicrobial peptide |
2015 |
Preclinical |
13 |
Anuran Trypsin Inhibitory Peptide SLF3
|
Antimicrobial peptide |
2015 |
Preclinical |
14 |
Anuran Trypsin Inhibitory Peptide SLF4
|
Antimicrobial peptide |
2015 |
Preclinical |
15 |
Anuran Trypsin Inhibitory Peptide SLF5
|
Antimicrobial peptide |
2015 |
Preclinical |
16 |
Bacteriocin LU11
|
Antimicrobial peptide |
2014 |
Preclinical |
17 |
BR003-cecropin A
|
Antimicrobial peptide |
2012 |
Preclinical |
18 |
Clavanin A
|
Antimicrobial peptide |
2003 |
Preclinical |
19 |
Dipeptidomimetic Compound 1a
|
Antimicrobial peptide |
2003 |
Preclinical |
20 |
Dipeptidomimetic Compound 1b
|
Antimicrobial peptide |
2014 |
Preclinical |
21 |
Dipeptidomimetic Compound 1c
|
Antimicrobial peptide |
2014 |
Preclinical |
22 |
Dipeptidomimetic Compound 1d
|
Antimicrobial peptide |
2014 |
Preclinical |
23 |
Dipeptidomimetic Compound 1e
|
Antimicrobial peptide |
2014 |
Preclinical |
24 |
Dipeptidomimetic Compound 1f
|
Antimicrobial peptide |
2014 |
Preclinical |
25 |
Dipeptidomimetic Compound 2a
|
Antimicrobial peptide |
2014 |
Preclinical |
26 |
Dipeptidomimetic Compound 2b
|
Antimicrobial peptide |
2014 |
Preclinical |
27 |
Dipeptidomimetic Compound 2c
|
Antimicrobial peptide |
2014 |
Preclinical |
28 |
Dipeptidomimetic Compound 2d
|
Antimicrobial peptide |
2014 |
Preclinical |
29 |
Dipeptidomimetic Compound 2e
|
Antimicrobial peptide |
2014 |
Preclinical |
30 |
Dipeptidomimetic Compound 2f
|
Antimicrobial peptide |
2014 |
Preclinical |
31 |
DP7
|
Antimicrobial peptide |
2014 |
Preclinical |
32 |
eCATH1
|
Antimicrobial peptide |
2012 |
Preclinical |
33 |
Epinecidin-1
|
Antimicrobial peptide |
2006 |
Preclinical |
34 |
G3KL
|
Antimicrobial peptide |
2014 |
Preclinical |
35 |
hBD-1
|
Antimicrobial peptide |
1999 |
Preclinical |
36 |
hBD-2
|
Antimicrobial peptide |
1999 |
Preclinical |
37 |
Lycosin 1
|
Antimicrobial peptide |
2012 |
Preclinical |
38 |
Myxinidin
|
Antimicrobial peptide |
2009 |
Preclinical |
39 |
NAI-603
|
Glycolipodepsipeptide |
2014 |
Preclinical |
40 |
Pumicin NI04
|
Antimicrobial peptide |
2015 |
Preclinical |
41 |
Pardaxin (GE33)
|
Antimicrobial peptide |
2013 |
Preclinical |
42 |
Peptide 1018
|
Antimicrobial peptide |
2012 |
Preclinical |
43 |
Kocurin
|
Antimicrobial peptide |
2013 |
Preclinical |
44 |
Protonectin
|
Antimicrobial peptide |
1993 |
Preclinical |
45 |
PXL150
|
Antimicrobial peptide |
2013 |
Preclinical |
46 |
RRIKA
|
Antimicrobial peptide |
2014 |
Preclinical |
47 |
RR
|
Antimicrobial peptide |
2014 |
Preclinical |
48 |
SASPject3.1
|
Antimicrobial peptide |
2014 |
Preclinical |
49 |
SASPject4
|
Antimicrobial peptide |
2014 |
Preclinical |
50 |
Temporin A
|
Antimicrobial peptide |
2000 |
Preclinical |
51 |
Temporin B
|
Antimicrobial peptide |
2000 |
Preclinical |
52 |
TP10 (transportan-10)
|
Antimicrobial peptide |
2003 |
Preclinical |
53 |
Tripropeptin C
|
Antimicrobial peptide (tripropeptin lipodepsipeptide) |
2001 |
Preclinical |
54 |
Xenohagxin
|
Antimicrobial peptide |
2014 |
Preclinical |
55 |
LTX-109
|
Antimicrobial peptidomimetic |
2008 |
Phase 2 |
56 |
Pexiganan
|
Antimicrobial peptide |
1998 |
Phase 3 |
57 |
WR12
|
Antimicrobial peptide |
2015 |
Preclinical |
58 |
WLBU2
|
Antimicrobial peptide |
2006 |
Preclinical |
59 |
Subtilosin
|
Antimicrobial peptide |
1985 |
Preclinical |
60 |
AS10
|
Antimicrobial peptide |
2014 |
Preclinical |
61 |
Dermaseptin S4 derivative: K4-K20-S4
|
Antimicrobial peptide |
2001 |
Preclinical |
62 |
R-thanatin
|
Antimicrobial peptide |
2013 |
Preclinical |
63 |
GL13K
|
Antimicrobial peptide |
2011 |
Preclinical |
64 |
AP138 (Plectasin)
|
Antimicrobial peptide |
2004 |
Preclinical |
65 |
NAI-107, microbisporicin
|
Antimicrobial peptide (lantibiotic) |
2009 |
Preclinical |
66 |
P10/P60.4Ac
|
Antimicrobial peptide (LL-37 derivative) |
2014 |
Preclinical |
67 |
Streptomyces papain inhibitor [SPI]
|
Antimicrobial peptide (papain inhibitory protein) |
2011 |
Preclinical |
68 |
SASPject1.2
|
Bacteriophage |
2014 |
Phase 1 |
69 |
ClyH
|
Bacteriophage lysin |
2014 |
Preclinical |
70 |
HY-133
|
Bacteriophage lysin |
2011 |
Preclinical |
71 |
PRF-119
|
Bacteriophage lysin |
2011 |
Preclinical |
72 |
Ply187AN-KSH3b
|
Bacteriophage lysin |
2014 |
Preclinical |
73 |
PlyF307
|
Bacteriophage lysin |
2015 |
Preclinical |
74 |
PlyPy
|
Bacteriophage lysin |
2014 |
Preclinical |
75 |
PlySK1249
|
Bacteriophage lysin |
2013 |
Preclinical |
76 |
PlySs2
|
Bacteriophage lysin |
2013 |
Preclinical |
77 |
SAL200
|
Bacteriophage lysin |
2013 |
Phase 2 (NCT05329168) |
78 |
Art-175
|
Bacteriophage lysin (artilysins) |
2014 |
Preclinical |
79 |
Cefepime + enmetazobactam (Exblifep)
|
Beta-lactam (cephalosporin, fourth generation) + beta-lactamase inhibitor (penicillanic acid sulfone) |
2015 |
Approved by FDA in 2024 |
80 |
MG96077
|
Beta-lactamase inhibitor |
2009 |
Preclinical |
83 |
EDP-788
|
Macrolide (bicyclic macrolide) |
2013 |
Phase 1 (NCT02255968) |
84 |
FSI-1671
|
Beta-lactam (carbapenem) |
2014 |
Preclinical |
85 |
FSI-1686
|
Beta-lactam (carbapenem) |
2014 |
Preclinical |
86 |
Imipenem + cilastatin/relebactam
|
Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2011 |
Approved by FDA in 2019 |
87 |
OSU-03012 (AR-12)
|
Celecoxib-derived antibacterial inhibitor |
2009 |
Preclinical |
88 |
CB-027
|
Beta-lactam (cephalosporin) |
2013 |
Preclinical |
89 |
S201
|
Beta-lactam (cephalosporin) |
2014 |
Preclinical |
90 |
Cefiderocol (Fetroja)
|
Beta-lactam (cephalosporin) |
2013 |
Approved by FDA in 2019 |
91 |
Ceftobiprole (active moiety of ceftobiprole medocaril)
|
Beta-lactam (cephalosporin) |
2002 |
Approved by FDA in 2024 |
92 |
Avycaz/Zavicefta (Ceftazidime/Avibactam)
|
Drug combination: beta-lactam (cephalosporin) + beta-lactamase inhibitor |
2005 |
Approved by FDA in 2015 |
93 |
Ceftolozane + tazobactam (Zerbaxa)
|
Drug combination: beta-lactam (cephalosporin, fourth generation) + beta-lactamase inhibitor (penicillanic acid sulfone) |
2012 |
Approved by FDA in 2014 |
94 |
1-O-methyl-NBD-ceramide-C16
|
Antichlamydial ceramide |
2014 |
Preclinical |
95 |
DAV131
|
Activated charcoal, absorbant |
2013 |
|
96 |
Brilacidin
|
Antimicrobial peptide (defensin mimetic) |
2012/13 |
Phase 2 (NCT02052388) |
98 |
ABEPI 1
|
Efflux pump inhibitor |
2014 |
Preclinical |
99 |
ABEPI 2
|
Efflux pump inhibitor |
2014 |
Preclinical |
100 |
Zempia (E-101)
|
Antiseptic |
2008 |
Phase 3 (NCT01297959) |
101 |
Lysostaphin
|
Zinc metalloprotease (glycyl-glycine endopeptidase) |
1964 |
|
103 |
Benzimidazole-Based FABI inhibitor 1
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
104 |
Benzimidazole-Based FABI inhibitor 2
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
105 |
Benzimidazole-Based FABI inhibitor 3
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
106 |
Benzimidazole-Based FABI inhibitor 4
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
107 |
Benzimidazole-Based FABI inhibitor 5
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
108 |
Benzimidazole-Based FABI inhibitor 6
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
109 |
Benzimidazole-Based FABI inhibitor 7
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
110 |
Benzimidazole-Based FABI inhibitor 8
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
111 |
Benzimidazole-Based FABI inhibitor 9
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
112 |
Benzimidazole-Based FABI inhibitor 10
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
113 |
PT52 (Diphenyl ether)
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2013 |
|
114 |
PT68 (Diphenyl ether)
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2013 |
|
115 |
VT-02-00068
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
|
116 |
FAB001
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2009 |
Phase 1 |
117 |
Nilofabicin
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2006 |
Phase 2 (NCT01593761) |
118 |
Afabicin dephosphono
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2014 |
Phase 2 (NCT03723551) |
119 |
cis-6-hexadecenoic acid (C6H)
|
Human skin fatty acid |
2014 |
|
122 |
Delafloxacin
|
Fluoroquinolone |
2009 (phase 2 trials) |
Approved by FDA in 2017 |
123 |
WCK771
|
Fluoroquinolone |
2001 |
Phase 3 (NCT03405064) |
124 |
Alalevonadifloxacin
|
Fluoroquinolone |
2001 |
Phase 1 (NCT04874324) |
125 |
Zabofloxacin
|
Fluoroquinolone |
2003 |
Phase 3 (NCT01658020) |
126 |
MBX-500
|
Fluoroquinolone |
2012 |
Preclinical |
127 |
Oxantel
|
Fumarate reductase inhibitor |
1975 |
Preclinical |
128 |
Fusidic acid
|
Fusidane |
2010 |
Phase 3 |
129 |
Vcn-PF (Vancomycin derivative)
|
Glycopeptide |
unknown |
Preclinical |
130 |
Vcn-A (Vancomycin derivative)
|
Glycopeptide |
unknown |
Preclinical |
131 |
Vcn-B (Vancomycin derivative)
|
Glycopeptide |
unknown |
Preclinical |
132 |
Oritavancin (Orbactiv)
|
Glycopeptide |
1996 |
Approved by FDA in 2014 |
133 |
TD-1607
|
Glycopeptide-cephalosporin heterodimer |
2010 |
Phase 1 (NCT01949103) |
134 |
Ramoplanin
|
Glycolipodepsipeptide |
2003 |
Phase 2 |
135 |
Dalbavancin (Dalvance)
|
Glycolipodepsipeptide |
2001 |
Approved by FDA in 2014 |
136 |
GP-2
|
Bacterial topoisomerase inhibitor |
2013 |
Preclinical |
137 |
GP-4
|
Bacterial topoisomerase inhibitor |
2014 |
Preclinical |
138 |
2,3-Dihydroxybenzoic Acid (DHBA)
|
Antibiofilm agent (iron chelator) |
1986 |
Preclinical |
139 |
ACH-702
|
Isothiazoloquinolone |
2008 |
Preclinical |
140 |
Nafithromycin
|
Macrolide (16-membered macrolide, ketolide) |
2013 |
Phase 2 |
141 |
Liamocin Oil dervatives
|
Liamocin oil |
2014 |
Preclinical |
142 |
Surotomycin, CB-183,315
|
Lipopeptide |
2011 |
Phase 3 |
143 |
ACHN-975
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
2012 |
Phase 1 |
144 |
Murepavadin
|
Lipopolysaccharide synthesis inhibitor (LptD inhibitor) |
2008 |
Phase 3 (NCT03582007) |
145 |
RBx 14255
|
Macrolide (16-membered macrolide, fluoroketolide) |
2012 |
Preclinical |
146 |
Solithromycin
|
Macrolide (16-membered macrolide, fluoroketolide) |
2008 |
Phase 3 |
147 |
MB-1
|
Beta-lactam (siderophore-monobactam conjugate) |
2015 |
Preclinical |
148 |
Meropenem + Vaborbactam
|
Beta-lactam (carbapenem) + beta-lactamase inhibitor (heterocyclic boron) |
2013 |
Approved by FDA in 2017 |
149 |
CRS3123
|
Aminoacyl-tRNA synthetase inhibitor (methionyl tRNA synthetase [MetRS] inhibitor) |
2007 |
Phase 2 (NCT04781387) |
150 |
Aztreonam + Avibactam
|
Beta-lactam (monobactam) + beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2012 |
Phase 3 (NCT03329092) |
151 |
BAL30072
|
Beta-lactam (siderophore-sulfactam) |
2008 |
Phase 1 |
152 |
AiiA AuNPs (gold nano particles)
|
Nanoparticles (gold) in combination with lactonase |
|
Preclinical |
153 |
CAL02
|
Nanoparticles (liposomes) |
2013 |
Phase 2 (NCT05776004) |
154 |
AgNP (silver nanoparticles)
|
Nanoparticles (silver) citrate capped |
|
Preclinical |
155 |
Amixicile
|
Antibiofilm agent (nitazoxanide derivative) |
2012 |
Preclinical |
156 |
Glyceryl Trinitrate (GTN)/Citrate/Ethanol (CAP) (GTN-CAP)
|
Antibiofilm agent |
2013 |
Preclinical |
157 |
Ozenoxacin
|
Quinolone |
2007 |
Approved by FDA in 2017 |
158 |
Nemonoxacin
|
Quinolone |
2007 |
|
159 |
SQ641
|
MraY inhibitor |
1986 |
Preclinical |
160 |
Colostrum Hexasaccharide
|
Quorum-sensing inhibitor |
1976 (for compound) 2015 (for research) |
Preclinical |
161 |
IMT504
|
Immunomodulator |
2005 |
Preclinical |
162 |
Surgihoney™ (SH)
|
Bioengineered honey |
2015 |
Preclinical |
163 |
MRX-II
|
Oxazolidinone |
2015 |
Preclinical |
164 |
Delpazolid (LCB01-0371)
|
Oxazolidinone |
2010 |
Phase 2 (NCT05225558; NCT06004037) |
165 |
Contezolid (MRX-4/MRX-1)
|
Oxazolidinone |
2014 |
Phase 3 (NCT06081361) |
167 |
Tedizolid (Sivextro)
|
Oxazolidinone |
2007 |
Approved by FDA in 2014 |
168 |
F2Pal
|
Immunomodulator (pepducin class) |
2010 |
Preclinical |
169 |
PLNA787
|
Peptide-locked nucleic acid |
2015 |
Preclinical |
170 |
Ceragenins (CSA-131)
|
Peptidomimetic |
2015 |
Preclinical |
171 |
MBX 1641
|
Antivirulence agent (T3SS inhibitor) |
2014 |
Preclinical |
172 |
BC-7641
|
Pleuromutilin |
2010 |
Preclinical |
173 |
BC-9074
|
Pleuromutilin |
2010 |
Preclinical |
174 |
BC-9077
|
Pleuromutilin |
2010 |
Preclinical |
175 |
BC-9505
|
Pleuromutilin |
2010 |
Preclinical |
176 |
BC-9514
|
Pleuromutilin |
2010 |
Preclinical |
177 |
BC-9520
|
Pleuromutilin |
2010 |
Preclinical |
178 |
BC-9529
|
Pleuromutilin |
2010 |
Preclinical |
179 |
BC-9538
|
Pleuromutilin |
2010 |
Preclinical |
180 |
BC-9539
|
Pleuromutilin |
2010 |
Preclinical |
181 |
BC-9540
|
Pleuromutilin |
2010 |
Preclinical |
182 |
BC-9543
|
Pleuromutilin |
2010 |
Preclinical |
183 |
BC-9545
|
Pleuromutilin |
2010 |
Preclinical |
184 |
BC-9556
|
Pleuromutilin |
2010 |
Preclinical |
185 |
BC-9561
|
Pleuromutilin |
2010 |
Preclinical |
186 |
Lefamulin
|
Pleuromutilin |
2010 |
Approved by FDA in 2019 |
187 |
Lefamulin (BC-3781)
|
Pleuromutilin |
2011 |
Approved by FDA in 2019 |
188 |
ω-Hydroxyemodin
|
Quorum-sensing inhibitor |
2015 |
Preclinical |
189 |
Dextrin-colistin polymer conjugate
|
Polymyxin-polymer conjugate |
2014 |
Preclinical |
190 |
NAB739
|
Polymyxin-polymer conjugate |
2008 |
Preclinical |
191 |
G2cps
|
Inhibitor of biofilm formation |
2013 |
Preclinical |
192 |
MBX 2319, MBX2319, MBX-2319
|
Efflux pump inhibitor |
2013 |
Preclinical |
193 |
LolCDE Inhibitor 10
|
LolCDE ABC transporter inhibitor |
2014 |
Preclinical |
194 |
RX-P873
|
Protein synthesis inhibitor (pyrrolocytosine series) |
2015 |
Preclinical |
195 |
Lascufloxacin
|
Fluoroquinolone |
2013 |
|
196 |
Cadazolid
|
Quinolonyl-oxazolidinone |
2012 |
Phase 3 |
197 |
QSi413
|
Quorum sensing inhibitor |
2014 |
Preclinical |
198 |
QSi129
|
Quorum sensing inhibitor |
2014 |
Preclinical |
199 |
QSi303
|
Quorum sensing inhibitor |
2014 |
Preclinical |
200 |
Aptamer Antagonist A11
|
Antivirulence agent |
2015 |
Preclinical |
202 |
DNAC-1
|
Quinolinol derivative |
2015 |
Preclinical |
203 |
HPi1
|
3-hydrazinoquinoxaline-2-thiol |
2014 |
Preclinical |
204 |
PT-8420 and PT-8541
|
Lethal factor protease inhibitor |
2013 |
Preclinical |
206 |
MAC-0170636
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
207 |
MAC-0174466
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
208 |
MAC-0080655
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
209 |
MAC-0177727
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
210 |
MAC-0020108
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
211 |
MAC-0020111
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
212 |
MAC-0026022
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
213 |
MAC-0042770
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
214 |
MAC-0045389
|
Cell-wall synthesis inhibitor |
2014 |
Preclinical |
215 |
RNPA 1000
|
RnpA inhibitor |
2011 |
Preclinical |
216 |
RNPA 2000
|
RnpA inhibitor |
2011 |
Preclinical |
217 |
Ridinilazole
|
DNA minor groove binder |
2011 |
Phase 3 |
218 |
N-Chlorotaurine (NCT)
|
Antiseptic |
1998 |
Preclinical |
219 |
PC190723
|
FtsZ inhibitor |
2008 |
Preclinical |
220 |
Menadione
|
Menaquinone analogue |
2013 |
Preclinical |
221 |
1,4-Naphthoquinone
|
Menaquinone analogue |
2013 |
Preclinical |
222 |
Menaquinolone Analogue: Coenzyme Q1
|
Menaquinone analogue |
2013 |
Preclinical |
223 |
Menaquinolone Analogue: Coenzyme Q2
|
Menaquinone analogue |
2013 |
Preclinical |
224 |
Menaquinolone Analogue: Coenzyme Q3
|
Menaquinone analogue |
2013 |
Preclinical |
225 |
Q24DA (Quinazoline-2,4-Diamino Analogue)
|
Antivirulence agent |
2011 |
Preclinical |
226 |
DS-96
|
Vaginal microbicide |
2008 |
Preclinical |
227 |
CL-55
|
Antivirulence agent (T3SS inhibitor) |
2015 |
Phase 2 (NCT03638830) |
228 |
KS100
|
Antivirulence agent (T6SS inhibitor) |
2014 |
Preclinical |
229 |
KS200
|
Antivirulence agent (T6SS inhibitor) |
2014 |
Preclinical |
230 |
KKL-35
|
Trans-translation inhibitor |
2013 |
Preclinical |
231 |
Pyridodiazepine amine compound A
|
MurI inhibitor |
2014 |
Preclinical |
232 |
C11
|
Quorum sensing inhibitor |
2015 |
Preclinical |
233 |
RX-04A
|
Protein synthesis inhibitor (pyrrolocytosine) |
2015 |
Preclinical |
234 |
RX-04B
|
Protein synthesis inhibitor (pyrrolocytosine) |
2015 |
Preclinical |
235 |
RX-04C
|
Protein synthesis inhibitor (pyrrolocytosine) |
2015 |
Preclinical |
236 |
RX-04D
|
Protein synthesis inhibitor (pyrrolocytosine) |
2015 |
Preclinical |
237 |
Compound 7955004
|
Adenosine mimetic |
2015 |
Preclinical |
238 |
Teixobactin
|
Cell-wall synthesis inhibitor (lipid II inhibitor) |
2015 |
Preclinical |
239 |
BAS00127538
|
Cell-wall synthesis inhibitor (lipid II inhibitor) |
2013 |
Preclinical |
240 |
GPI0363
|
RNA synthesis inhibitor |
2014 |
Preclinical |
241 |
TP-076
|
Tetracycline |
2014 |
Phase 1 |
242 |
TP-138
|
Tetracycline |
2014 |
Preclinical |
243 |
TP-600
|
Tetracycline |
2014 |
Preclinical |
245 |
Eravacycline (Xerava)
|
Tetracycline |
2012 |
Approved by FDA in 2018 |
246 |
Omadacycline (Nuzyra)
|
Tetracycline |
2006 |
Approved by FDA in 2018 |
247 |
Thiazomycin
|
Thiazolyl peptide |
2007 |
Preclinical |
248 |
NxtSc-G5
|
|
2014 |
Preclinical |
249 |
Benzothiazole Ethyl Urea Inhibitor Compound A
|
Bacterial topoisomerase inhibitor |
2013 |
Preclinical |
250 |
Benzothiazole Ethyl Urea Inhibitor Compound B
|
Bacterial topoisomerase inhibitor |
2013 |
Preclinical |
251 |
Kibdelomycin
|
Bacterial topoisomerase inhibitor |
2011 |
Preclinical |
252 |
NBTI 5463
|
Bacterial topoisomerase inhibitor |
2014 |
Preclinical |
253 |
Gepotidacin
|
Bacterial topoisomerase inhibitor |
2011 |
Phase 3 |
254 |
Amycolamicin
|
Bacterial topoisomerase inhibitor |
2010 |
Preclinical |
255 |
Cytosporone B derivative
|
Antivirulence agent |
2010/2013 |
Preclinical |
256 |
SRI-20864
|
Dihydrofolate reductase inhibitor |
2004 |
Preclinical |
257 |
SRI-20920
|
Dihydrofolate reductase inhibitor |
2004 |
Preclinical |
258 |
Research Program: (259C)
|
6-anilinouracil-fluoroquinolone hybrid |
2003 |
Preclinical |
259 |
SRI 9581
|
Ababinose dissacharide analogue |
2000 |
Preclinical |
260 |
FMA 1082
|
Acylide |
2003 |
|
261 |
OPT-382
|
Aminoglycoside |
2003 |
Preclinical |
262 |
TS2037 (derivative of arbekicin)
|
Aminoglycoside |
2004 |
|
263 |
Vancomyquine (PA1409)
|
Aminoquinoline-glycopeptide hybride |
2009 |
Preclinical |
265 |
IT-62-B
|
Anthracycline |
1995 |
Preclinical |
266 |
Altromycin B
|
DNA minor groove binder |
1989 |
Preclinical |
267 |
VIC-104988
|
Oxazolidinone (azabicyclic analogue) |
2005 |
Preclinical |
268 |
L-701,103
|
Macrolide (15-membered macrolide) |
1993 |
Preclinical |
269 |
L-701,677
|
Macrolide (15-membered macrolide) |
1993 |
Preclinical |
270 |
L-708,299
|
Macrolide (15-membered macrolide) |
1993 |
Preclinical |
271 |
L-708,365
|
Macrolide (15-membered macrolide) |
1993 |
Preclinical |
273 |
5-Deoxyenterocin
|
Antimicrobial peptide (bacteriocin) |
1986 |
Preclinical |
274 |
BAS-118
|
Benzamide |
2001 |
Preclinical |
275 |
RP60556A
|
Benzo[b]naphthyridone |
2000 |
Preclinical |
276 |
PD-0162819
|
Biotin carboxylase inhibitor |
2009 |
Preclinical |
278 |
MBX1162
|
Bis-indole |
2009 |
Preclinical |
279 |
MBX1090
|
Bis-indole |
2009 |
Preclinical |
280 |
MBX1113
|
Bis-indole |
2009 |
Preclinical |
281 |
MBX1128
|
Bis-indole |
2009 |
Preclinical |
282 |
A358
|
Sulfa drug / Sulphonamide |
2001 |
Preclinical |
283 |
AN0128
|
Borinic acid ester |
2005 |
Phase 2 |
284 |
PMX100
|
Calixarene |
2010 |
Preclinical |
285 |
PMX223
|
Calixarene |
2010 |
Preclinical |
286 |
PMX243
|
Calixarene |
2010 |
Preclinical |
287 |
BMS 181139
|
Beta-lactam (carbapenem) |
1994 |
Preclinical |
288 |
BO-3482
|
Beta-lactam (carbapenem) |
1996 |
Preclinical |
289 |
CL 188624
|
Beta-lactam (carbapenem) |
1994 |
Preclinical |
290 |
CL 191121
|
Beta-lactam (carbapenem) |
1994 |
Preclinical |
291 |
DU 6681
|
Beta-lactam (carbapenem) |
1995 |
Preclinical |
293 |
DX-8739
|
Beta-lactam (carbapenem) |
1992 |
Preclinical |
294 |
FR 21818
|
Beta-lactam (carbapenem) |
1995 |
Preclinical |
295 |
J-111,225
|
Beta-lactam (carbapenem) |
1998 |
Preclinical |
296 |
J-114,871
|
Beta-lactam (carbapenem) |
1998 |
Preclinical |
297 |
J-114,870
|
Beta-lactam (carbapenem) |
1998 |
Preclinical |
298 |
KR-21012
|
Beta-lactam (carbapenem) |
1998 |
Preclinical |
299 |
L-695256
|
Beta-lactam (carbapenem) |
1994 |
Preclinical |
300 |
L-786392
|
Beta-lactam (carbapenem) |
1998 |
Preclinical |
301 |
Lenapenem (Bo- 2727)
|
Beta-lactam (carbapenem) |
1990 |
Phase 2 |
302 |
Saccharomicin A
|
Antimicrobial peptide (heptadecaglycoside) |
1999 |
Preclinical |
303 |
Saccharomicin B
|
Antimicrobial peptide (heptadecaglycoside) |
1999 |
Preclinical |
304 |
LICA/WRAIR
|
Membrane-active agent (chalcone) |
1999 |
Preclinical |
305 |
Epidermicin NI01
|
Antimicrobial peptide |
2010 |
Preclinical |
306 |
Guanacastepene
|
Membrane-active agent |
1998 |
Preclinical |
307 |
CA(1-8)M(1-18)
|
Antimicrobial peptide |
1999 |
Preclinical |
308 |
Lactoferricin B (bovine)
|
Antimicrobial peptide |
1999 |
Preclinical |
309 |
Cecropin P1
|
Antimicrobial peptide |
1998 |
Preclinical |
310 |
LY264826 (A82846B)
|
Glycopeptide |
1995 |
Preclinical |
311 |
LY307599
|
Glycopeptide |
1997 |
Preclinical |
312 |
PGE-956 7567
|
Cell-wall synthesis inhibitor (biarylamide) |
1999 |
Preclinical |
313 |
BP-102
|
Beta-lactam (cephalosporin, carbacephem) |
2005 |
Preclinical |
314 |
CP-5068
|
Beta-lactam (carbapenem) |
2000 |
Preclinical |
315 |
ME1036 (CP5609)
|
Beta-lactam (carbapenem) |
2003 |
Preclinical |
316 |
P-91022
|
Beta-lactam (carbapenem) |
2004 |
Preclinical |
317 |
P-21028
|
Beta-lactam (carbapenem) |
2004 |
Preclinical |
318 |
Research Programme-2-(Thiazol-2ylthio)-1β-Methylcarbapenem: SM-197436
|
Beta-lactam (carbapenem) |
2001 |
Preclinical |
319 |
Research Programme-2-(Thiazol-2ylthio)-1β-Methylcarbapenem: SM-232721
|
Beta-lactam (carbapenem) |
2001 |
Preclinical |
320 |
Research Programme-2-(Thiazol-2ylthio)-1β-Methylcarbapenem: SM-232724
|
Beta-lactam (carbapenem) |
2001 |
Preclinical |
321 |
Tomopenem
|
Beta-lactam (carbapenem) |
2000 |
Phase 2 |
322 |
BMS-195059
|
Beta-lactam (cephalosporin) |
2000 |
|
323 |
BMS-217441
|
Beta-lactam (cephalosporin) |
2000 |
|
324 |
BC-2901
|
Beta-lactam (cephalosporin) |
2005 |
Preclinical |
325 |
BMS-247243
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
326 |
BMS-28232
|
Beta-lactam (cephalosporin) |
1987 |
Preclinical |
327 |
BO-1341
|
Beta-lactam (cephalosporin) |
1987 |
Preclinical |
329 |
CP6162
|
Beta-lactam (cephalosporin) |
1989 |
Preclinical |
330 |
L-658,310 (BO1236)
|
Beta-lactam (cephalosporin) |
1987 |
Preclinical |
331 |
LB 11058
|
Beta-lactam (cephalosporin) |
2002 |
Preclinical |
332 |
LY193239 (methyl-sulfanato at C-3 version of LY173013)
|
Beta-lactam (cephalosporin) |
1987 |
Preclinical |
333 |
ME1220
|
Beta-lactam (cephalosporin) |
1986 |
Preclinical |
334 |
ME1221
|
Beta-lactam (cephalosporin) |
1986 |
Preclinical |
335 |
NB2001
|
Beta-lactam (cephalosporin) |
2001 |
Preclinical |
336 |
OCP 9-176
|
Beta-lactam (cephalosporin) |
1987 |
Preclinical |
337 |
PGE 6737410
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
338 |
PGE 856854
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
339 |
PGE 9739390
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
340 |
PGE 9882816
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
341 |
PGE 9951357
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
342 |
RWJ-333441
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
343 |
RWJ 333442 (Prodrug of RWJ-333441)
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
345 |
RWJ-442831 (Prodrug of RWJ-54428)
|
Beta-lactam (cephalosporin) |
2000 |
Preclinical |
346 |
SR 44337
|
Beta-lactam (cephalosporin) |
1989 |
Preclinical |
347 |
YJP-40102
|
Beta-lactam (cephalosporin) |
2005 |
Preclinical |
348 |
Cefetecol (GR69153)
|
Beta-lactam (cephalosporin) |
1989 |
Phase 1 |
350 |
FK518
|
Beta-lactam (cephalosporin) |
1990 |
Phase 1 |
351 |
HR 916B (Prodrug of RU29246)
|
Beta-lactam (cephalosporin) |
1991 |
Phase 1 |
352 |
M14659 (GR 63116)
|
Beta-lactam (cephalosporin) |
1986 |
Phase 1 |
354 |
RU29246 (Orally active version of HR916)
|
Beta-lactam (cephalosporin) |
1990 |
Phase 1 |
355 |
Cefclidine
|
Beta-lactam (cephalosporin) |
1987 |
Phase 2 |
356 |
ME1228 (sulphur analogue of OCP9176)
|
Beta-lactam (cephalosporin) |
1987 |
Phase 2 |
357 |
Cefluprenam
|
Beta-lactam (cephalosporin) |
1991 |
Phase 3 |
358 |
Ceftizoxime alapivoxil (prodrug)
|
Beta-lactam (cephalosporin) |
1983 |
Approved by FDA in 1983 |
359 |
CM 40876
|
Beta-lactam (cephalosporin) |
1986 |
|
360 |
KP-736
|
Beta-lactam (cephalosporin) |
1989 |
Phase 2/3 |
361 |
BMS-234138
|
Beta-lactam (cephalosporin) |
2000 |
|
362 |
DQ-2556
|
Beta-lactam (cephalosporin) |
1988 |
|
363 |
RU 45978 (isocephem of RU 46069)
|
Beta-lactam (cephalosporin) |
1988 |
|
364 |
RU 46069 (isocephem of RU 45978)
|
Beta-lactam (cephalosporin) |
1988 |
|
365 |
SPD 135
|
Beta-lactam (cephalosporin) |
1990 |
|
366 |
YM-22561 (YM561)
|
Beta-lactam (cephalosporin) |
1990 |
|
367 |
S-3578
|
Beta-lactam (cephalosporin) |
2001 |
Phase 1 |
368 |
CS 834 (Prodrug of R-95867)
|
Beta-lactam (cephalosporin) |
2001 |
Phase 2 |
369 |
Tacapenem
|
Beta-lactam (cephalosporin) |
1996 |
Phase 2 |
372 |
Plusbacin A3
|
Cyclic-lipodepsipeptide |
1999 |
Preclinical |
373 |
A40926 (MDL 63042)
|
Glycopeptide |
1987 |
Preclinical |
374 |
AC98-6446
|
Glycopeptide |
2002 |
Preclinical |
375 |
LT-00029
|
Glycopeptide |
2009 |
Preclinical |
377 |
SKF 104662
|
Glycopeptide |
1988 |
Phase 1 |
378 |
Eremomycin
|
Glycopeptide |
1988 |
Phase 2 |
379 |
U-78608
|
Beta-lactam (monocarbam) |
1988 |
Preclinical |
380 |
BO-1165
|
Beta-lactam (monocarbam) |
1986 |
Preclinical |
381 |
RU44790
|
Beta-lactam (monocarbam) |
1986 |
Preclinical |
383 |
SQ-31299
|
Beta-lactam (monocarbam) |
1987 |
|
384 |
SQ 32633
|
Beta-lactam (monocarbam) |
1990 |
|
385 |
SQ 33110
|
Beta-lactam (monocarbam) |
1990 |
|
387 |
CGP-31608
|
Beta-lactam (penem) |
1986 |
Preclinical |
388 |
HRE 664
|
Beta-lactam (penem) |
1986 |
Preclinical |
389 |
Tirandalydigin
|
Beta-lactam (penem) |
1987 |
Preclinical |
390 |
Razupenem
|
Beta-lactam (penem) |
2004 |
Phase 2 |
391 |
Sulopenem
|
Beta-lactam (penem) |
1980 |
Phase 3 |
392 |
Ritipenem
|
Beta-lactam (penem) |
1986 |
Phase 3 |
394 |
FCE 25199
|
Beta-lactam (penem) |
1989 |
Preclinical? |
395 |
BRL 44154
|
Beta-lactam (penicillin) |
1989 |
Phase 1 |
396 |
HKI 9924109
|
Beta-lactam (siderophore acylaminopenicillin) |
2001 |
Preclinical |
397 |
HKI 9924154
|
Beta-lactam (siderophore acylaminopenicillin) |
2001 |
Preclinical |
398 |
HKI 9924155 (amoxicillin adduct with synthetic catecholate)
|
Beta-lactam (siderophore acylaminopenicillin) |
2001 |
Preclinical |
399 |
NZ2114
|
Antimicrobial peptide (plectasin derived) |
2007 |
Preclinical |
400 |
Mideplanin
|
Glycopeptide (teicoplanin derivative) |
1988 |
Preclinical |
401 |
Mersacidin
|
Antimicrobial peptide (lantibiotic) |
1989 |
|
402 |
Mureidomycin A
|
MraY inhibitor |
1991 |
|
403 |
Mureidomycin B
|
MraY inhibitor |
1991 |
|
404 |
Mureidomycin C
|
MraY inhibitor |
1991 |
|
405 |
Mureidomycin D
|
MraY inhibitor |
1991 |
|
406 |
Pyrazolidinedione series - Wyeth
|
MurB inhibitor |
2003 |
|
407 |
SC 44914
|
Cell-wall synthesis inhibitor (quinoxaline) |
1991 |
Preclinical |
408 |
SC-44942-A
|
Cell-wall synthesis inhibitor (quinoxaline) |
1991 |
Preclinical |
409 |
LY228238
|
Beta-lactam (cephalosporin, carbacephem [loracarbef derivative]) |
1988 |
Preclinical |
410 |
LY257128
|
Beta-lactam (cephalosporin, carbacephem [loracarbef derivative]) |
1988 |
Preclinical |
411 |
BMY 28232 (BMY 28271 is the prodrug)
|
Beta-lactam (cephalosporin) |
1988 |
Phase 1 |
412 |
Ro 23-9424 (fleroxacin + desacetylcefotaxime)
|
Drug combination: beta-lactam (cephalosporin) + fluoroquinolone |
1988 |
Phase 2 |
413 |
LB 10827
|
Beta-lactam (cephalosporin) |
1999 |
Preclinical |
414 |
E1010 (ER-35786)
|
Beta-lactam (carbapenem) |
1995 |
Phase 1 |
415 |
Ro 244383
|
Beta-lactam (cephalosporin) |
1990 |
Preclinical |
416 |
Ro 246392
|
Beta-lactam (cephalosporin) |
1990 |
Preclinical |
417 |
Ro 246778
|
Beta-lactam (cephalosporin) |
1990 |
Preclinical |
418 |
CB-182,548
|
Lipopeptide |
|
Preclinical |
419 |
CB-182,549
|
Lipopeptide |
|
Preclinical |
420 |
CB-182,561
|
Lipopeptide |
2008 |
Preclinical |
421 |
A54145 complex
|
Lipopeptide |
1988 |
Preclinical |
422 |
ECO-0501
|
Envelope-active compound (glycosylated polyketide) |
2004 |
Preclinical |
423 |
AM 1732
|
Beta-lactam (cephalosporin) |
1996 |
Preclinical |
424 |
AM 1817
|
Beta-lactam (cephalosporin) |
1996 |
Preclinical |
425 |
FK041
|
Beta-lactam (cephalosporin) |
1996 |
Preclinical |
426 |
KA-094
|
Beta-lactam (cephalosporin) |
1993 |
Preclinical |
427 |
KST-150257
|
Beta-lactam (cephalosporin) |
1997 |
Preclinical |
428 |
KST-150290
|
Beta-lactam (cephalosporin) |
1997 |
Preclinical |
429 |
LB10522
|
Beta-lactam (cephalosporin) |
1995 |
Preclinical |
430 |
MC-02,306
|
Beta-lactam (cephalosporin) |
1995 |
Preclinical |
431 |
MC-02,331
|
Beta-lactam (cephalosporin) |
1996 |
Preclinical |
432 |
ME1209
|
Beta-lactam (cephalosporin) |
1995 |
Preclinical |
433 |
Ro 25-2016
|
Beta-lactam (cephalosporin) |
1994 |
Preclinical |
434 |
Ro 25-4835
|
Beta-lactam (cephalosporin) |
1994 |
Preclinical |
435 |
Ro 25-6833
|
Beta-lactam (cephalosporin) |
1995 |
Preclinical |
436 |
Ro 25-7103
|
Beta-lactam (cephalosporin) |
1995 |
Preclinical |
437 |
Ro 48-8391
|
Beta-lactam (cephalosporin) |
1996 |
Preclinical |
438 |
RU 59863
|
Beta-lactam (cephalosporin) |
1994 |
Preclinical |
439 |
TOC-39
|
Beta-lactam (cephalosporin) |
1993 |
Preclinical |
440 |
TOC-50
|
Beta-lactam (cephalosporin) |
1993 |
Preclinical |
441 |
YM-40220
|
Beta-lactam (cephalosporin) |
1994 |
Preclinical |
442 |
MC-02479
|
Beta-lactam (cephalosporin) |
1997 |
Phase 1 |
443 |
Ro 40-6890
|
Beta-lactam (cephalosporin) |
1992 |
Phase 1 |
444 |
Ceftrazonal bopentil (Ro 413399) (Prodrug of Ro 406890)
|
Beta-lactam (cephalosporin) |
1992 |
Phase 1 |
445 |
SC-002
|
Beta-lactam (cephalosporin) |
1992 |
Phase 1 |
446 |
E1101
|
Beta-lactam (cephalosporin) |
1994 |
Phase 2 |
447 |
LK10517
|
Beta-lactam (cephalosporin) |
1994 |
Phase 2 |
448 |
Cefmatilen
|
Beta-lactam (cephalosporin) |
1992 |
Phase 3 |
449 |
Dual Action Cephalosporin (DAC) PD15768
|
Cephalosporin-quinolone |
1995 |
Preclinical |
450 |
Dual Action Cephalosporin (DAC) PD152912
|
Cephalosporin-quinolone |
1995 |
Preclinical |
451 |
Dual Action Cephalosporin (DAC) PD 152915
|
Cephalosporin-quinolone |
1995 |
Preclinical |
452 |
Ro 25-0534
|
Cephalosporin-quinolone |
1993 |
Preclinical |
453 |
NB2030
|
Cephalosporin-triclosan |
2003 |
Preclinical |
454 |
NB3352 (NB2030 analogue)
|
Cephalosporin-triclosan |
2003 |
Preclinical |
455 |
NB3353 (NB2030 analogue)
|
Cephalosporin-triclosan |
2003 |
Preclinical |
456 |
LY173013
|
Beta-lactam (cephalosporin) |
1986 |
Preclinical |
457 |
LY186826 (derived from LY173013)
|
Beta-lactam (cephalosporin) |
1986 |
Preclinical |
458 |
CP-0467
|
Beta-lactam (cephem) |
1992 |
Preclinical |
459 |
OPC-20000
|
Beta-lactam (cephem) |
1993 |
Preclinical |
460 |
Coumamidine Gamma 1
|
Coumamidine |
1988 |
|
461 |
BAL30544
|
Dihydrofolate reductase inhibitor (phthalazines) |
2007 |
Preclinical |
462 |
BAL30545
|
Dihydrofolate reductase inhibitor (phthalazines) |
2007 |
Preclinical |
463 |
AR-709
|
Dihydrofolate reductase inhibitor (diaminopyrimdine derivative) |
2006 |
Phase 1 |
464 |
Pafuramidine (Prodrug of DB-75), DB-289
|
Dicationic molecule (pentamidine related) |
2001 |
Phase 3 |
465 |
Diepoxin 1
|
Diepoxin |
1993 |
Preclinical |
466 |
Diepoxin 2
|
Diepoxin |
1993 |
Preclinical |
467 |
Diepoxin 3
|
Diepoxin |
1993 |
Preclinical |
468 |
Diepoxin 4
|
Diepoxin |
1993 |
Preclinical |
469 |
NB3322
|
Dihydrofolate reductase inhibitor |
2003 |
Preclinical |
470 |
Ro-474352
|
Dihydrofolate reductase inhibitor |
1999 |
Preclinical |
471 |
Ro-483706
|
Dihydrofolate reductase inhibitor |
1999 |
Preclinical |
472 |
Ro-619175
|
Dihydrofolate reductase inhibitor |
1999 |
Preclinical |
473 |
Ro-622753
|
Dihydrofolate reductase inhibitor |
1999 |
Preclinical |
474 |
Ro-626091
|
Dihydrofolate reductase inhibitor |
1999 |
Preclinical |
475 |
Ro-642550
|
Dihydrofolate reductase inhibitor |
1999 |
Preclinical |
476 |
KRQ-10018
|
Bacterial topoisomerase inhibitor |
1997 |
Preclinical |
477 |
RU 79115
|
Bacterial topoisomerase inhibitor (coumarin derivative) |
1999 |
Preclinical |
478 |
WCK-919
|
Fluoroquinolone |
2001 |
Preclinical |
479 |
BMY 41802
|
Bacterial topoisomerase inhibitor (napthyridone) |
1990 |
|
480 |
BMY 41889
|
Bacterial topoisomerase inhibitor (napthyridone) |
1990 |
|
481 |
WCK-771A
|
Fluoroquinolone |
2001 |
Phase 2 |
482 |
DC-159a
|
Fluoroquinolone |
2006 |
Phase 1 |
483 |
PGE-9509924
|
Quinolone |
2000 |
Preclinical |
484 |
CL 225014
|
DNA synthesis inhibitor (nitroimidazole) |
1994 |
Preclinical |
485 |
HB-EMAU
|
DNA polymerase III inhibitor (6-anilinouracils (dGTP analogue)) |
1999 |
Preclinical |
486 |
HB-IMAU
|
DNA polymerase III inhibitor (6-anilinouracils (dGTP analogue)) |
1999 |
Preclinical |
487 |
MB-EMAU
|
DNA polymerase III inhibitor (6-anilinouracils (dGTP analogue)) |
1999 |
Preclinical |
488 |
MB-IMAU
|
DNA polymerase III inhibitor (6-anilinouracils (dGTP analogue)) |
1999 |
Preclinical |
489 |
ME2303
|
DNA synthesis inhibitor (anthracycline) |
1991 |
Phase 2 |
490 |
A-867191
|
Fluoroquinolone |
1994 |
Phase 2 |
491 |
REP 6021
|
DNA synthesis inhibitor (pyrimidinone (thioxo-thiazolidin-4-one series)) |
2004 |
Preclinical |
492 |
DRG-16
|
DNA synthesis inhibitor (pyrrolobenzodiazepine) |
2004 |
Preclinical |
493 |
ELB-21
|
DNA synthesis inhibitor (pyrrolobenzodiazepine) |
2004 |
Preclinical |
494 |
SJG-136
|
DNA synthesis inhibitor (pyrrolobenzodiazepine) |
2004 |
Phase 2 |
495 |
MF-961
|
Fluoroquinolone (rufloxacin derivative) |
1989 |
Preclinical |
496 |
Bioxalomycin alpha 2
|
DNA synthesis inhibitor |
1993 |
Preclinical |
497 |
RP-67829
|
Bacterial topoisomerase inhibitor (benzonaphthyridine) |
1991 |
Preclinical |
498 |
DX-619
|
Fluoroquinolone |
2003 |
Phase 1 |
499 |
QX-2987
|
Bacterial topoisomerase inhibitor |
2004 |
Preclinical |
500 |
QX-3073
|
Bacterial topoisomerase inhibitor |
2004 |
Preclinical |
501 |
PD 0199646
|
Bacterial topoisomerase inhibitor (2-hydroxyisoquinolone) |
2000 |
|
502 |
WQ-3345
|
Fluoroquinolone |
2000 |
Preclinical |
503 |
WQ-2944 (7-methylamino)
|
Fluoroquinolone |
2000 |
Preclinical |
504 |
WQ-3188 (7-(2-hydroxyethylamino))
|
Fluoroquinolone |
2000 |
Preclinical |
505 |
WQ-3198 (7-(3-hydroxypropylamino))
|
Fluoroquinolone |
2000 |
Preclinical |
506 |
E-3846
|
Fluoroquinolone |
1989 |
Preclinical |
507 |
WQ-2756
|
Fluoroquinolone |
1996 |
Preclinical |
508 |
WQ-2765
|
Fluoroquinolone |
1996 |
Preclinical |
510 |
WQ 3330
|
Fluoroquinolone |
1999 |
Preclinical |
511 |
BMY 40062
|
Fluoroquinolone |
1988 |
Preclinical |
512 |
WQ-3335
|
Fluoroquinolone |
2005 |
Preclinical |
513 |
KB-5246
|
Fluoroquinolone (tetracyclic quinolone) |
1988 |
Phase 1 (2) |
514 |
Oxaquin (prodrug of MCB3681)
|
Fluoroquinolone-oxazolidinone hybrid |
2005 |
Phase 1 |
515 |
Clinafloxacin
|
Fluoroquinolone |
1986 |
Phase 3 |
516 |
ABI-0094
|
Rifamycin |
2005 |
Preclinical |
517 |
ABI-0299
|
Rifamycin |
2005 |
Preclinical |
518 |
CHP-105
|
DnaK inhibitor |
2008 |
Preclinical |
519 |
Fosmidomycin (FR 31564)
|
DXP reductoisomerase inhibitor (phosphonic acid derivative) |
|
Phase 2 |
521 |
MC-04124
|
Efflux pump inhibitor |
2000 |
Preclinical |
522 |
MC207110
|
Efflux pump inhibitor |
2000 |
Preclinical |
523 |
MC-278,537
|
Efflux pump inhibitor |
2001 |
Preclinical |
524 |
MC-04112
|
Efflux pump inhibitor |
2001 |
Preclinical |
526 |
MC 02595
|
Efflux pump inhibitor |
2000 |
Preclinical |
527 |
UK-57-562
|
Efflux pump inhibitor |
1999 |
Preclinical |
528 |
MC-210375
|
Efflux pump inhibitor |
2001 |
Preclinical |
529 |
MC 510050 (MF-EA-371 δ)
|
Efflux pump inhibitor (O-sulfates of benastatins A and B) |
2000 |
Preclinical |
530 |
MC 510051 (MF-EA-371 α)
|
Efflux pump inhibitor (O-sulfates of benastatins A and B) |
2000 |
Preclinical |
531 |
GE 21640A
|
Protein synthesis inhibitor (elfamycin) |
1993 |
Preclinical |
532 |
RU 75411
|
MraY inhibitor (nucleoside) |
2002 |
Preclinical |
533 |
MUT37307
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2008 |
Preclinical |
534 |
CG-400462
|
Fatty acid synthesis inhibitor (FabI inhibitor, naphthylidine derivative) |
2004 |
Preclinical |
535 |
CG-400463
|
Fatty acid synthesis inhibitor (FabI inhibitor, naphthylidine derivative) |
2006 |
Preclinical |
536 |
JNJ-17156581
|
Macrolide (14-membered macrolide, fluoroketolide) |
2003 |
Preclinical |
537 |
JNJ-17156815
|
Macrolide (14-membered macrolide, fluoroketolide) |
2003 |
Preclinical |
539 |
A-80556 (A-65326.HCL)
|
Fluoroquinolone |
1992 |
Preclinical |
543 |
DC 756
|
Fluoroquinolone |
1998 |
Preclinical |
544 |
DQ-113
|
Fluoroquinolone |
2000 |
Preclinical |
545 |
E-4721
|
Fluoroquinolone |
1992 |
Preclinical |
546 |
CI-990
|
Fluoroquinolone |
1990 |
Preclinical |
548 |
PD 138312
|
Fluoroquinolone |
1993 |
Preclinical |
549 |
PD 140248
|
Fluoroquinolone |
1993 |
Preclinical |
550 |
Premafloxacin (U95376)
|
Fluoroquinolone |
1995 |
Preclinical |
551 |
PD 135661
|
Fluoroquinolone |
1996 |
Preclinical |
552 |
PD 161144
|
Fluoroquinolone |
1996 |
Preclinical |
553 |
PD-161148
|
Fluoroquinolone |
1996 |
Preclinical |
554 |
PD 161314
|
Fluoroquinolone |
1996 |
Preclinical |
555 |
PD 161315
|
Fluoroquinolone |
1996 |
Preclinical |
556 |
PD 163048
|
Fluoroquinolone |
1996 |
Preclinical |
557 |
PD 163049
|
Fluoroquinolone |
1996 |
Preclinical |
558 |
PD 163753
|
Fluoroquinolone |
1996 |
Preclinical |
559 |
S-32730
|
Fluoroquinolone |
1995 |
Preclinical |
560 |
S-34109
|
Fluoroquinolone |
1998 |
Preclinical |
561 |
Y-688
|
Fluoroquinolone |
1995 |
Preclinical |
562 |
Cetefloxacin
|
Fluoroquinolone |
1992 |
Phase 1 |
563 |
DK-507k
|
Fluoroquinolone |
2001 |
Phase 1 |
564 |
DW-286a
|
Fluoroquinolone |
2001 |
Phase 1 |
565 |
Olamufloxacin (HSR-903)
|
Fluoroquinolone |
1998 |
Phase 3 |
566 |
A245475
|
Fluoroquinolone |
1999 |
|
567 |
ABI200
|
Engineered bacteriophage endolysin |
2009 |
Preclinical |
568 |
Balhimycin
|
Glycopeptide |
1993 |
Preclinical |
570 |
UK 68,597
|
Glycopeptide |
1989 |
|
571 |
Chloroorienticin B (S-3662)
|
Glycopeptide |
1991 |
|
572 |
LT-00786
|
Glycopeptide |
2010 |
Preclinical |
573 |
Glycothiohexide
|
Glycothiopeptide |
1993 |
Preclinical |
574 |
PGE 4175997
|
Quinolone |
1999 |
Preclinical |
575 |
PGE 9262932
|
Quinolone |
1999 |
Preclinical |
576 |
A-170568
|
Fluoroquinolone |
1998 |
Preclinical |
577 |
A-238086
|
Bacterial topoisomerase inhibitor (pyridone derivative) |
1999 |
|
578 |
A270117
|
Bacterial topoisomerase inhibitor (pyridone derivative) |
1999 |
|
579 |
Walkmycin A
|
Histidine kinase inhibitor |
2010 |
Preclinical |
580 |
Walkmycin B
|
Histidine kinase inhibitor |
2010 |
Preclinical |
581 |
Walkmycin C
|
Histidine kinase inhibitor |
2010 |
Preclinical |
582 |
Walkmycin D
|
Histidine kinase inhibitor |
2010 |
Preclinical |
583 |
Walkmycin E
|
Histidine kinase inhibitor |
2010 |
Preclinical |
584 |
Walkmycin F
|
Histidine kinase inhibitor |
2010 |
Preclinical |
585 |
PGE 1818689
|
Quinoyl-carbacephem |
1998 |
Preclinical |
586 |
CE-129941
|
Hygromycin A |
2006 |
Preclinical |
587 |
CRL-1018
|
Immunomodulator |
1995 |
Preclinical |
588 |
CRL 1072
|
Immunomodulator (poloaxmer) |
1995 |
Preclinical |
590 |
RWJ-49815
|
Antivirulence agent (two-component system inhibitor) |
1997 |
Preclinical |
591 |
RWJ-60563
|
Antivirulence agent (two-component system inhibitor) |
1997 |
Preclinical |
592 |
CP 654743
|
Macrolide (16-membered macrolide, ketolide) |
2000 |
Preclinical |
595 |
CHIR 380
|
Macrolide (16-membered macrolide, ketolide) |
2003 |
Preclinical |
596 |
CHIR 988
|
Macrolide (16-membered macrolide, ketolide) |
2003 |
Preclinical |
597 |
JNJ-17155437
|
Macrolide (15-membered macrolide, ketolide) |
2002 |
Preclinical |
598 |
JNJ-17155528
|
Macrolide (15-membered macrolide, ketolide) |
2002 |
Preclinical |
599 |
API7444
|
Antimicrobial peptide (lantibiotic) |
2004 |
|
600 |
MF-BA1768-a
|
Antimicrobial peptide (lantibiotic) |
2001 |
|
601 |
MF-BA1768-b
|
Antimicrobial peptide (lantibiotic) |
2001 |
|
602 |
Plectasin
|
Antimicrobial peptide (fungal defensin, lipid II binder) |
2006 |
Preclinical |
603 |
Caprazamycin A
|
MraY inhibitor (liponucleoside) |
2002 |
Preclinical |
604 |
Caprazamycin B
|
MraY inhibitor (liponucleoside) |
2002 |
Preclinical |
605 |
Caprazamycin C
|
MraY inhibitor (liponucleoside) |
2002 |
Preclinical |
606 |
Caprazamycin D
|
MraY inhibitor (liponucleoside) |
2002 |
Preclinical |
607 |
Caprazamycin E
|
MraY inhibitor (liponucleoside) |
2002 |
Preclinical |
608 |
Caprazamycin F
|
MraY inhibitor (liponucleoside) |
2002 |
Preclinical |
609 |
HMR 1043
|
Lipopeptide |
2000 |
Preclinical |
610 |
Laspartomycin and analogues
|
Lipopeptide |
2001 |
|
611 |
CHIR-090
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
2010 |
Preclinical |
612 |
Socorromycin
|
Macrolactam |
1993 |
Preclinical |
613 |
CP-544372
|
Macrolide |
1998 |
Preclinical |
614 |
GW 708408
|
Macrolide |
2004 |
Preclinical |
615 |
GW 773546
|
Macrolide |
2004 |
Preclinical |
616 |
Macquarimicin A
|
Macrolide |
1986 |
Preclinical |
617 |
YM17K (MC 352)
|
Macrolide |
1993 |
Preclinical |
618 |
EP-014598
|
Macrolide (6,11-bicyclolide scaffold) |
2007 |
|
619 |
EP-014413
|
Macrolide (bridged bicyclic) |
2007 |
|
620 |
EP-014887
|
Macrolide (oxime 3,6-bicyclolide) |
2007 |
|
621 |
P91022
|
Methylcarbapenem |
2006 |
|
622 |
CP-919471
|
Hygromycin A |
2006 |
Preclinical |
623 |
CP-929898
|
Hygromycin A |
2006 |
Preclinical |
624 |
CE-156811
|
Hygromycin A |
2006 |
Preclinical |
626 |
PTX2416
|
Beta-lactam (monobactam) |
2003 |
Preclinical |
627 |
SQ 83,831
|
Beta-lactam (monobactam) |
1988 |
|
628 |
Pirazmonam
|
Beta-lactam (monocarbam, siderophore monobactam) |
1985 |
Preclinical |
630 |
Munumbicin A
|
Antimicrobial peptide |
2003 |
Preclinical |
631 |
Munumbicin B
|
Antimicrobial peptide |
2003 |
Preclinical |
632 |
Munumbicin C
|
Antimicrobial peptide |
2003 |
Preclinical |
633 |
Munumbicin D
|
Antimicrobial peptide |
2003 |
Preclinical |
634 |
DQ-1
|
MurF inhibitor (diarylquinoline) |
2007 |
Preclinical |
635 |
DQ-2
|
MurF inhibitor (diarylquinoline) |
|
Phase 1 |
636 |
Sch 38519
|
Naphthaquinone |
1986 |
Preclinical |
637 |
Napsamycin A
|
Peptidylnucleoside |
1992 |
Preclinical |
638 |
Napsamycin B
|
Peptidylnucleoside |
1992 |
Preclinical |
639 |
Napsamycin C
|
Peptidylnucleoside |
1992 |
Preclinical |
640 |
Napsamycin D
|
Peptidylnucleoside |
1992 |
Preclinical |
641 |
PA-1297
|
Protein synthesis inhibitor |
1997 |
Preclinical |
642 |
PA-1343
|
Protein synthesis inhibitor |
1997 |
Preclinical |
643 |
Pretomanid
|
Nitroimidazole |
1997 |
Phase 3 |
644 |
Rodaplutin
|
Nucleoside |
1986 |
Preclinical |
645 |
AM-7359
|
Oxazolidinone |
2006 |
Preclinical |
646 |
AM-7383
|
Oxazolidinone |
2006 |
Preclinical |
647 |
LCB01-0062
|
Oxazolidinone |
2007 |
Preclinical |
648 |
PF-00708093
|
Oxazolidinone |
2009 |
Preclinical |
649 |
PF-02341752
|
Oxazolidinone |
2009 |
Preclinical |
650 |
Sutezolid
|
Oxazolidinone |
2009 |
Phase 2 (NCT05971602) |
651 |
PNU-101603
|
Oxazolidinone |
2009 |
Preclinical |
652 |
PNU-107922
|
Oxazolidinone |
1998 |
Preclinical |
653 |
PNU-140457
|
Oxazolidinone |
1998 |
Preclinical |
657 |
MCB3130
|
Oxazolidinone-quinolone |
2003 |
Preclinical |
658 |
MCB3382
|
Oxazolidinone-quinolone |
2003 |
Preclinical |
659 |
MCB116
|
Oxazolidinone |
2002 |
Preclinical |
660 |
MCB1033
|
Oxazolidinone |
2002 |
Preclinical |
661 |
OX-22-043
|
Oxazolidinone |
2002 |
Preclinical |
662 |
OX-22-045
|
Oxazolidinone |
2002 |
Preclinical |
663 |
Benzoxazinone
|
Oxazolidinone |
1999 |
|
664 |
Benzthiazinone
|
Oxazolidinone |
1999 |
|
665 |
Pyrazinoindole
|
Oxazolidinone |
1999 |
|
666 |
Oxazinoindole
|
Oxazolidinone |
1999 |
|
667 |
Saigenmycin
|
Oxazolomycin |
1986 |
Preclinical |
668 |
Actinonin (VRC483)
|
Peptide deformylase inhibitor |
1999 |
Preclinical |
669 |
BB-3497
|
Peptide deformylase inhibitor |
2000 |
Preclinical |
672 |
NVD PDF 713
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
673 |
VIC-104959
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
674 |
VRC3852
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
675 |
VRC-3324
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
676 |
VRC3375
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
677 |
VRC4307
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
678 |
VRC4887
|
Peptide deformylase inhibitor |
2000 |
Phase 1 |
680 |
FCE 24964 (Prodrug FCE 25199)
|
Beta-lactam (penem) |
1992 |
Preclinical |
681 |
CP-65-207
|
Beta-lactam (penem) |
1988 |
Phase 1 |
682 |
Calpinactam
|
Antimicrobial peptide |
2009 |
Preclinical |
683 |
Cypemycin
|
Antimicrobial peptide |
1994 |
Preclinical |
684 |
PMT-1185
|
Antimicrobial peptide |
2007 |
Preclinical |
685 |
PR-39
|
Antimicrobial peptide |
1995 |
Preclinical |
686 |
RTA-3
|
Antimicrobial peptide |
2007 |
Preclinical |
688 |
BPI 23
|
Antimicrobial peptide |
1992 |
Phase 2 |
689 |
E 5531
|
Antimicrobial peptide |
1992 |
Phase 2 |
690 |
XMP-629
|
Antimicrobial peptide |
2001 |
Phase 2 |
691 |
Iseganan
|
Antimicrobial peptide |
1997 |
Phase 3 |
692 |
Dermaseptin Derivative- K4-S4(1-13)
|
Antimicrobial peptide |
2001 |
|
693 |
Dermaseptin Derivative- K4-S4(1-16)
|
Antimicrobial peptide |
2001 |
|
694 |
PAD-1.17
|
Antimicrobial peptide |
2007 |
|
695 |
Eurocin
|
Antimicrobial peptide (defensin) |
2007 |
|
696 |
GE37468A
|
Antimicrobial peptide (thiazolyl peptide antibiotic) |
1994 |
Preclinical |
697 |
BB-83698, GBB 83698, GSQ 83698
|
Peptide deformylase inhibitor |
2001 |
Preclinical |
698 |
BB 83815
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
699 |
BB 83857
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
700 |
BB 84234
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
701 |
BB 84416
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
702 |
BB 84518
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
703 |
BB 84887
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
704 |
BB 84888
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
705 |
BB 85035
|
Peptide deformylase inhibitor |
2002 |
Preclinical |
706 |
BL2060
|
Antimicrobial peptide (peptidomimetic oligomer) |
2008 |
Preclinical |
707 |
Oleuropein
|
Phenolic sarcolid antioxidant |
2005 |
|
708 |
Neopyrrolomycin
|
Phenylpyrrole |
1994 |
Preclinical |
709 |
BAL0030543
|
Dihydrofolate reductase inhibitor |
2007 |
Preclinical |
710 |
A82810
|
Polyether |
1989 |
|
711 |
CP-73064
|
Polyether |
1989 |
|
712 |
GL 047374
|
Polyheterocyclic amide |
2001 |
Preclinical |
713 |
GL 118172
|
Polyheterocyclic amide |
2001 |
Preclinical |
714 |
GL 243287
|
Polyheterocyclic amide |
2001 |
Preclinical |
715 |
GL 359986
|
Polyheterocyclic amide |
2001 |
Preclinical |
716 |
GL 478057
|
Polyheterocyclic amide |
2001 |
Preclinical |
717 |
GL 48087
|
Polyheterocyclic amide |
2001 |
Preclinical |
718 |
GL 521997
|
Polyheterocyclic amide |
2001 |
Preclinical |
719 |
GL 548043
|
Polyheterocyclic amide |
2001 |
Preclinical |
720 |
GL 568816
|
Polyheterocyclic amide |
2001 |
Preclinical |
721 |
GL 579225
|
Polyheterocyclic amide |
2001 |
Preclinical |
722 |
GL 663142
|
Polyheterocyclic amide |
2001 |
Preclinical |
723 |
GL 700241
|
Polyheterocyclic amide |
2001 |
Preclinical |
724 |
GL 701649
|
Polyheterocyclic amide |
2001 |
Preclinical |
725 |
GL 703027
|
Polyheterocyclic amide |
2001 |
Preclinical |
726 |
GL 832293
|
Polyheterocyclic amide |
2001 |
Preclinical |
727 |
GL 886217
|
Polyheterocyclic amide |
2001 |
Preclinical |
728 |
GL 898298
|
Polyheterocyclic amide |
2001 |
Preclinical |
729 |
Tolevamer
|
Polymer |
2000 |
Phase 3 |
730 |
CB-182804, CB-182,804
|
Polymyxin |
2010 |
Phase 1 |
731 |
Trospectomycin (U 63366 F)
|
Aminoglycoside |
1984 |
Phase 3 |
732 |
Decaplanin (M 861410)
|
Glycopeptide |
1991 |
Preclinical |
733 |
PNU-179004
|
Oxazolidinone |
1999 |
Preclinical |
734 |
PNU-171832
|
Oxazolidinone |
1999 |
Preclinical |
735 |
PNU-173954
|
Oxazolidinone |
1999 |
Preclinical |
736 |
PNU-176665
|
Oxazolidinone |
1999 |
Preclinical |
737 |
PNU-179954
|
Oxazolidinone |
1999 |
Preclinical |
738 |
PNU-288034
|
Oxazolidinone |
2002 |
Phase 1 |
739 |
S-6123
|
Oxazolidinone |
1987 |
Preclinical |
740 |
DuP 105
|
Oxazolidinone |
1987 |
Phase 1 |
741 |
DuP 721
|
Oxazolidinone |
1987 |
Phase 1 |
742 |
FMA 0122
|
Macrolide (14-membered macrolide) |
1999 |
Preclinical |
743 |
FMA 0713
|
Macrolide (14-membered macrolide) |
1999 |
Preclinical |
744 |
FMA 122
|
Macrolide (14-membered macrolide) |
1999 |
Preclinical |
745 |
FMA-1485
|
Macrolide (14-membered macrolide, ketolide) |
1999 |
Preclinical |
746 |
FMA199
|
Macrolide (14-membered macrolide) |
1999 |
Preclinical |
747 |
FMA481
|
Macrolide (14-membered macrolide) |
1999 |
Preclinical |
748 |
TEA 0929
|
Macrolide (14-membered macrolide) |
1999 |
Preclinical |
749 |
EP 12344
|
Macrolide (ketolide) |
2003 |
Preclinical |
750 |
A-217213
|
Macrolide (ketolide) |
2001 |
Preclinical |
751 |
CP 642959
|
Macrolide (ketolide) |
2001 |
Preclinical |
752 |
GI-448
|
Macrolide (ketolide) |
2001 |
Preclinical |
753 |
HMR 3004
|
Macrolide (ketolide) |
1996 |
Phase 2 |
754 |
HMR 3787 (RU64399)
|
Macrolide (ketolide) |
1999 |
Preclinical |
755 |
CGP7040
|
Rifamycin |
1987 |
Preclinical |
756 |
HMR 3562
|
Macrolide (ketolide) |
1999 |
Preclinical |
757 |
Eperezolid
|
Oxazolidinone |
1995 |
Phase 3 |
758 |
PNU-173995
|
Oxazolidinone |
2001 |
Preclinical |
759 |
A-40,926 (MDL 63042)
|
Glycopeptide |
2002 |
Preclinical |
760 |
Vertilmicin
|
Aminoglycoside |
2010 |
Preclinical |
761 |
MDL 62879
|
Protein synthesis inhibitor |
1993 |
Preclinical |
762 |
PD 155392
|
Protein synthesis inhibitor (boxazomycin derivative) |
1995 |
Preclinical |
763 |
PD 149060
|
Protein synthesis inhibitor (boxazomycin derivative) |
1995 |
Preclinical |
764 |
Boxazomycin B
|
Protein synthesis inhibitor (boxazomycin derivative) |
1995 |
Preclinical |
765 |
AM-3005
|
Mutilin-quinolone hybrid |
2008 |
Preclinical |
766 |
Antibiotic 89-07
|
Aminoglycoside |
1995 |
Preclinical |
768 |
EP 1304
|
Macrolide (ketolide) |
2003 |
Preclinical |
769 |
VRC 4219
|
Protein synthesis inhibitor |
2001 |
Preclinical |
770 |
EP 13159
|
Macrolide (ketolide) |
2003 |
Preclinical |
771 |
EP-13417
|
Macrolide (ketolide) |
2003 |
Preclinical |
772 |
EP-13420
|
Macrolide (ketolide) |
2003 |
Preclinical |
773 |
TP-271
|
Tetracycline |
2010 |
Preclinical |
774 |
WAY 152288
|
Tetracycline |
1998 |
Preclinical |
775 |
GINA-220
|
Protein synthesis inhibitor |
2005 |
Preclinical |
776 |
GINA-301
|
Protein synthesis inhibitor |
2005 |
Preclinical |
777 |
CL-329998 (DMG-MINO)
|
Glycylcycline |
1993 |
Preclinical |
778 |
CL-331002 (DMG-DMDOT)
|
Glycylcycline |
1993 |
Preclinical |
779 |
CHIR 281
|
Macrolide (ketolide) |
2003 |
Preclinical |
780 |
CHIR 787
|
Macrolide (ketolide) |
2003 |
Preclinical |
781 |
EP 13543
|
Macrolide (ketolide) |
2003 |
Preclinical |
782 |
EP 1562
|
Macrolide (ketolide) |
2003 |
Preclinical |
783 |
Difficidin
|
Protein synthesis inhibitor |
1986 |
Preclinical |
784 |
Oxydifficidin
|
Protein synthesis inhibitor |
1986 |
Preclinical |
785 |
Sorangicin A
|
RNA Polymerase inhibitor |
1986 |
|
786 |
A-63075
|
Macrolide |
1987 |
Preclinical |
787 |
LY281389
|
Macrolide |
1989 |
Preclinical |
788 |
SCH 37644
|
Macrolide |
1987 |
Preclinical |
789 |
TE-802
|
Macrolide |
1995 |
Preclinical |
790 |
YM133 (IMC-XV)
|
Macrolide |
1990 |
Preclinical |
791 |
BAL19403
|
Macrolide |
2006 |
Phase 1 |
792 |
YM 17K (MC 352)
|
Macrolide |
1991 |
Phase 2 |
793 |
A-72299
|
Macrolide |
1990 |
|
794 |
A-74950
|
Macrolide |
1990 |
|
795 |
A-75835
|
Macrolide |
1990 |
|
797 |
acpP PMO
|
Phosphorodiamidate morpholino oligomer (PMO) |
2004 |
Preclinical |
798 |
VIC-106632
|
Oxazolidinone |
2005 |
Preclinical |
799 |
VIC-106675
|
Oxazolidinone |
2005 |
Preclinical |
800 |
VIC-106701
|
Oxazolidinone |
2005 |
Preclinical |
801 |
VIC-106734
|
Oxazolidinone |
2005 |
Preclinical |
802 |
VIC-106822
|
Oxazolidinone |
2005 |
Preclinical |
803 |
VIC-106828
|
Oxazolidinone |
2005 |
Preclinical |
804 |
VIC-106841
|
Oxazolidinone |
2005 |
Preclinical |
805 |
VIC-106871
|
Oxazolidinone |
2005 |
Preclinical |
806 |
VIC-106922
|
Oxazolidinone |
2005 |
Preclinical |
807 |
DA-7686
|
Oxazolidinone |
2000 |
Preclinical |
808 |
Imidazole-Benzoxazinyl-Oxazolidonones
|
Oxazolidinone |
2000 |
Preclinical |
809 |
OCHID 0619
|
Oxazolidinone |
2011 |
Preclinical |
810 |
Oxazolidinones with acetaminomethyl side chains
|
Oxazolidinone |
2000 |
Preclinical |
811 |
PF-00422602
|
Oxazolidinone |
2006 |
Preclinical |
812 |
PF-987296
|
Oxazolidinone |
2006 |
Preclinical |
813 |
PNU-177553
|
Oxazolidinone |
2001 |
Preclinical |
814 |
PNU-182347
|
Oxazolidinone |
2000 |
Preclinical |
815 |
Ranbezolid (RBx 7644)
|
Oxazolidinone |
2004 |
Preclinical |
816 |
RWJ 306490
|
Oxazolidinone |
2000 |
Preclinical |
818 |
Rx-01 series: Rx-01_413
|
Oxazolidinone |
2005 |
Preclinical |
819 |
Rx-01 series: Rx-01_445
|
Oxazolidinone |
2005 |
Preclinical |
820 |
Radezolid
|
Oxazolidinone |
2005 |
Preclinical |
821 |
Rx-01_423
|
Oxazolidinone |
2005 |
Preclinical |
822 |
VRC-3055
|
Oxazolidinone |
2000 |
Preclinical |
823 |
VRC-3406
|
Oxazolidinone |
2000 |
Preclinical |
824 |
VRC-3599
|
Oxazolidinone |
2000 |
Preclinical |
825 |
VRC-3808
|
Oxazolidinone |
2001 |
Preclinical |
826 |
VRC-3816
|
Oxazolidinone |
2000 |
Preclinical |
827 |
VRC-3923
|
Oxazolidinone |
2001 |
Preclinical |
828 |
VRC-4003
|
Oxazolidinone |
2001 |
Preclinical |
829 |
VRC3054
|
Oxazolidinone |
2000 |
Preclinical |
830 |
VRC3889
|
Oxazolidinone |
2000 |
Preclinical |
833 |
RWJ-416457
|
Oxazolidinone |
2002 |
Preclinical |
834 |
OCID 0050
|
Oxazolidinone |
2003 |
Preclinical |
835 |
VRC 3807
|
Oxazolidinone |
2003 |
Preclinical |
836 |
VRC 3924
|
Oxazolidinone |
2003 |
Preclinical |
837 |
VRC-3125
|
Oxazolidinone |
2002 |
Preclinical |
838 |
VRC-3783
|
Oxazolidinone |
2002 |
Preclinical |
839 |
VRC-4228
|
Oxazolidinone |
2002 |
Preclinical |
840 |
Paldimycin (U-70138F)
|
Paulomycin |
1986 |
|
841 |
Thiocillin
|
Antimicrobial peptide (protein synthesis inhibitor) |
1990 |
|
842 |
VIC-105535
|
Oxazolidinone |
2005 |
Preclinical |
843 |
SB-264128
|
Pleuromutilin |
2000 |
Preclinical |
844 |
SB-247386
|
Pleuromutilin |
1999 |
Preclinical |
845 |
SB-268091
|
Pleuromutilin |
1999 |
|
846 |
Rx100472
|
Aminoacyl-tRNA synthetase inhibitor (methionyl tRNA synthetase [MetRS] inhibitor , pyrimidine) |
2008 |
Preclinical |
847 |
RBX 8700
|
Oxazolidinone |
2004 |
Preclinical |
848 |
Efepristin
|
Streptogramin |
1995 |
Phase 2 |
849 |
VIC-104742
|
Oxazolidinone |
2005 |
Preclinical |
850 |
VIC-105277
|
Oxazolidinone |
2005 |
Preclinical |
851 |
Bederocin
|
Aminoacyl-tRNA synthetase inhibitor (methionyl tRNA synthetase [MetRS] inhibitor) |
2004 |
Phase 1 |
852 |
EP 1350
|
Macrolide (16-membered macrolide, tylosine derivative) |
2003 |
Preclinical |
853 |
MCB-3681 (prodrug of MCB3837)
|
Oxazolidinone-quinolone |
2006 |
|
854 |
ABX-96
|
Oxazolidinone |
2001 |
Preclinical |
855 |
Tan 1057
|
Protein synthesis inhibitor (dipeptide) |
2001 |
Preclinical |
856 |
BC-3205
|
Pleuromutilin |
2009 |
Phase 1 |
857 |
Timcodar
|
Efflux pump inhibitor (pyridine) |
2009 |
Preclinical |
858 |
Pyrroindomicin A and B
|
Pyrroindomicin |
1993 |
Preclinical |
859 |
A-77143
|
Quinolone |
1992 |
Preclinical |
860 |
Cyclothialidine (Ro 09-1437)
|
Quinolone |
1992 |
Preclinical |
861 |
DN3 27-1
|
Quinolone |
1997 |
Preclinical |
863 |
E-4767
|
Quinolone |
1993 |
Preclinical |
864 |
NM-394
|
Quinolone |
1992 |
Preclinical |
865 |
PD-117558
|
Fluoroquinolone |
1986 |
Preclinical |
867 |
Ro091168
|
Quinolone |
1991 |
Preclinical |
868 |
S-31076
|
Quinolone |
1993 |
Preclinical |
869 |
U-87947
|
Quinolone |
1991 |
Preclinical |
870 |
U-91939E
|
Quinolone |
1991 |
Preclinical |
871 |
WQ 0835
|
Quinolone |
1995 |
Preclinical |
872 |
WQ 1197
|
Quinolone |
1992 |
Preclinical |
873 |
WQ 2128
|
Quinolone |
1994 |
Preclinical |
874 |
WQ1101
|
Quinolone |
1991 |
Preclinical |
875 |
WQ175
|
Quinolone |
1992 |
Preclinical |
876 |
Y-34867
|
Quinolone |
1998 |
Preclinical |
877 |
CS-940
|
Fluoroquinolone |
1993 |
Phase 2 |
878 |
Y-25024
|
Quinolone |
1988 |
|
879 |
SEP-132617
|
Quinoline-indole |
1999 |
Preclinical |
880 |
SEP-32196
|
Quinoline-indole |
1999 |
Preclinical |
881 |
SEP 118843
|
Quinoline-indole |
2000 |
Preclinical |
882 |
SEP 137199
|
Quinoline-indole |
2000 |
Preclinical |
883 |
SEP 147960
|
Quinoline-indole |
2000 |
Preclinical |
884 |
SEP 155342
|
Quinoline-indole |
2000 |
Preclinical |
885 |
SEP 155347
|
Quinoline-indole |
2000 |
Preclinical |
886 |
SEP 156117
|
Quinoline-indole |
2000 |
Preclinical |
887 |
SEP 156131
|
Quinoline-indole |
2000 |
Preclinical |
888 |
PGE 7119699
|
Quinolonyl-carbacephem |
1997 |
Preclinical |
890 |
CP111905-00
|
Hygromycin A |
1992 |
Preclinical |
891 |
Rifaquizinone
|
Rifamycin-quinolone hybrid |
2007 |
Phase 2 (NCT03964493) |
892 |
ABI-0010N
|
Rifamycin |
2004 |
Preclinical |
893 |
ABI-0047N
|
Rifamycin |
2004 |
Preclinical |
894 |
ABI-0185N
|
Rifamycin |
2004 |
Preclinical |
895 |
ABI-0197N
|
Rifamycin |
2004 |
Preclinical |
896 |
GSQ 10547
|
RNA synthesis inhibitor (hetero ARomatic Polyamide [HARP]) |
2001 |
Preclinical |
897 |
GSQ 11203
|
RNA synthesis inhibitor (hetero ARomatic Polyamide [HARP]) |
2001 |
Preclinical |
898 |
GSQ 2287
|
RNA synthesis inhibitor (hetero ARomatic Polyamide [HARP]) |
2001 |
Preclinical |
899 |
GSQ 5028
|
RNA synthesis inhibitor (hetero ARomatic Polyamide [HARP]) |
2001 |
Preclinical |
900 |
GSQ 7302
|
RNA synthesis inhibitor (hetero ARomatic Polyamide [HARP]) |
2001 |
Preclinical |
901 |
s-Triazines compounds
|
s-Triazine |
2009 |
Preclinical |
902 |
AM-114
|
Beta-lactamase inhibitor (oxapenem) |
2002 |
Preclinical |
903 |
RP 106,972
|
Streptogramin |
1997 |
Preclinical |
905 |
RP 74501/RP 74502
|
Streptogramin |
1992 |
Phase 1 |
906 |
Reutericyclin Analogue: 867
|
Tetramic acid |
2010 |
Preclinical |
907 |
Reutericyclin Analogue: 1135
|
Tetramic acid |
2010 |
Preclinical |
908 |
Reutericyclin Analogue: 1137
|
Tetramic acid |
2010 |
Preclinical |
909 |
Reutericyclin Analogue: 1138
|
Tetramic acid |
2010 |
Preclinical |
910 |
Reutericyclin Analogue: 1139
|
Tetramic acid |
2010 |
Preclinical |
911 |
RM4809
|
Thiazolide |
|
Preclinical |
912 |
RM4807
|
Thiazolide |
2005 |
|
913 |
MDL 63246
|
Glycopeptide, thiazolopeptide |
1993 |
Preclinical |
914 |
Nocathiacin I
|
Thiazolyl peptide |
2003 |
Preclinical |
915 |
BMS-411886 (Water Soluble analogue of BMS-249524)
|
Thiazolyl peptide |
2003 |
Preclinical |
916 |
BMS-461996 (Water Soluble analogue of BMS-249524)
|
Thiazolyl peptide |
2003 |
Preclinical |
917 |
A10255
|
Thiopeptide |
1989 |
|
918 |
NXL101
|
Quinolone |
2005 |
Phase 1 |
919 |
CNH365.396
|
Tricyclic dione ester |
2012 |
Preclinical |
920 |
Tripropeptin A
|
Tripropeptin lipodepsipeptide |
2005 |
|
921 |
Tripropeptin B
|
Tripropeptin lipodepsipeptide |
2005 |
|
923 |
Tripropeptin D
|
Tripropeptin lipodepsipeptide |
2005 |
|
924 |
Tripropeptin E
|
Tripropeptin lipodepsipeptide |
2005 |
|
925 |
Tripropeptin Z
|
Tripropeptin lipodepsipeptide |
2005 |
|
926 |
CB 102930
|
Aminoacyl-tRNA synthetase inhibitor (phenylanalyl-tRNA synthetase [PheRS] inhibitor) |
2001 |
Preclinical |
927 |
AM-1939
|
Fluoroquinolone |
2003 |
Preclinical |
928 |
CP-74667
|
Fluoroquinolone |
1991 |
Preclinical |
929 |
WIN 57273
|
Fluoroquinolone |
1989 |
Preclinical |
930 |
WQ-2724
|
Fluoroquinolone |
1997 |
Preclinical |
931 |
WQ-2743
|
Fluoroquinolone |
1997 |
Preclinical |
932 |
Ecenofloxacin (CFC-222)
|
Fluoroquinolone |
1995 |
Phase 1 |
933 |
Amifloxacin
|
Fluoroquinolone |
|
Phase 2 |
934 |
Bay Y3118
|
Fluoroquinolone |
1992 |
Phase 2 |
935 |
BMY 43748
|
Fluoroquinolone |
1991 |
Preclinical |
936 |
Grepafloxacin
|
Fluoroquinolone |
1991 |
Approved by FDA in 1997 |
937 |
Difloxacin
|
Fluoroquinolone |
|
Phase 2 |
938 |
AM-1174
|
Fluoroquinolone |
1990 |
Preclinical |
939 |
Y-26611
|
Fluoroquinolone |
1990 |
Phase 2 |
940 |
Gatifloxacin
|
Fluoroquinolone |
1992 |
Approved by FDA in 2010 |
944 |
CP-67,015
|
Quinolone |
1987 |
Preclinical |
946 |
PD 124816
|
Quinolone |
1988 |
Preclinical |
948 |
Citreamicin α
|
Xanthone |
1988 |
Preclinical |
949 |
Citreamicin β
|
Xanthone |
1988 |
Preclinical |
950 |
Vermisporin
|
Xanthone |
1990 |
Preclinical |
951 |
D2A22
|
Synthetic peptide |
2003 |
|
952 |
Sanfetrinem
|
Beta-lactam (tribactam) |
1992 |
Phase 2 (NCT05388448) |
953 |
SRI-011225
|
Beta-lactam |
2012 |
Preclinical |
954 |
T-5575
|
Beta-lactam (carboxypenam) |
1992 |
Preclinical |
955 |
T-5578
|
Beta-lactam (carboxypenam) |
1992 |
Preclinical |
956 |
GD-40
|
Beta-lactamase inhibitor |
1996 |
Preclinical |
957 |
MC-207252
|
Antibiotic adjuvant |
1995 |
Preclinical |
958 |
Ro 48-1256
|
Beta-lactamase inhibitor (monobactam) |
1995 |
Preclinical |
959 |
Ro 481220
|
Beta-lactamase inhibitor (penicillanic acid sulfone) |
1994 |
Preclinical |
960 |
Syn-2190
|
Beta-lactamase inhibitor (monobactam) |
1997 |
Preclinical |
961 |
BRL-42715
|
Beta-lactamase inhibitor (penem) |
1987 |
Phase 1 |
962 |
CP-72,193
|
Beta-lactamase inhibitor |
1988 |
|
963 |
RWJ 157479
|
Beta-lactamase inhibitor |
1999 |
|
964 |
LEK-157
|
Beta-lactamase inhibitor (carbapenem) |
2007 |
Preclinical |
965 |
BLI-489
|
Beta-lactamase inhibitor (carbapenem) |
2007 |
Phase 1 |
967 |
J110441
|
Beta-lactamase inhibitor (methylcarbapenem) |
1999 |
Preclinical |
968 |
2-aminoquinolone
|
|
2008 |
Preclinical |
969 |
A63483
|
|
1989 |
Preclinical |
970 |
Aryl Rhodanine
|
|
2008 |
Preclinical |
971 |
ATWL25
|
|
2008 |
Preclinical |
972 |
CB-182575
|
|
2008 |
Preclinical |
973 |
CX1 (para-guanidinoethylcalix[4]arene)
|
|
2008 |
Preclinical |
974 |
Dihydroxybenzofuran
|
|
2008 |
Preclinical |
975 |
EXEG1706
|
|
2003 |
Preclinical |
976 |
MBX-1066
|
Small molecule |
2009 |
|
977 |
VRC 5264
|
|
2002 |
Preclinical |
978 |
Squalamine
|
|
1996 |
Phase 2 |
979 |
Aldeomycin
|
|
1989 |
|
980 |
Chloraziomycin
|
|
1989 |
|
981 |
Leinamycin, DC107
|
|
1990 |
|
982 |
MC21A
|
|
2001 |
|
983 |
Poststatin
|
|
1990 |
|
984 |
SB22484
|
|
1989 |
|
985 |
Ferrimycin A
|
Sideromycin |
1960 |
Preclinical |
986 |
N-methyl/ethyl-lincomycin stereochemical derivatives
|
Lincosamide |
1965 |
Preclinical |
987 |
Ziracin
|
Aminoglycoside |
1965 |
Phase 3 |
988 |
Phleomycin
|
Glycopeptide |
|
Preclinical |
989 |
Actinocyl-gramicidin S
|
Gramicidin |
1966 |
Preclinical |
990 |
Hedamycin
|
Pluramycin |
1966 |
|
991 |
Coumermycin A1
|
Aminocoumarin |
1966 |
|
992 |
Cirolemycin
|
|
1967 |
Preclinical |
993 |
1,2,5-Selenadiazole derivatives, Inc: NSC 93169
|
|
1966 |
Preclinical |
994 |
1,2,5-Selenadiazole derivatives, Inc: NSC 84963
|
|
1966 |
Preclinical |
995 |
LL-RA6950-BA
|
|
1965 |
Preclinical |
996 |
LL-RA6950-BB
|
|
1965 |
Preclinical |
997 |
LL-AE705-Y
|
Quinone |
1965 |
Preclinical |
998 |
Rancomycin 1 (U-22583)
|
Lincosamide |
1967 |
Preclinical |
999 |
Rancomycin 2 (U-25873)
|
Lincosamide |
1967 |
Preclinical |
1000 |
Biphenomycin A (LL-AF283α)
|
Biphenomycin |
1967 |
Preclinical |
1001 |
Halomicin complex
|
Ansamycin |
1967 |
Preclinical |
1002 |
LL-AB 664
|
Steptothricin |
1967 |
Preclinical |
1003 |
N-methoxy-benzylpenicillinamide
|
Beta-lactam (penicillin) |
1967 |
Preclinical |
1004 |
N-ethoxy-benzylpenicillinamide
|
Beta-lactam (penicillin) |
1967 |
Preclinical |
1005 |
N-propoxy-benzylpenicillinamide
|
Beta-lactam (penicillin) |
1967 |
Preclinical |
1006 |
N-methoxy-phenoxymethylpenicillinamide
|
Beta-lactam (penicillin) |
1967 |
Preclinical |
1007 |
N-methoxy-(2,6-dimethoxyphenyl)penicillinamide
|
Beta-lactam (penicillin) |
1967 |
Preclinical |
1008 |
N-benzyloxy-benzylpenicillinamide
|
Beta-lactam (penicillin) |
1967 |
Preclinical |
1009 |
Furazolium Chloride/ NF-963
|
Nitrofuran |
1967 |
Preclinical |
1010 |
2-Nitroimidazole derivatives
|
Nitroimidazole |
1967 |
Preclinical |
1011 |
LL-Z1220
|
Natural product antibiotic |
1969 |
Preclinical |
1012 |
Aliphatic acylamido derivatives of Coumermycin A1
|
Aminocoumarin |
1969 |
Preclinical |
1013 |
SQ 18506
|
Nitrofuran |
1969 |
Preclinical |
1014 |
Mannosidostreptomycin (Streptomycin analogue)
|
Aminoglycoside |
1969 |
Preclinical |
1015 |
Meonomycin complex A
|
Moenomycin |
1965 |
Preclinical |
1016 |
Meonomycin complex B
|
Moenomycin |
1965 |
Preclinical |
1017 |
Meonomycin complex C
|
Moenomycin |
1965 |
Preclinical |
1018 |
Meonomycin complex D
|
Moenomycin |
1965 |
Preclinical |
1019 |
C-73X
|
Natural small molecule |
1966 |
Preclinical |
1020 |
CIBA 36278A-Ba
|
Beta-lactam (cephalosporin) |
1970 |
Preclinical |
1022 |
6-methoxy-1-phenazinol 5,10-dioxide cupric complex
|
|
1970 |
Preclinical |
1023 |
Nifuratrone (N-(2-hydroxyethyl)-a-(5.nitro-2-furyl) nitrone)
|
|
1970 |
Preclinical |
1024 |
BL-P 1654
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1026 |
Acetoxymethyl ester of Ampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1027 |
Propionyloxymethyl ester of Ampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1028 |
n-Butyryloxymethyl ester of Ampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1029 |
Isobutyryloxymethyl ester of Ampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1030 |
Pivampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1031 |
Alpha-Ethyl-n-butyryloxymethyl ester of Ampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1032 |
Benzoyloxymethyl ester of Ampicillin
|
Beta-lactam (penicillin) |
1970 |
Preclinical |
1033 |
7-Methoxy Cephalosporin Derivatives
|
Beta-lactam (cephalosporin) |
1973 |
Preclinical |
1034 |
Verdamicin
|
Aminoglycoside |
1993 |
Preclinical |
1036 |
Novel aminoglycosides from garamine
|
Aminoglycoside |
1974 |
Preclinical |
1038 |
A2315A (madumycin II)
|
Virginiamycin |
1974 |
Preclinical |
1039 |
Cefazaflur, SKF 59962
|
Beta-lactam (cephalosporin) |
1974 |
Preclinical |
1040 |
FR10612
|
Beta-lactam (cephalosporin) |
1974 |
Preclinical |
1042 |
Antibiotic XK-88-1
|
Aminoglycoside |
1975 |
Preclinical |
1043 |
Seldomycin factor 2
|
Aminoglycoside |
1975 |
Preclinical |
1044 |
Seldomycin factor 3
|
Aminoglycoside |
1975 |
Preclinical |
1045 |
Seldomycin factor 5
|
Aminoglycoside |
1975 |
Preclinical |
1046 |
Nocardin
|
Beta-lactam (monobactam) |
1975 |
Phase 4 |
1047 |
Fludalanine/pentizadone
|
D-alanine racemase inhibitor |
1975 |
Preclinical |
1048 |
Pirbenicillin
|
Beta-lactam (penicillin) |
1975 |
Preclinical |
1049 |
PC-455
|
Beta-lactam (penicillin) |
1975 |
Preclinical |
1050 |
Apalcillin (PC-904)
|
Beta-lactam (penicillin) |
1975 |
Preclinical |
1051 |
CP-32,656
|
Ansamycin |
1976 |
Preclinical |
1052 |
Feldamycin
|
Aminoglycoside |
1976 |
Preclinical |
1053 |
Nojirimycin
|
Aminoglycoside |
1976 |
Preclinical |
1054 |
Etheromycin
|
Aminoglycoside |
1976 |
Preclinical |
1055 |
Narasin
|
Diterpene glycoside |
1976 |
Preclinical |
1056 |
A35512 complex, including A35512B
|
Glycopeptide |
1977 |
Preclinical |
1057 |
Thiacycline
|
Tetracycline |
1977 |
|
1058 |
EMD32412
|
Beta-lactam (penicillin) |
1977 |
Preclinical |
1059 |
Epithienamycin
|
Beta-lactam (carbapenem) |
1977 |
|
1060 |
Butikacin
|
Aminoglycoside |
1977 |
Preclinical |
1061 |
Cefsulodin
|
Beta-lactam (cephalosporin) |
1977 |
Phase 4 |
1062 |
Sulbactam + Carbenicillin
|
Drug combination: beta-lactam (Penicillin) + beta-lactamase inhibitor |
1978 |
Preclinical |
1063 |
Indanomycin
|
Ionophore |
1978 |
|
1064 |
Enocin
|
Natural product antibiotic |
1978 |
|
1065 |
Dipeptide variants of Alafosfalin
|
Phosphonodipeptide |
1979 |
Preclinical |
1066 |
Alafosfalin
|
Phosphonodipeptide |
1979 |
Preclinical |
1067 |
CI-867
|
Beta-lactam (penicillin) |
1979 |
Preclinical |
1068 |
SCH 24893
|
Phenicol |
1979 |
Preclinical |
1069 |
SCH 25393
|
Phenicol |
1979 |
Preclinical |
1070 |
SCH 24298
|
Phenicol |
1979 |
Preclinical |
1071 |
Propikacin
|
Aminoglycoside |
1979 |
Preclinical |
1072 |
DJ 6783
|
Quinolone |
1979 |
Preclinical |
1073 |
CP-47,433
|
Polycyclic ether antibiotic |
1979 |
Preclinical |
1074 |
CP-47,434
|
Polycyclic ether antibiotic |
1979 |
Preclinical |
1075 |
Glysperin complex A
|
Atypical aminoglycoside |
1980 |
Preclinical |
1076 |
Glysperin complex B
|
Atypical aminoglycoside |
1980 |
Preclinical |
1077 |
Glysperin complex C
|
Atypical aminoglycoside |
1980 |
Preclinical |
1078 |
MS-19-Q
|
Macrolide |
1980 |
Preclinical |
1079 |
Noboritomycin A
|
Halogen containing polyether antibiotic |
1980 |
|
1080 |
EMD 39734
|
Beta-lactam |
1980 |
|
1081 |
Carpetimycin A
|
Carbapenem (with beta-lactamase inhibitor properties) |
1980 |
|
1082 |
Carpetimycin B
|
Carbapenem (with beta-lactamase inhibitor properties) |
1980 |
|
1083 |
E-0702 antibiotic
|
Beta-lactam |
1981 |
|
1084 |
Lysinomicin
|
Aminoglycoside |
1981 |
|
1087 |
SK&F 88070
|
Beta-lactam |
1981 |
|
1088 |
Cefatiolene
|
Beta-lactam |
1981 |
|
1089 |
FCE21420
|
Beta-lactam |
1981 |
|
1090 |
Thiosporamicin
|
Thiostrepton |
1982 |
Preclinical |
1091 |
Maduramicin
|
Polyether antibiotic |
1982 |
Preclinical |
1092 |
X-14868B
|
Polyether antibiotic |
1982 |
Preclinical |
1093 |
X-14868C
|
Polyether antibiotic |
1982 |
Preclinical |
1094 |
X-14868D
|
Polyether antibiotic |
1982 |
Preclinical |
1095 |
X-14868G
|
Polyether antibiotic |
1986 |
Preclinical |
1096 |
X-14868H
|
Polyether antibiotic |
1986 |
Preclinical |
1097 |
Cationomycin
|
Polyether antibiotic |
1982 |
Preclinical |
1098 |
L-681,217
|
Efrotomycin |
1982 |
Preclinical |
1099 |
Cefpimizole
|
Beta-lactam |
1982 |
|
1100 |
Sch 29482
|
Beta-lactam |
1982 |
Phase 1 |
1102 |
OA-6129 D + E
|
Beta-lactam (carbapenem) |
1982 |
Preclinical |
1103 |
Pluracidomycin
|
Beta-lactam (carbapenem) |
1982 |
|
1104 |
L-640876
|
Beta-lactam (cephalosporin) |
1982 |
|
1105 |
SQ 81,377
|
Beta-lactam (monobactam) |
1982 |
|
1106 |
Sarafloxacin
|
Quinolone |
1984 |
Phase 4 |
1109 |
Chlorocardicin
|
Beta-lactam |
1984 |
Preclinical |
1111 |
LY171217
|
Beta-lactam (cephalosporin) |
1984 |
Preclinical |
1112 |
Antibiotic 87-351
|
Aminoglycoside |
1984 |
Preclinical |
1113 |
CGP 17520
|
Beta-lactam (cephalosporin) |
1984 |
Preclinical |
1114 |
DN-9550
|
Beta-lactam (cephalosporin) |
1984 |
Preclinical |
1115 |
SCH 34343
|
Beta-lactam (cephalosporin) |
1984 |
Preclinical |
1116 |
Spenolimycin
|
Aminocyclitol |
1984 |
Preclinical |
1117 |
Biphenomycin A
|
Peptide antibiotic |
1984 |
Preclinical |
1118 |
Biphenomycin B
|
Peptide antibiotic |
1984 |
Preclinical |
1119 |
Ibafloxacin
|
Quinolone |
1984 |
Preclinical |
1120 |
CL 118523
|
Beta-lactam (cephalosporin) |
1984 |
Preclinical |
1121 |
3’-quaternary ammonium Cephalosporins
|
Beta-lactam (cephalosporin) |
1984 |
Preclinical |
1122 |
Tigemonam
|
Beta-lactam (monobactam) |
1985 |
Preclinical |
1123 |
Formidacillin
|
Beta-lactam |
1985 |
Preclinical |
1124 |
AT-3765
|
Quinolone |
1985 |
Preclinical |
1125 |
LY164846
|
Beta-lactam (cephalosporin) |
1985 |
Preclinical |
1126 |
M119-a
|
Macrolide |
1985 |
Preclinical |
1127 |
SC-44914
|
Quinoxaline |
1991 |
Preclinical |
1128 |
E-4695
|
Quinolone |
1991 |
Preclinical |
1129 |
HSR-501
|
Quinolone |
1991 |
Preclinical |
1130 |
Sanfetrinem cilexetil
|
Beta-lactam |
1992 |
Phase 2 |
1131 |
Fluoroshikimic acid
|
Aromatase inhibitor |
1993 |
Preclinical |
1132 |
E 1101
|
Beta-lactam (cephalosporin) |
1993 |
Preclinical |
1133 |
SYN987
|
Quinolone |
1993 |
Preclinical |
1134 |
BMS-180680
|
Beta-lactam (monobactam) |
1994 |
Phase 2 |
1135 |
DZ-2640
|
Beta-lactam (carbapenem) |
1995 |
Preclinical |
1136 |
Fandofloxacin
|
Fluoroquinolone |
1995 |
Preclinical |
1137 |
SYN 1903
|
Beta-lactamase inhibitor |
1995 |
Preclinical |
1138 |
MEN 10700
|
Beta-lactam (penem) |
1998 |
Preclinical |
1139 |
Cethromycin
|
Ketolide |
1998 |
Preclinical (suspended for Plague ad melidiosis) |
1140 |
AY-60042
|
Tetracycline |
1961 |
Preclinical |
1142 |
Antibiotic 19A
|
|
1961 |
Preclinical |
1143 |
Chalcomycin
|
Macrolide (16-membered macrolide) |
1961 |
Preclinical |
1144 |
Narangomycin
|
|
1961 |
Preclinical |
1145 |
levopropylcillin
|
Beta-lactam (penicillin) |
1961 |
Preclinical |
1146 |
Wy-3206
|
Beta-lactam (penicillin) |
1961 |
Preclinical |
1148 |
SKF 12141 (2-biphenyl penicillin)
|
Beta-lactam (penicillin) |
1961 |
Preclinical |
1149 |
AS17665
|
Nitrofuran |
1962 |
Preclinical |
1150 |
Bluensomycin
|
Aminoglycoside |
1962 |
Preclinical |
1151 |
N-(5-nitro furfurylidene)-1-amino-2-imidazolidinone
|
Nitrofuran |
1963 |
Preclinical |
1152 |
Nifurprazine
|
Nitrofuran |
1963 |
Preclinical |
1153 |
Stravidin
|
Antimicrobial peptide (biotin antimetabolie) |
1963 |
Preclinical |
1154 |
Neutramycin
|
Macrolide |
1963 |
Preclinical |
1155 |
Sarganin
|
Natural product antibiotic |
1963 |
Preclinical |
1156 |
Chonalgin
|
Natural product antibiotic |
1963 |
Preclinical |
1158 |
Almarcetin
|
Natural product antibiotic |
1964 |
Preclinical |
1159 |
Seligocidin
|
Natural small molecule |
1964 |
Preclinical |
1160 |
U-22956
|
Aminoglycoside |
1964 |
Preclinical |
1161 |
MSD-819
|
|
1968 |
Preclinical |
1163 |
BL-S 217
|
Beta-lactam (cephalosporin, first generation) |
1971 |
Preclinical |
1164 |
Maridomycin
|
Macrolide |
1971 |
Preclinical |
1165 |
CP-53,607
|
Polyether ionophore |
1983 |
Preclinical |
1166 |
KY-101
|
Beta-lactam (cephalosporin, second generation) |
1983 |
Preclinical |
1167 |
KY-107
|
Beta-lactam (cephalosporin, second generation) |
1983 |
Preclinical |
1168 |
KY-109
|
Beta-lactam (cephalosporin, second generation) |
1983 |
Preclinical |
1169 |
LL-D4207
|
|
1986 |
Preclinical |
1171 |
RU 44790
|
Beta-lactam (monobactam) |
1986 |
Preclinical |
1172 |
Pyrroxamycin
|
Pyrrolomycin |
1986 |
Preclinical |
1174 |
A-65636
|
Anthramycin |
1987 |
Preclinical |
1175 |
Endusamycin
|
Polycyclic Ether |
1987 |
Preclinical |
1176 |
Ro-239424
|
Beta-lactam (fluoroquinolone-cephalosporin) |
1988 |
Preclinical |
1177 |
PD 117596-2
|
Fluoroquinolone |
1988 |
Preclinical |
1178 |
LY249902
|
Beta-lactam (cephalosporin, carbacephem) |
1989 |
Preclinical |
1179 |
MT 0703S
|
Beta-lactam (cephalosporin) |
1989 |
Preclinical |
1180 |
Ro 09-1428
|
Beta-lactam (cephalosporin) |
1989 |
Preclinical |
1181 |
E19085A
|
|
1990 |
Preclinical |
1182 |
Enduracidin
|
Cell-wall biosynthesis inhibitor |
1970 |
Preclinical |
1183 |
Cetocycline (Chelocardin/Cetotetrin)
|
Tetracycline |
1970 |
Preclinical |
1184 |
Ficellomycin
|
Aziridine |
1976 |
Preclinical |
1185 |
Zoliflodacin
|
Bacterial topoisomerase inhibitor |
2014 |
Phase 3 |
1186 |
Faropenem medoxomil
|
Beta-lactam |
1995 |
Phase 3 (suspended) |
1188 |
MGB-BP-3
|
DNA synthesis inhibitor |
2015 |
Phase 2 (NCT03824795) |
1189 |
CB-618
|
Beta-lactamase inhibitor |
2015 |
Phase 1 |
1190 |
TXA-709, active metabolite TXA-707
|
FtsZ inhibitor |
2015 |
Phase 1 |
1192 |
ACT 387042
|
Bacterial topoisomerase inhibitor |
2015 |
Preclinical |
1193 |
ACT-292706
|
Bacterial topoisomerase inhibitor |
2015 |
Preclinical |
1194 |
Danirixin
|
CXCR2 antagonist |
2015 |
Phase 2 |
1195 |
ML302F
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2015 |
Preclinical |
1196 |
FKI-6801
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2015 |
Preclinical |
1197 |
HT-06
|
Beta-lactam (cephalosporin, carbacephem [loracarbef-conjugate]) |
2015 |
Preclinical |
1198 |
RPX7381
|
Beta-lactamase inhibitor (carbapenemase inhibitor) |
2015 |
Preclinical |
1199 |
CA-824
|
Polymyxin |
2015 |
Preclinical |
1200 |
CA-900
|
Polymyxin |
2015 |
Preclinical |
1201 |
CA-1049
|
Polymyxin |
2015 |
Preclinical |
1202 |
MiBIECT
|
Oxazolidinone |
2015 |
Preclinical |
1203 |
P300847
|
Pyridone |
2015 |
Preclinical |
1204 |
HT-10
|
Lipopeptide-siderophore conjugate |
2015 |
Preclinical |
1205 |
AM-1977
|
Quinolone |
2015 |
Preclinical |
1206 |
REDX04139
|
Bacterial topoisomerase inhibitor |
2015 |
Preclinical |
1207 |
REDX05604
|
Bacterial topoisomerase inhibitor |
2015 |
Preclinical |
1208 |
APY281 (aryl myxopyronin class)
|
|
2016 |
Preclinical |
1209 |
CSE-1034
|
Beta-lactam |
2004 |
Phase 3 (Clinical Trial) |
1210 |
Avarofloxacin
|
Fluoroquinolone |
2008 |
Phase 2 (NCT01128530) |
1211 |
CS-4771
|
|
2014 |
Phase 1 |
1212 |
DS-8587
|
Fluoroquinolone |
2014 |
Phase 1 |
1213 |
DSTA4637S
|
Antibody-antibiotic conjugate |
|
Phase 1 |
1214 |
MET-2
|
Probiotic |
|
Phase 1 |
1215 |
LFF571
|
Antimicrobial peptide |
|
Phase 2 |
1216 |
Cefilavacin, TD-1792
|
Glycopeptide-cephalosporin heterodimer |
|
Phase 3 |
1218 |
Meropenem + Nacubactam (OP0595/ RG6080)
|
Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor (diazabicyclooctane) |
|
Phase 1 |
1219 |
ETX2514SUL (Sulbactam + ETX2514)
|
Drug combination: beta-lactam (carbapenem ) + beta-lactam (sulbactam) + beta-lactamase inhibitor (diazabicyclooctane) |
|
Phase 2 |
1220 |
Imipenem with cilastatin
|
Beta-lactam (thienamycin) |
|
Approved by FDA in 1985 |
1221 |
Cefepime/VNRX-5133
|
Beta-lactamase inhibitor (broad spectrum) |
|
Phase 2 |
1222 |
AIC499
|
Beta-lactam (monobactam) |
|
Phase 2 |
1224 |
SPR994
|
Beta-lactam (carbapenem) |
|
Phase 3 |
1225 |
BOS 228
|
Beta-lactam (monobactam) |
|
Phase 2 |
1226 |
OPS-2071
|
Quinolone |
|
Phase 2 |
1227 |
Zifanocycline
|
Tetracycline |
|
Phase 1 |
1228 |
SPR741
|
Polymyxin |
|
Phase 1 |
1229 |
GSK-3342830, GSK3342830
|
Beta-lactam (cephalosporin) |
|
Phase 1 |
1230 |
Zidebactam + Cefepime
|
Beta-lactam + beta-lactamase inhibitor |
|
Phase 3 (NCT04979806) |
1231 |
Ibezapolstat
|
DNA synthesis inhibitor |
|
Phase 2 |
1232 |
Upleganan
|
Polymyxin |
|
Phase 1 |
1234 |
Debio1453
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
|
Preclinical |
1235 |
GYROX
|
Bacterial topoisomerase inhibitor |
|
Phase 1 |
1237 |
ETX0282CPDP (ETX0282 + cefpodoxime)
|
Beta-lactam (cephalosporin) |
|
Phase 1 |
1239 |
FG-LpxC-LUNG
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
|
Preclinical |
1240 |
FG-LpxC-UTI
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
|
Preclinical |
1241 |
TopESKAPE
|
Bacterial topoisomerase inhibitor |
|
Preclinical |
1242 |
MRX-8
|
Polymyxin |
|
Phase 1 (NCT04649541) |
1245 |
RC-01, T-1228
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
|
Phase 1 |
1246 |
SMT-571 (DDS-01 Series)
|
|
|
Preclinical |
1247 |
VNRX-PBP
|
Cell-wall synthesis inhibitor (beta-lactamase resistant PBP inhibitor) |
|
Preclinical |
1248 |
MDN-0207
|
Antimicrobial peptide (glycosylated lanthipeptide) |
|
Preclinical |
1249 |
Fosfomycin
|
Phosphonic acid antibacterial |
|
Approved by FDA in 1996 |
1250 |
Minocycline
|
Tetracycline |
|
Approved by FDA in 1992 |
1252 |
RX-P2382
|
Pyrrolocytosine |
2018 |
Preclinical |
1253 |
Exebacase, CF-301
|
Bacteriophage lysin |
2015 |
Phase 2 |
1254 |
CRS0540
|
PolC inhibitor (thiadiazole urea derived) |
2019 |
Preclinical |
1255 |
Apigenin
|
Natural flavonoid |
|
Preclinical |
1256 |
Chrysin
|
Natural flavonoid |
|
Preclinical |
1257 |
Kaempferol
|
Natural flavonoid |
|
Preclinical |
1258 |
Hesperetin
|
Natural flavonoid |
|
Preclinical |
1259 |
MBN-101
|
|
2015 |
Phase 2 |
1260 |
AuC1 (gold(III) complex)
|
Gold(III) complex |
2019 |
Preclinical |
1261 |
DA-7310
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
|
Preclinical |
1263 |
Tebipenem
|
Beta-lactam |
2009 |
Phase 3 |
1264 |
WB1
|
2-trifluoroacetonylbenzoxazole ligand |
2019 |
Preclinical |
1265 |
WB2
|
2-trifluoroacetonylbenzoxazole ligand |
2019 |
Preclinical |
1266 |
W3
|
2-trifluoroacetonylbenzoxazole ligand |
2019 |
Preclinical |
1267 |
Ivermectin/Colistin
|
|
2019 |
Preclinical |
1268 |
Lysin GN123/Imipenem
|
|
2019 |
Preclinical |
1269 |
Cycloberberine analogue 5b
|
13-substituted cycloberberine derivative |
2019 |
Preclinical |
1270 |
Cycloberberine analogue 5w
|
13-substituted cycloberberine derivative |
2019 |
Preclinical |
1271 |
AKAO-LpxC
|
Lipopolysaccharide synthesis inhibitor (LpxC inhibitor) |
2017 |
Preclinical |
1272 |
Next-Generation AG
|
Aminoglycoside |
|
Preclinical |
1273 |
Helical AMP
|
Antimicrobial peptide |
|
Preclinical |
1274 |
NBTI
|
Bacterial topoisomerase inhibitor |
|
Preclinical |
1275 |
AGN-BL
|
Beta-lactam |
|
Preclinical |
1276 |
VIS705
|
Antibody-drug conjugate |
|
Preclinical |
1277 |
P128
|
Bacteriophage lysin |
2017 |
Preclinical |
1278 |
Zidebactam
|
Beta-lactamase inhibitor |
2017 |
Phase 1 |
1279 |
NXL-105
|
Cell-wall synthesis inhibitor (PBP2 inhibitor) |
2019 |
Preclinical |
1280 |
ETX'991
|
Cell-wall synthesis inhibitor (PBP3 inhibitor) |
2019 |
Preclinical |
1281 |
ETX'678
|
Cell-wall synthesis inhibitor (PBP3 inhibitor) |
2019 |
Preclinical |
1282 |
ETX'054
|
Cell-wall synthesis inhibitor (PBP3 inhibitor) |
2019 |
Preclinical |
1283 |
LL-37
|
Antimicrobial peptide (cationic, human cathelicidin) |
2013 |
Preclinical |
1284 |
Melittin
|
Antimicrobial peptide (cationic, cecropin(1-7)-melittin A(2-9) amide) |
2019 |
Preclinical |
1285 |
Magainin-II
|
Antimicrobial peptide (cationic) |
1990 |
|
1286 |
Nisin
|
Antimicrobial peptide (cationic) |
2019 |
Preclinical |
1289 |
Ethyl bromopyruvate
|
Derivative of 3-bromo-pyruvic acid (3- BPA) |
2009 |
Preclinical |
1290 |
IARR-mBjAMP1
|
Antimicrobial peptide (derivate of mBjAMP1) |
2018 |
Preclinical |
1291 |
IARR-Anal10
|
Antimicrobial peptide (derivate of mBjAMP1) |
2018 |
Preclinical |
1292 |
Ellagic acid
|
Naturally occurring dietary polyphenol |
2005 |
Preclinical |
1293 |
pepR
|
Antimicrobial peptide (viral-derived peptide) |
2015 |
Preclinical |
1294 |
NAB815
|
Polymyxin |
2017 |
Preclinical |
1295 |
CAMP113
|
Polymyxin |
2018 |
Preclinical |
1296 |
CAMP207
|
Polymyxin |
2018 |
Preclinical |
1297 |
ALX-009 (Hypothiocyanite/Lactoferrin)
|
Combination of bovine lactoferrin and hypothiocyanite |
2018 |
Preclinical |
1298 |
POL7001
|
Lipopolysaccharide synthesis inhibitor (LptD inhibitor) |
2016 |
Preclinical |
1299 |
DA-7010
|
Aminoacyl-tRNA synthetase inhibitor (leucyl-tRNA synthetase [LeuRs] inhibitor) |
2017 |
Preclinical |
1300 |
Seleno compound 3
|
Symmetric di(selenoester)pyridine |
2017 |
Preclinical |
1301 |
M33
|
Antimicrobial peptide |
2017 |
Preclinical |
1302 |
REDX08106
|
Bacterial topoisomerase inhibitor |
2017 |
Preclinical |
1303 |
CSA-142
|
Ceragenin |
2017 |
Preclinical |
1304 |
CSA-192
|
Ceragenin |
2017 |
Preclinical |
1305 |
LN-1-255
|
Beta-lactamase inhibitor (inhibitor of class D carbapenemases of A. baumannii) |
2017 |
Preclinical |
1306 |
Novarifyn
|
Antimicrobial peptide |
2017 |
Preclinical |
1307 |
CD201
|
Lipopolysaccharide-binding immunotherapy agent |
2017 |
Preclinical |
1308 |
ASN-4
|
Antibody (monoclonal antibody [mAb]) |
2017 |
Preclinical |
1309 |
Salvecin
|
Antibody (monoclonal antibody [mAb]) |
|
Phase 3 |
1310 |
Aerucin
|
Antibody (monoclonal antibody [mAb]) |
|
Phase 2 |
1311 |
Omodenbamab
|
Antibody (monoclonal antibody [mAb]) |
|
Phase 2 |
1312 |
ASN-100
|
Antibody (monoclonal antibody [mAb]) |
|
Phase 2 |
1313 |
Sibofimloc
|
|
|
Phase1 |
1314 |
Chinfloxacin
|
Fluoroquinolone |
2012 |
Phase 1 |
1315 |
Antofloxacin
|
Fluoroquinolone |
2008 |
Phase 2 |
1316 |
PFK-158
|
Glycolytic inhibitor |
|
Phase 1 |
1317 |
Diacerein
|
Anthraquinone |
|
Phase 4 |
1318 |
DS86760016
|
Aminoacyl-tRNA synthetase inhibitor (leucyl-tRNA synthetase [LeuRs] inhibitor) |
|
Preclinical |
1319 |
Indolmycin
|
Aminoacyl-tRNA synthetase inhibitor (tryptophanyl-tRNA synthetase [TrpS] inhibitor) |
1980 |
Preclinical |
1320 |
Lactivicin
|
Cell-wall synthesis inhibitor (non-beta-lactam antibiotic) |
1986 |
Preclinical |
1321 |
BVL-GSK098
|
|
2009 |
Phase 2 |
1322 |
Thiram and Disulfiram
|
|
2017 |
Preclinical |
1323 |
Niclosamide
|
|
2018 |
Preclinical |
1326 |
Ceftriaxone and Cefotaxime
|
Beta-lactam (cephalosporin) |
1987 |
Preclinical |
1327 |
Human Defensin
|
Antimicrobial peptide |
1997 |
Preclinical |
1328 |
ZY354
|
|
2019 |
Preclinical |
1329 |
ZTI-01 (Fosfomycin for Injection)
|
Phosphonic acid antibacterial |
|
Phase 4 |
1330 |
Bac7(1–35)
|
Antimicrobial peptide |
|
Preclinical |
1331 |
N2,N4-Disubstituted Quinazoline-2,4-Diamines
|
Quinazoline |
|
Preclinical |
1332 |
Poly (acetyl, arginyl) glucosamine (PAAG) is
|
Cationic glycopolymer |
|
Preclinical |
1333 |
Doxercalciferol
|
|
|
Preclinical |
1334 |
N-acetylcysteine
|
Thiol antioxidant |
1993 |
Preclinical |
1335 |
Celecoxib
|
COX-2 inhibitor |
1999 |
Approved by FDA in 1998 |
1336 |
IITR06144
|
Nitrofuran |
2019 |
Preclinical |
1337 |
Bronopol
|
Membrane-active agent (antibiofilm) |
1978 |
Phase 4 |
1338 |
Bronidox
|
Membrane-active agent (antibiofilm) |
1986 |
Phase 4 |
1339 |
Mecillinam
|
Amidinopenicillin |
1972 |
Approved by FDA in 1984 |
1340 |
Pivmecillinam (Prodrug of Amdinocillin)
|
Beta-lactam (penicillin) |
1975 |
Approved by FDA in 2024 |
1341 |
Temocillin
|
Beta-lactam (penicillin) |
1982 |
Phase 4 |
1342 |
Azithromycin
|
Macrolide (azalide) |
1980 |
Approved by FDA in 2005 |
1343 |
Rafoxanide
|
Salicylanilide |
2018 |
Preclinical |
1344 |
LMB-1
|
Beta-lactamase inhibitor (metallo-beta-lactamas) |
2018 |
Preclinical |
1345 |
Sutezolid
|
Oxazolidinone |
1996 |
Preclinical |
1347 |
Tridecaptin M
|
Lipopeptide |
2019 |
Preclinical |
1349 |
WAP-8294A1
|
Cyclodepsipeptide |
1997 |
Preclinical |
1350 |
Lotilibcin
|
Cyclodepsipeptide |
1997 |
Preclinical |
1351 |
WAP-8294A4
|
Cyclodepsipeptide |
1997 |
Preclinical |
1352 |
IID572
|
Beta-lactamase inhibitor |
|
Preclinical |
1353 |
IID572 + Piperacillin
|
Drug combination: beta-lactam + beta-lactamase inhibitor |
|
Preclinical |
1354 |
[S,S]-ethylenediamine-N,N′-disuccinic acid
|
Beta-lactamase inhibitor (metallo-beta-lactamas) |
|
Preclinical |
1355 |
Diphenyleneiodonium chloride
|
NADH inhibitor |
|
Preclinical |
1356 |
Acidocin 4356
|
Antimicrobial peptide |
|
Preclinical |
1357 |
AA139-PNP
|
Antimicrobial peptide |
2020 |
Preclinical |
1358 |
AA139-MCL
|
Antimicrobial peptide |
2020 |
Preclinical |
1359 |
PQ401
|
Diarylurea derivative |
2020 |
Preclinical |
1360 |
Pin2[G]
|
Antimicrobial peptide (host defense peptide) |
2020 |
Preclinical |
1361 |
FA1
|
Antimicrobial peptide (host defense peptide) |
2020 |
Preclinical |
1362 |
RB1
|
|
2020 |
Preclinical |
1363 |
CB1
|
|
2020 |
Preclinical |
1364 |
RB16
|
|
2020 |
Preclinical |
1365 |
RB6
|
|
2020 |
Preclinical |
1366 |
IB1
|
|
2020 |
Preclinical |
1367 |
Monosulfactam 0073
|
Monosulfactam |
2020 |
Preclinical |
1368 |
Thymol
|
Natural small molecule |
|
Phase 2 |
1369 |
Carvacrol
|
Natural small molecule |
|
Preclinical |
1370 |
trans-Cinnamaldehyde
|
Natural small molecule |
|
Phase 4 |
1372 |
CORM-3
|
Carbon-monoxide releasing molecule |
2003 |
Preclinical |
1373 |
NU-6027
|
Cyclin dependant kinase-2 inhibitor/ ATR inhibitor |
2011 |
Preclinical |
1374 |
SPR1205
|
Polymixin B analogue |
2019 |
Preclinical |
1375 |
SPR946
|
Polymyxin E analogue |
2019 |
Preclinical |
1376 |
Pyrrolomycin C
|
Natural product antibiotic |
1983 |
Preclinical |
1377 |
Pyrrolomycin D
|
Natural product antibiotic |
1983 |
Preclinical |
1378 |
Pyrrolomycin I
|
Natural product antibiotic |
2019 |
Preclinical |
1379 |
Pyrrolomycin J
|
Natural product antibiotic |
2019 |
Preclinical |
1380 |
Polymyxin B
|
Polymyxin |
1964 |
Approved by FDA in 1994 |
1381 |
Romo1
|
Mitochondrial protein |
2018 |
Preclinical |
1382 |
AMPR-11
|
Antimicrobial peptide |
2020 |
Preclinical |
1383 |
Xeruborbactam
|
Beta-lactamase inhibitor |
2020 |
Phase 1 (NCT04380207) |
1384 |
HT61
|
Quinoline |
2020 |
Preclinical |
1385 |
GC-072
|
Oxoquinolizine |
2019 |
Preclinical |
1386 |
Paenipeptin analogue 1
|
Lipopeptide |
2018 |
Preclinical |
1387 |
Paenipeptin analogue 15
|
Lipopeptide |
2018 |
Preclinical |
1388 |
Quinazolinone 1
|
Quinazolinone (PBP1 and 2a inhibitor) |
2019 |
Preclinical |
1389 |
Quinazolinone 2
|
Quinazolinone (PBP1 and 2a inhibitor) |
2019 |
Preclinical |
1390 |
Quinazolinone 3
|
Quinazolinone (PBP1 and 2a inhibitor) |
2019 |
Preclinical |
1391 |
Quinazolinone 4
|
Quinazolinone (PBP1 and 2a inhibitor) |
2019 |
Preclinical |
1392 |
Quinazolinone 5
|
Quinazolinone (PBP1 and 2a inhibitor) |
2019 |
Preclinical |
1394 |
TBAJ-876
|
Diarylquinoline |
2019 |
Phase 2 |
1395 |
DAV131A
|
Antibiotic adjuvant |
2017 |
Preclinical |
1396 |
TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl)
|
Nitroxide |
2019 |
Preclinical |
1397 |
CTEMPO (4-carboxy-2,2,6,6-tetramethylpiperidin-1-yloxyl)
|
Nitroxide |
2019 |
Preclinical |
1398 |
CTMIO (5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl)
|
Nitroxide |
2019 |
Preclinical |
1399 |
cipro-PROXYL
|
Nitroxide |
2017 |
Preclinical |
1400 |
cipro-TEMPO
|
Nitroxide |
2017 |
Preclinical |
1401 |
cipro-TMIO
|
Nitroxide |
2017 |
Preclinical |
1402 |
Fluoroquinolone- TEMPO
|
Nitroxide |
2019 |
Preclinical |
1403 |
Fluoroquinolone- TEMPMe
|
Nitroxide |
2019 |
Preclinical |
1404 |
3-O-methyl-butylgallate
|
Natural product antibiotic |
2019 |
Preclinical |
1405 |
3-O-methyl-hexylgallate
|
Natural product antibiotic |
2019 |
Preclinical |
1406 |
3-O-methyl-octylgallate
|
Natural product antibiotic |
2019 |
Preclinical |
1408 |
Thioridazine
|
Phenothiazine |
|
Approved by FDA in 1962 |
1409 |
MEDI6389 (MEDI4893*, SAR114 and SAN481)
|
Antibody (monoclonal antibody [mAb]) |
2019 |
Preclinical |
1410 |
Bedaquiline (Sirturo)
|
Diarylquinoline |
2004 |
Approved by FDA in 2012 |
1411 |
Cefepime + Taniborbactam
|
Beta-lactam + beta-lactamase inhibitor (boronate) |
|
Phase 3 |
1412 |
Lee-3464
|
Disubstituted urea |
2019 |
Preclinical |
1413 |
F2619-0556
|
Sulfonamide |
2019 |
Preclinical |
1414 |
F1374-0037
|
Oxadiazole |
2019 |
Preclinical |
1415 |
p-Anisaldehyde
|
Natural product antibiotic |
|
Preclinical |
1417 |
1,2,4-Oxadiazole derivatives
|
1,2,4-oxadiazole |
2015 |
Preclinical |
1418 |
JRH-24-1
|
1,2,4-oxadiazole |
2018 |
Preclinical |
1420 |
Clofazimine
|
Riminophenazine |
1986 |
Approved by FDA in 1986 |
1421 |
Clarithromycin
|
Macrolide |
1980 |
Approved by FDA in 1991 |
1422 |
GSK3036656
|
Aminoacyl-tRNA synthetase inhibitor (leucyl-tRNA synthetase [LeuRs] inhibitor) |
2019 |
Phase 2 |
1423 |
WCK 4234
|
Beta-lactamase inhibitor (diazabicyclooctane) |
2017 |
Preclinical |
1424 |
Mutacin B-Ny266
|
Antimicrobial peptide (bacteriocin, lantibiotic) |
2020 |
Preclinical |
1425 |
Quabodepistat
|
3,4-dihydrocarbostyril derivative |
2020 |
Phase 2 (NCT05971602) |
1426 |
Actifensin
|
Antimicrobial peptide (bacteriocin) |
2019 |
Preclinical |
1427 |
Arachidonic Acid
|
Polyunsaturated fatty acid |
2019 |
Preclinical |
1428 |
Pyrazinamide
|
Prodrug |
1972 |
Approved by FDA in 1971 |
1429 |
Verapamil
|
Efflux pump inhibitor (ABC family inhibitor) |
1981 |
|
1430 |
GH12
|
Antimicrobial peptide |
2020 |
Preclinical |
1431 |
DIBI
|
3-hydroxypyridin-4-one chelator |
2018 |
Preclinical |
1432 |
GI262866A
|
Quinazoline |
2019 |
Preclinical |
1433 |
GI261520A
|
Quinazoline |
2019 |
Preclinical |
1434 |
EJMCh4 {5-bromo-2-(2-cyclohexylethyl)-1H-benzo[d]imidazole}
|
1H-benzo[d]imidazole derivative |
2015 |
Preclinical |
1435 |
EJMCh6 {2-(2-cyclohexylethyl)-5,6-dimethyl-1H-benzo[d]imidazole}
|
1H-benzo[d]imidazole derivative |
2015 |
Preclinical |
1436 |
2,5-dimethyl-4-sulfamoylfuran-3-carboxylic acid (SFC)
|
Beta-lactamase inhibitor (metallo-beta-lactamase inhibitor) |
2020 |
Preclinical |
1437 |
2,5-diethyl-1-methyl-4-sulfamoylpyrrole-3-carboxylic acid (SPC)
|
Beta-lactamase inhibitor (metallo-beta-lactamase inhibitor) |
2020 |
Preclinical |
1438 |
Walrycin B
|
|
2010 |
|
1439 |
AZD9742
|
Bacterial topoisomerase inhibitor |
2009 |
Phase 1 |
1440 |
AZD5099
|
Pyrrolamide |
2011 |
Phase 1 |
1441 |
TP-2758
|
Tetracycline |
2011 |
Phase 1 (Eudract number 2011-001204-35) |
1442 |
Posizolid
|
Oxazolidinone |
2004 |
Phase 2 (NCT01516203) |
1443 |
Lanopepden
|
Peptide deformylase inhibitor |
2009 |
Phase 2 |
1444 |
Ceftaroline
|
Beta-lactam (cephalosporin) |
2008 |
Approved by FDA in 2010; Approved for pediatric use in 2016 |
1445 |
DPK-060, CD-1
|
Antimicrobial peptide |
2017 |
Preclinical |
1446 |
IMX 942
|
Immune defense activator |
2009 |
Preclinical |
1447 |
Caffeic Acid Phenethyl Acid
|
Natural small molecule |
1979 |
Preclinical |
1448 |
AIP-1
|
Antimicrobial peptide |
|
Preclinical |
1449 |
Nitazoxanide
|
Thiazolide |
1980 |
Approved by FDA in 2005 |
1450 |
Rifampicin
|
Rifamycin |
1965 |
Approved by FDA in 1971 |
1451 |
Linezolid
|
Oxazolidinone |
1990 |
Approved by FDA in 2000 |
1452 |
Isoniazid
|
Cell-wall synthesis inhibitor |
1952 |
Approved by FDA in 1983 |
1453 |
Redx03863
|
Bacterial topoisomerase inhibitor |
2020 |
Preclinical |
1454 |
Redx04739
|
Bacterial topoisomerase inhibitor |
2020 |
Preclinical |
1455 |
Inhibitor Peptide P1
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1456 |
Inhibitor Peptide P2
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1457 |
Inhibitor Peptide P3
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1458 |
Inhibitor Peptide P4
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1459 |
Inhibitor Peptide P5
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1460 |
Inhibitor Peptide P6
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1461 |
Inhibitor Peptide P7
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1462 |
Inhibitor Peptide P8
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1463 |
Inhibitor Peptide P9
|
Beta-lactamase inhibitor (metallo-beta lactamase) |
2020 |
Preclinical |
1464 |
Macfarlandin D
|
Natural product antibiotic |
2020 |
Preclinical |
1465 |
Macfarlandin F
|
Natural product antibiotic |
2020 |
Preclinical |
1466 |
Macfarlandin G
|
Natural product antibiotic |
2020 |
Preclinical |
1467 |
Macfarlandin H
|
Natural product antibiotic |
2020 |
Preclinical |
1468 |
Steffimycin E
|
Steffimycin |
2020 |
Preclinical |
1469 |
Streptovertimycin A
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1470 |
Streptovertimycin B
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1471 |
Streptovertimycin C
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1472 |
Streptovertimycin D
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1473 |
Streptovertimycin E
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1474 |
Streptovertimycin F
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1475 |
Streptovertimycin G
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1476 |
Streptovertimycin H
|
Fasamycin-type polyketide |
2020 |
Preclinical |
1477 |
Methyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1478 |
Ethyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1479 |
Propyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1480 |
Butyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1481 |
Pentyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1482 |
Hexyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1483 |
Heptyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1484 |
Octyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1485 |
Nonyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1486 |
Decyl ferrocenyl chalcone
|
Flavonoid |
2020 |
Preclinical |
1487 |
Benzyl Phenyl Sulfide derivative 5d
|
Benzyl phenyl sulfide derivative |
2020 |
Preclinical |
1488 |
Benzyl Phenyl Sulfide derivative 5e
|
Benzyl phenyl sulfide derivative |
2020 |
Preclinical |
1489 |
Benzyl Phenyl Sulfide derivative 5f
|
Benzyl phenyl sulfide derivative |
2020 |
Preclinical |
1490 |
Benzyl Phenyl Sulfide derivative 5h
|
Benzyl phenyl sulfide derivative |
2020 |
Preclinical |
1491 |
Benzyl Phenyl Sulfide derivative 5j
|
Benzyl phenyl sulfide derivative |
2020 |
Preclinical |
1492 |
Closantel
|
Salicylanilide |
2019 |
Preclinical |
1493 |
Oxyclozanide
|
Salicylanilide |
2019 |
Preclinical |
1495 |
Dichlorophene
|
Diarylmethane |
2005 |
Preclinical |
1496 |
Triclabendazole (Egaten)
|
Benzimidazole |
2019 |
Preclinical |
1497 |
Nithiamide
|
Acetamide |
2005 |
Preclinical |
1498 |
Ursolic Acid
|
Triterpenoid |
1920 |
Preclinical |
1501 |
TZ40-J
|
Polymyxin |
2019 |
Preclinical |
1502 |
TZ40-K
|
Polymyxin |
2019 |
Preclinical |
1503 |
Pyridine-2-thiol 1-oxide sodium salt
|
Synthetic small molecule |
2019 |
Preclinical |
1504 |
Metronidazole (Flagyl)
|
Nitroimidazole |
1960 |
Approved by FDA in 1995 |
1505 |
Vancomycin
|
Glycopeptide |
1956 |
Approved by FDA in 1986 |
1506 |
Ronidazole
|
Nitroimidazole |
2005 |
Preclinical |
1507 |
Dimetridazole
|
Nitroimidazole |
2005 |
Preclinical |
1508 |
Ornidazole
|
Nitroimidazole |
2016 |
Preclinical |
1510 |
Secnidazole
|
Nitroimidazole |
2003 |
Preclinical |
1511 |
7,8-dideoxygriseorhodin C
|
Griseorhodin |
|
Preclinical |
1512 |
Pentaminomycin C
|
Cyclic pentapeptide |
|
Preclinical |
1513 |
Teicoplanin
|
Glycopeptide |
1989 |
Phase 4 |
1514 |
Teicoplanin intermediate dicarbamate derivative (Analogue 4)
|
Glycopeptide |
2020 |
Preclinical |
1515 |
Teicoplanin pseudoaglycone derivative (Analogue 5)
|
Glycopeptide |
2020 |
Preclinical |
1516 |
Teicoplanin pseudoaglycon guanidine derivative 13a (diphenylmethyl ester)
|
Glycopeptide |
2020 |
Preclinical |
1517 |
Teicoplanin pseudoaglycon guanidine derivative 13b (diphenylmethyl ester)
|
Glycopeptide |
2020 |
Preclinical |
1518 |
Teicoplanin pseudoaglycon guanidine derivative 13c (diphenylmethyl ester)
|
Glycopeptide |
2020 |
Preclinical |
1519 |
Teicoplanin pseudoaglycon guanidine derivative 13d (diphenylmethyl ester)
|
Glycopeptide |
2020 |
Preclinical |
1520 |
Teicoplanin pseudoaglycon guanidine derivative 14a (Free C-Terminus)
|
Glycopeptide |
2020 |
Preclinical |
1521 |
Teicoplanin pseudoaglycon guanidine derivative 14b (Free C-Terminus)
|
Glycopeptide |
2020 |
Preclinical |
1522 |
Teicoplanin pseudoaglycon guanidine derivative 14c (Free C-Terminus)
|
Glycopeptide |
2020 |
Preclinical |
1523 |
Teicoplanin pseudoaglycon guanidine derivative 14d (Free C-Terminus)
|
Glycopeptide |
2020 |
Preclinical |
1524 |
Teicoplanin pseudoaglycon guanidine derivative 15a (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1525 |
Teicoplanin pseudoaglycon guanidine derivative 15b (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1526 |
Teicoplanin pseudoaglycon guanidine derivative 15c (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1527 |
Teicoplanin pseudoaglycon guanidine derivative 15d (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1528 |
Teicoplanin guanidine derivative 16b (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1529 |
Teicoplanin guanidine derivative 16e (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1530 |
Teicoplanin guanidine derivative 16f (Amide)
|
Glycopeptide |
2020 |
Preclinical |
1533 |
Muraminomicin F
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1534 |
Muraminomicin G
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1535 |
Muraminomicin H
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1536 |
Muraminomicin Z1
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1537 |
Muraminomicin Z2
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1538 |
DS60182922
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1539 |
DS14450354
|
MraY inhibitor (nucleoside antibiotic) |
2019 |
Preclinical |
1541 |
CPZEN-45 analog 1
|
Mycolyl arabinogalactan biosynthesis inhibitor |
2019 |
Preclinical |
1542 |
CPZEN-45 analog 2
|
Mycolyl arabinogalactan biosynthesis inhibitor |
2019 |
Preclinical |
1543 |
CPZEN-45 analog 3
|
Mycolyl arabinogalactan biosynthesis inhibitor |
2019 |
Preclinical |
1544 |
CPZEN-45 analog 4
|
Mycolyl arabinogalactan biosynthesis inhibitor |
2019 |
Preclinical |
1545 |
CPZEN-45 analog 5
|
Mycolyl arabinogalactan biosynthesis inhibitor |
2019 |
Preclinical |
1546 |
2-(pyrazol-1-yl)- thiazole Compound 1
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1547 |
2-(pyrazol-1-yl)- thiazole Compound 2
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1548 |
2-(pyrazol-1-yl)- thiazole Compound 3
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1549 |
2-(pyrazol-1-yl)- thiazole Compound 4
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1550 |
2-(pyrazol-1-yl)- thiazole Compound 5
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1551 |
2-(pyrazol-1-yl)- thiazole Compound 6
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1552 |
2-(pyrazol-1-yl)- thiazole Compound 7
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1553 |
2-(pyrazol-1-yl)- thiazole Compound 8
|
Protein synthesis inhibitor |
2019 |
Preclinical |
1554 |
CXP18.6-012
|
PanK inhibitor |
2019 |
Preclinical |
1555 |
CXP18.6-013
|
PanK inhibitor |
2019 |
Preclinical |
1556 |
CXP18.6-014
|
PanK inhibitor |
2019 |
Preclinical |
1557 |
CXP18.6-017
|
PanK inhibitor |
2019 |
Preclinical |
1558 |
CXP18.6-069
|
PanK inhibitor |
2019 |
Preclinical |
1559 |
CXP18.6-047
|
PanK inhibitor |
2019 |
Preclinical |
1560 |
CXP18.6-057
|
PanK inhibitor |
2019 |
Preclinical |
1561 |
CXP18.6-064
|
PanK inhibitor |
2019 |
Preclinical |
1562 |
CXP14.18–028
|
PanK inhibitor |
2019 |
Preclinical |
1563 |
CXP14.18–005
|
PanK inhibitor |
2019 |
Preclinical |
1564 |
CXP14.26–007
|
PanK inhibitor |
2019 |
Preclinical |
1565 |
CXP14.18–037
|
PanK inhibitor |
2019 |
Preclinical |
1566 |
CXP14.18–038
|
PanK inhibitor |
2019 |
Preclinical |
1567 |
CXP14.18–034
|
PanK inhibitor |
2019 |
Preclinical |
1568 |
CXP14.18–012
|
PanK inhibitor |
2019 |
Preclinical |
1569 |
NPS-2143
|
CaSR antagonist |
2001 |
Preclinical |
1570 |
NPS-2143 derivative 19
|
CaSR antagonist |
2019 |
Preclinical |
1571 |
NPS-2143 derivative 20
|
CaSR antagonist |
2019 |
Preclinical |
1572 |
NPS-2143 derivative 21
|
CaSR antagonist |
2019 |
Preclinical |
1573 |
NPS-2143 derivative 22
|
CaSR antagonist |
2019 |
Preclinical |
1574 |
NPS-2143 derivative 23
|
CaSR antagonist |
2019 |
Preclinical |
1575 |
NPS-2143 derivative 24
|
CaSR antagonist |
2019 |
Preclinical |
1576 |
NPS-2143 derivative 25
|
CaSR antagonist |
2019 |
Preclinical |
1577 |
NPS-2143 derivative 26
|
CaSR antagonist |
2019 |
Preclinical |
1578 |
NPS-2143 derivative 27
|
CaSR antagonist |
2019 |
Preclinical |
1579 |
NPS-2143 derivative 28
|
CaSR antagonist |
2019 |
Preclinical |
1580 |
NPS-2143 derivative 29
|
CaSR antagonist |
2019 |
Preclinical |
1581 |
NPS-2143 derivative 30
|
CaSR antagonist |
2019 |
Preclinical |
1582 |
NPS-2143 derivative 31
|
CaSR antagonist |
2019 |
Preclinical |
1583 |
NPS-2143 derivative 32
|
CaSR antagonist |
2019 |
Preclinical |
1584 |
NPS-2143 derivative 33
|
CaSR antagonist |
2019 |
Preclinical |
1585 |
NPS-2143 derivative 34
|
CaSR antagonist |
2019 |
Preclinical |
1586 |
NPS-2143 derivative 35
|
CaSR antagonist |
2019 |
Preclinical |
1587 |
NPS-2143 derivative 36
|
CaSR antagonist |
2019 |
Preclinical |
1588 |
NPS-2143 derivative 37
|
CaSR antagonist |
2019 |
Preclinical |
1589 |
NPS-2143 derivative 38
|
CaSR antagonist |
2019 |
Preclinical |
1590 |
NPS-2143 derivative 39
|
CaSR antagonist |
2019 |
Preclinical |
1591 |
NPS-2143 derivative 43
|
CaSR antagonist |
2019 |
Preclinical |
1592 |
NPS-2143 derivative 44
|
CaSR antagonist |
2019 |
Preclinical |
1593 |
NPS-2143 derivative 48
|
CaSR antagonist |
2019 |
Preclinical |
1594 |
NPS-2143 derivative 49
|
CaSR antagonist |
2019 |
Preclinical |
1595 |
NPS-2143 derivative 50
|
CaSR antagonist |
2019 |
Preclinical |
1596 |
Aminobenzopentathiepine amide compound 13
|
|
2019 |
Preclinical |
1597 |
Aminobenzopentathiepine amide compound 14
|
|
2019 |
Preclinical |
1598 |
Aminobenzopentathiepine amide compound 15
|
|
2019 |
Preclinical |
1599 |
Aminobenzopentathiepine amide compound 16
|
|
2019 |
Preclinical |
1600 |
Aminobenzopentathiepine amide compound 17
|
|
2019 |
Preclinical |
1601 |
Trifluoroacetamide analog compound 18
|
|
2019 |
Preclinical |
1602 |
Trifluoroacetamide analog compound 19
|
|
2019 |
Preclinical |
1603 |
Novel Phloroglucinol Derivative 1
|
|
2019 |
Preclinical |
1604 |
Novel Phloroglucinol Derivative 2
|
|
2019 |
Preclinical |
1605 |
Novel Phloroglucinol Derivative 3
|
|
2019 |
Preclinical |
1606 |
Novel Phloroglucinol Derivative 4
|
|
2019 |
Preclinical |
1607 |
Novel Phloroglucinol Derivative 5
|
|
2019 |
Preclinical |
1608 |
Novel Phloroglucinol Derivative 6
|
|
2019 |
Preclinical |
1609 |
Novel Phloroglucinol Derivative 7
|
|
2019 |
Preclinical |
1610 |
Novel Phloroglucinol Derivative 8
|
|
2019 |
Preclinical |
1611 |
Novel Phloroglucinol Derivative 9
|
|
2019 |
Preclinical |
1612 |
Novel Phloroglucinol Derivative 10
|
|
2019 |
Preclinical |
1613 |
Novel Phloroglucinol Derivative 11
|
|
2019 |
Preclinical |
1614 |
Novel Phloroglucinol Derivative 12
|
|
2019 |
Preclinical |
1615 |
2-thio-5-(tert-butyl)-6-azauracil
|
Nucleoside analog |
2019 |
Preclinical |
1616 |
2-thio-5-phenyl-6-azauracil
|
Nucleoside analog |
2019 |
Preclinical |
1617 |
5-(tert-butyl)-6-azauracil
|
Nucleoside analog |
2019 |
Preclinical |
1618 |
5-phenyl-6-azauracil
|
Nucleoside analog |
2019 |
Preclinical |
1619 |
2’-Deoxy-2-thio-5-phenyl-6-azauridine
|
Nucleoside analog |
2019 |
Preclinical |
1620 |
2’-Deoxy-5-(tert-butyl)-6-azauridine
|
Nucleoside analog |
2019 |
Preclinical |
1621 |
2’-Deoxy-5-phenyl-6-azauridine
|
Nucleoside analog |
2019 |
Preclinical |
1622 |
2’-Deoxy-2-thio-5-(tert-butyl)-6-azauridine
|
Nucleoside analog |
2019 |
Preclinical |
1623 |
Xenematide F
|
Antimicrobial peptide (cyclic depsipeptide) |
2019 |
Preclinical |
1624 |
Xenematide G
|
Antimicrobial peptide (cyclic depsipeptide) |
2019 |
Preclinical |
1625 |
Spectinamide
|
Aminocyclitol |
2019 |
Preclinical |
1626 |
Aminomethyl Spectinomicin
|
Aminocyclitol |
2019 |
Preclinical |
1627 |
Spectinomicin analog 1950
|
Aminocyclitol |
2019 |
Preclinical |
1628 |
Spectinomicin analog 1951
|
Aminocyclitol |
2019 |
Preclinical |
1629 |
Spectinomicin analog 2241
|
Aminocyclitol |
2019 |
Preclinical |
1630 |
Spectinomicin analog 2324
|
Aminocyclitol |
2019 |
Preclinical |
1631 |
Synthesized Azolylthioacetamide 1
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1632 |
Synthesized Azolylthioacetamide 2
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1633 |
Synthesized Azolylthioacetamide 3
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1634 |
Synthesized Azolylthioacetamide 4
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1635 |
Synthesized Azolylthioacetamide 5
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1636 |
Synthesized Azolylthioacetamide 6
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1637 |
Synthesized Azolylthioacetamide 7
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1638 |
Synthesized Azolylthioacetamide 8
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1639 |
Synthesized Azolylthioacetamide 9
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1640 |
Synthesized Azolylthioacetamide 10
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1641 |
Synthesized Azolylthioacetamide 11
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1642 |
Synthesized Azolylthioacetamide 12
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1643 |
Synthesized Azolylthioacetamide 13
|
Beta-lactamase inhibitor |
2019 |
Preclinical |
1644 |
Novel thiourea ligand HL
|
Cell metabolism inhibitor |
2019 |
Preclinical |
1645 |
Novel thiourea ligand 1a
|
Cell metabolism inhibitor |
2019 |
Preclinical |
1646 |
Novel thiourea ligand 1b
|
Cell metabolism inhibitor |
2019 |
Preclinical |
1647 |
Novel thiourea ligand 1c
|
Cell metabolism inhibitor |
2019 |
Preclinical |
1648 |
3,4-bis(arylthio)maleimide compound 3a
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1649 |
3,4-bis(arylthio)maleimide compound 3b
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1650 |
3,4-bis(arylthio)maleimide compound 3c
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1651 |
3,4-bis(arylthio)maleimide compound 3d
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1652 |
3,4-bis(arylthio)maleimide compound 3e
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1653 |
3,4-bis(arylthio)maleimide compound 3f
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1654 |
3,4-bis(arylthio)maleimide compound 3g
|
3,4-bis(arylthio)maleimide |
2019 |
Preclinical |
1655 |
Benzoxaborole derivative of azithromycin compound 7
|
Macrolide |
2019 |
Preclinical |
1656 |
Benzoxaborole derivative of azithromycin compound 13
|
Macrolide |
2019 |
Preclinical |
1657 |
Benzoxaborole derivative of azithromycin compound 14
|
Macrolide |
2019 |
Preclinical |
1658 |
Benzoxaborole derivative of azithromycin compound 15
|
Macrolide |
2019 |
Preclinical |
1659 |
Benzoxaborole derivative of azithromycin compound 16
|
Macrolide |
2019 |
Preclinical |
1660 |
Benzoxaborole derivative of azithromycin compound 17
|
Macrolide |
2019 |
Preclinical |
1661 |
Benzoxaborole derivative of azithromycin compound 18
|
Macrolide |
2019 |
Preclinical |
1662 |
Benzoxaborole derivative of azithromycin compound 19
|
Macrolide |
2019 |
Preclinical |
1663 |
Benzoxaborole derivative of azithromycin compound 20
|
Macrolide |
2019 |
Preclinical |
1664 |
Benzoxaborole derivative of azithromycin compound 21
|
Macrolide |
2019 |
Preclinical |
1665 |
Benzoxaborole derivative of azithromycin compound 22
|
Macrolide |
2019 |
Preclinical |
1666 |
Benzoxaborole derivative of azithromycin compound 23
|
Macrolide |
2019 |
Preclinical |
1667 |
Benzoxaborole derivative of azithromycin compound 24
|
Macrolide |
2019 |
Preclinical |
1668 |
Benzoxaborole derivative of azithromycin compound 25
|
Macrolide |
2019 |
Preclinical |
1669 |
Benzoxaborole derivative of azithromycin compound 26
|
Macrolide |
2019 |
Preclinical |
1670 |
Benzoxaborole derivative of azithromycin compound 27
|
Macrolide |
2019 |
Preclinical |
1671 |
Benzoxaborole derivative of azithromycin compound 28
|
Macrolide |
2019 |
Preclinical |
1672 |
Benzoxaborole derivative of azithromycin compound 29
|
Macrolide |
2019 |
Preclinical |
1673 |
Benzoxaborole derivative of azithromycin compound 30
|
Macrolide |
2019 |
Preclinical |
1674 |
Acremotin A
|
Antimicrobial peptide (peptaibiotic) |
2018 |
Preclinical |
1675 |
Acremotin B
|
Antimicrobial peptide (peptaibiotic) |
2018 |
Preclinical |
1676 |
Acremotin C
|
Antimicrobial peptide (peptaibiotic) |
2018 |
Preclinical |
1677 |
Acremotin D
|
Antimicrobial peptide (peptaibiotic) |
2018 |
Preclinical |
1678 |
XR586
|
Antimicrobial peptide (peptaibiotic) |
2018 |
Preclinical |
1679 |
Elloramycin
|
Tetracenomycin |
1990 |
Preclinical |
1680 |
Tetracenomycin C
|
Tetracenomycin |
1979 |
Preclinical |
1681 |
Tetracenomycin X
|
Tetracenomycin |
|
Preclinical |
1682 |
Ala-geninthiocin
|
Antimicrobial peptide (thiopeptide) |
2018 |
Preclinical |
1683 |
Geninthiocin (Ala-geninthiocin analog)
|
Antimicrobial peptide (thiopeptide) |
2018 |
Preclinical |
1684 |
Val-geninthiocin (Ala-geninthiocin analog)
|
Antimicrobial peptide (thiopeptide) |
2018 |
Preclinical |
1686 |
Boromycin
|
Polyether macrolide |
2018 |
Preclinical |
1687 |
CD437
|
Retinoid |
2018 |
Preclinical |
1688 |
CD1530
|
Retinoid |
2018 |
Preclinical |
1689 |
Albicidin
|
Bacterial topoisomerase inhibitor |
2019 |
Preclinical |
1690 |
G0775
|
Type I signal peptidase inhibitor |
2018 |
Preclinical |
1691 |
Boeravirone B
|
Efflux pump inhibitor |
2017 |
Preclinical |
1692 |
Curvulaide A
|
Bicyclic polyketide |
|
Preclinical |
1693 |
BRD4592
|
Tryptophan synthase inhibitor |
2017 |
Preclinical |
1694 |
hdMolluscidin
|
Antimicrobial peptide |
2016 |
Preclinical |
1695 |
gcMolluscidin
|
Antimicrobial peptide |
2013 |
Preclinical |
1696 |
Enaminone-grafted trithiocarbonate compound 3
|
Eaminone |
2020 |
Preclinical |
1697 |
Seysara (Sarecycline)
|
Tetracycline |
2020 |
Preclinical |
1698 |
Pestiocandin
|
Papulacandin |
2018 |
Preclinical |
1699 |
ChBp
|
Antimicrobial peptide (choline binding polypeptide) |
2018 |
Preclinical |
1700 |
Mag(i+4)1,15(A9K,B21A,N22K,S23K)
|
Antimicrobial peptide |
2019 |
Preclinical |
1701 |
Dialkylresorcinol semi-synthetic derivative 1
|
Dialkylresorcinol |
2020 |
Preclinical |
1702 |
Dialkylresorcinol semi-synthetic derivative 2
|
Dialkylresorcinol |
2020 |
Preclinical |
1703 |
Dialkylresorcinol semi-synthetic derivative 3
|
Dialkylresorcinol |
2020 |
Preclinical |
1704 |
Dialkylresorcinol semi-synthetic derivative 5
|
Dialkylresorcinol |
2020 |
Preclinical |
1705 |
Dialkylresorcinol semi-synthetic derivative 7
|
Dialkylresorcinol |
2020 |
Preclinical |
1706 |
Dialkylresorcinol semi-synthetic derivative 10
|
Dialkylresorcinol |
2020 |
Preclinical |
1707 |
Dialkylresorcinol semi-synthetic derivative 13
|
Dialkylresorcinol |
2020 |
Preclinical |
1708 |
Dialkylresorcinol semi-synthetic derivative 15
|
Dialkylresorcinol |
2020 |
Preclinical |
1709 |
Dialkylresorcinol semi-synthetic derivative 17
|
Dialkylresorcinol |
2020 |
Preclinical |
1710 |
Dialkylresorcinol semi-synthetic derivative 19
|
Dialkylresorcinol |
2020 |
Preclinical |
1711 |
Dialkylresorcinol semi-synthetic derivative 22
|
Dialkylresorcinol |
2020 |
Preclinical |
1712 |
Virstatin
|
ToxT inhibitor |
2005 |
Preclinical |
1713 |
Quercitrin
|
SrtA inhibitor |
1996 |
Preclinical |
1714 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 5
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1715 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 6
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1716 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 7
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1717 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 8
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1718 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 9
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1719 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 10
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1720 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 11
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1721 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 12
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1722 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 13
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1723 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 14
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1724 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 15
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1725 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 16
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1726 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 17
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1727 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 18
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1728 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 19
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1729 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 20
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1730 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 21
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1731 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 22
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1732 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 23
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1733 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 24
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1734 |
4-[4-formyl-3-(2-naphthyl)pyrazol-1-yl]benzoic acid derivative 25
|
Naphthyl-substituted pyrazole-derived hydrazone |
2020 |
Preclinical |
1735 |
Raxibacumab
|
Antibody (monoclonal antibody [mAb]) |
2009 |
Approved by FDA in 2012 |
1736 |
Obiltoxaximab (Anthim)
|
Antibody (monoclonal antibody [mAb]) |
2005 |
Approved by FDA in 2016 |
1737 |
Bezlotoxumab, Zinplava
|
Antibody (monoclonal antibody [mAb]) |
2009 |
Approved by FDA in 2016 |
1738 |
AR-101
|
Antibody (monoclonal antibody [mAb]) |
2020 |
Phase 3 |
1739 |
Shigamab
|
Antibody (monoclonal antibody [mAb]) |
2020 |
Phase 2 |
1740 |
mAb926
|
Antibody (monoclonal antibody [mAb]) |
2020 |
Preclinical |
1741 |
mAb475
|
Antibody (monoclonal antibody [mAb]) |
2020 |
Preclinical |
1742 |
Dehydrocrepenynic acid
|
|
2020 |
Preclinical |
1743 |
2-Hexadecynoic acid
|
|
2020 |
Preclinical |
1744 |
Tanzawaic acid A
|
Bacterial conjugation inhibitor |
2020 |
Preclinical |
1745 |
Tanzawaic acid B
|
Bacterial conjugation inhibitor |
2020 |
Preclinical |
1746 |
CHIR-1
|
Cagα ATPase inhibitor |
2020 |
Preclinical |
1747 |
ID7146
|
Antivirulence agent (T3SS) |
2020 |
Preclinical |
1748 |
Clioxanide
|
Antivirulence agent (T3SS) |
2020 |
Preclinical |
1749 |
Caminoside A
|
Glycolipid |
2020 |
Preclinical |
1750 |
R1015PM
|
Antivirulence agent (T3SS) |
2020 |
Preclinical |
1751 |
Hopeaphenol
|
Antivirulence agent (T3SS) |
2020 |
Preclinical |
1752 |
Licoflavonol
|
Antivirulence agent (T3SS) |
2020 |
Preclinical |
1753 |
Goldinomycin
|
Antivirulence agent (T3SS) |
2020 |
Preclinical |
1754 |
Farnesol
|
pqsA inhibitor |
2020 |
Preclinical |
1755 |
Ajoene
|
RsmY and RsmZ inhibitor |
2020 |
Preclinical |
1756 |
Patulin
|
RhlR inhibitor |
2020 |
Preclinical |
1757 |
Savirin
|
AgrA inhibitor |
2020 |
Preclinical |
1758 |
Clotrimazole
|
PqsR inhibitor |
2020 |
Preclinical |
1759 |
Miconazole
|
PqsR inhibitor |
2020 |
Preclinical |
1760 |
Clofoctol
|
PqsR inhibitor |
1981 |
Preclinical |
1761 |
Chloptosin B
|
|
2021 |
Preclinical |
1762 |
Chloptosin C
|
|
2021 |
Preclinical |
1763 |
Cervinomycin C1
|
Natural product antibiotic (polycyclic xanthone) |
2020 |
Preclinical |
1764 |
Cervinomycin C2
|
Natural product antibiotic (polycyclic xanthone) |
2020 |
Preclinical |
1765 |
Cervinomycin C3
|
Natural product antibiotic (polycyclic xanthone) |
2020 |
Preclinical |
1766 |
Cervinomycin C4
|
Natural product antibiotic (polycyclic xanthone) |
2020 |
Preclinical |
1767 |
Termstrin A
|
Anthraquinone |
2020 |
Preclinical |
1768 |
Termstrin B
|
Anthraquinone |
2020 |
Preclinical |
1769 |
Termstrin C
|
Anthraquinone |
2020 |
Preclinical |
1770 |
Termstrin D
|
Anthraquinone |
2020 |
Preclinical |
1771 |
6-(pyrrolidin-2-yl)DAPG
|
Alkaloid |
2020 |
Preclinical |
1772 |
6-(piperidin-2-yl)DAPG
|
Alkaloid |
2020 |
Preclinical |
1773 |
Albiducin A
|
Polyketide |
2018 |
Preclinical |
1774 |
Albiducin B
|
Polyketide |
2018 |
Preclinical |
1775 |
NOSO-502
|
Odilorhabdin |
2015 |
Preclinical |
1776 |
SMT-738
|
LolCDE inhibitor |
2020 |
Preclinical |
1777 |
POL7306
|
Antimicrobial peptidomimetic (outer-membrane protein targeting antibiotic) |
2018 |
Preclinical |
1778 |
EBL-1463
|
Cell-wall synthesis inhibitor (dabocin) |
2017 |
Preclinical |
1779 |
2G-Dabocin
|
Cell-wall synthesis inhibitor (dabocin) |
2017 |
Preclinical |
1780 |
OMN6
|
Antimicrobial peptide |
2019 |
Phase 1 |
1781 |
LYT100
|
Lysin |
2019 |
Preclinical |
1782 |
Program 1
|
Aminoglycoside |
2019 |
Preclinical |
1783 |
TRL1068
|
Antibody (monoclonal antibody [mAb]) |
2016 |
Phase 2 (NCT06621251) |
1784 |
RESP-X
|
Antibody (monoclonal antibody [mAb]) |
2019 |
Phase 1 |
1785 |
MET-X
|
Beta-lactamase inhibitor (metallo beta-lactamase inhibitor) |
2022 |
|
1786 |
ALS-4
|
Antivirulence agent |
2017 |
Phase 1 |
1787 |
PED-011
|
Antisense oligonucleotide |
2019 |
Preclinical |
1788 |
PED-012
|
Antisense oligonucleotide |
2019 |
Preclinical |
1789 |
PED-013
|
Antisense oligonucleotide |
2019 |
Preclinical |
1790 |
PED-019
|
Antisense oligonucleotide |
2019 |
Preclinical |
1791 |
PLG0206
|
Antimicrobial peptide |
2021 |
Phase 2 |
1792 |
CMTX-101
|
Antibody (monoclonal antibody [mAb]) |
2020 |
Phase 1/Phase 2 (NCT06159725) |
1793 |
BV200
|
Antivirulence agent |
2021 |
Preclinical |
1794 |
RX-04
|
Pyrrolocytosine |
2018 |
Preclinical |
1795 |
Debio1454
|
Fatty acid synthesis inhibitor (FabI inhibitor) |
2019 |
Preclinical |
1796 |
Octapeptin
|
Lipopeptide |
2018 |
Preclinical |
1797 |
LasB inhibitor
|
LasB inhibitor (mercaptoacetamide) |
2020 |
Preclinical |
1798 |
α-hemolysin inhibitor
|
Alpha-hemolysin inhibitor |
2020 |
Preclinical |
1799 |
Cystobactamid
|
Bacterial topoisomerase inhibitor |
2019 |
Preclinical |
1800 |
Stapled Antimicrobial Peptides
|
Antimicrobial peptide |
2019 |
Preclinical |
1801 |
DaaRS
|
Aminoacyl-tRNA synthetase inhibitor |
2019 |
Preclinical |
1802 |
Pei
|
Pseudomonas elastase inhibitor |
2021 |
Preclinical |
1803 |
Amurin
|
Amurin |
2019 |
Preclinical |
1804 |
ASN-4
|
Antibody (monoclonal antibody [mAb]) |
2018 |
Preclinical |
1805 |
INBRX-111
|
Antibody (monoclonal antibody [mAb]) |
2017 |
Preclinical |
1806 |
MRL-494
|
BamA inhibitor |
2019 |
Preclinical |
1807 |
Actinocarbasin
|
Lipoglycopeptide (arilomycin) |
2012 |
Preclinical |
1808 |
Krisynomycin
|
Cyclic depsipeptide |
2012 |
Preclinical |
1809 |
G2824
|
Lgt inhibitor |
2021 |
Preclinical |
1810 |
Globomycin
|
Lipopeptide |
1978 |
Preclinical |
1811 |
Myxovirescin
|
Macrocyclic antibiotic |
1982 |
Preclinical |
1812 |
G0507
|
Pyrrolopyrimidinedione |
2018 |
Preclinical |
1813 |
Epetraborole
|
Aminoacyl-tRNA synthetase inhibitor (boron-heterocyclic leucyl-tRNA synthetase [LeuRS] inhibitor) |
2013 |
Phase 2 |
1814 |
Bicyclomycin
|
Cyclic dipeptide (2,5-diketopiperazine) |
1974 |
|
1815 |
CBR703
|
RNA polymerase inhibitor (hydroxamidine) |
2003 |
Preclinical |
1816 |
Roseoflavin
|
FMN riboswitch binder |
1974 |
Preclinical |
1817 |
MAC13772
|
Biotin biosynthesis inhibitor |
2013 |
Preclinical |
1818 |
Darobactin
|
BamA inhibitor (bicyclic heptapeptide antibiotic) |
2019 |
Preclinical |
1819 |
MUT350
|
Beta-lactamase inhibitor (diazabicyclooctane [DBO]) |
2019 |
Preclinical |
1820 |
ETX0462
|
Beta-lactamase inhibitor (diazabicyclooctane [DBO]) |
2021 |
Preclinical |
1821 |
ANT3310
|
Beta-lactamase inhibitor (diazabicyclooctane [DBO]) |
2020 |
Preclinical |
1822 |
ANT2681
|
Beta-lactamase inhibitor (thiazole metallo beta-lactamase inhibitor ) |
2019 |
Preclinical |
1823 |
MBX-4132
|
Uriedooxadiazole |
2020 |
Preclinical |
1824 |
Klebicin
|
Antimicrobial peptide (Klebsiella colicin-like bacteriocin) |
1987 |
Preclinical |
1825 |
OPT-200
|
Lipopolysaccharide synthesis inhibitor |
2017 |
Preclinical |
1826 |
OPT-500
|
Isoprenoid inhibitor |
2020 |
Preclinical |
1827 |
OPT-600
|
Isoprenoid inhibitor |
2020 |
Preclinical |
1828 |
GSK3882347
|
FimH antagonist |
2020 |
Phase 1 |
1829 |
CMTX-001
|
Antibody (monoclonal antibody [mAb]) |
2020 |
Preclinical |
1830 |
Corbomycin
|
Glycopeptide |
2020 |
Preclinical |
1831 |
Complestatin
|
Glycopeptide |
1989 |
Preclinical |
1832 |
DIS-73285
|
Electron transport chain inhibitor |
2018 |
Preclinical |
1833 |
Novobiocin
|
Aminocoumarin |
1955 |
Approved by FDA in 1964 |
1834 |
Chlorobiocin (NSC 227186 in NCI compound library)
|
Aminocoumarin |
1972 |
|
1835 |
Declovanillobiocin
|
Aminocoumarin |
2004 |
|
1836 |
Isovanillobiocin
|
Aminocoumarin |
2004 |
|
1837 |
Novclobiocin 101
|
Aminocoumarin |
2003 |
|
1838 |
Vanillobiocin
|
Aminocoumarin |
2004 |
|
1839 |
Gentamicin
|
Aminoglycoside |
1962 |
Approved by FDA in 1970 |
1840 |
Kanamycin
|
Aminoglycoside |
1957 |
Approved by FDA in 1973 |
1841 |
Amikacin
|
Aminoglycoside |
1976 |
Approved by FDA in 1981 |
1842 |
Spectinomycin
|
Aminoglycoside |
1961 |
Approved by FDA in 1971 |
1843 |
Capreomycin
|
Tuberactinomycin (cyclic peptide often grouped with aminoglycoside) |
1960 |
Approved by FDA in 1971 |
1844 |
Tobramycin
|
Aminoglycoside |
1965 |
Approved by FDA in 1975 |
1845 |
Apramycin
|
Aminoglycoside |
1979 |
Phase 1 for human use (as of 2022) |
1846 |
Arbekacin
|
Aminoglycoside |
1973 |
Phase 1 for inhalation (since 2013) |
1847 |
Dibekacin
|
Aminoglycoside |
1975 |
|
1848 |
Netilmicin
|
Aminoglycoside |
1973 |
Approved by FDA in 1983 |
1849 |
Isepamicin
|
Aminoglycoside |
1973 |
|
1850 |
Neomycin
|
Aminoglycoside |
1947 |
Approved by FDA in 1964 |
1851 |
Sisomicin
|
Aminoglycoside |
1950 |
Phase 4 (NCT00202891) |
1852 |
Paromomycin
|
Aminoglycoside |
1960 |
Approved by FDA in 1969 |
1853 |
Ribostamycin
|
Aminoglycoside |
1970 |
|
1854 |
Micronomicin
|
Aminoglycoside |
1983 |
|
1855 |
Dihydrostreptomycin
|
Aminoglycoside |
1949 |
|
1856 |
Bekanamycin
|
Aminoglycoside |
1969 |
|
1857 |
Rifabutin
|
Rifamycin |
1975 |
Approved by FDA in 1992 |
1858 |
Rifapentine
|
Rifamycin |
1965 |
Approved by FDA in 1998 |
1859 |
Rifaximin
|
Rifamycin |
1980 |
Approved by FDA in 2004 |
1860 |
Rifamycin
|
Rifamycin |
1957 |
Approved by FDA in 2018 |
1861 |
Imipenem
|
Beta-lactam (carbapenem) |
1977 |
Approved by FDA in 2019 |
1862 |
Meropenem
|
Beta-lactam (carbapenem) |
1983 |
Approved by FDA in 1996 |
1863 |
Biapenem
|
Beta-lactam (carbapenem) |
1995 |
Phase 1 (NCT01772836) |
1864 |
Doripenem
|
Beta-lactam (carbapenem) |
2003 |
Approved by FDA in 2007 |
1865 |
Ertapenem
|
Beta-lactam (carbapenem) |
1992 |
Approved by FDA in 2001 |
1866 |
Olivanic acid
|
Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor |
1974 |
|
1867 |
Panipenem
|
Beta-lactam (carbapenem) |
1982 |
Approved (not in US) |
1868 |
Benapenem
|
Beta-lactam (carbapenem) |
2015 |
Phase 3 (NCT04505683) |
1869 |
Sulopenem
|
Beta-lactam (penem) |
1989 |
Approved by FDA in 2024 |
1870 |
Clavulanic acid
|
Beta-lactamase inhibitor (clavam, bicyclic beta-lactam without a penicillin or cephalosporin nucleus) |
1976 |
|
1871 |
Sulbactam
|
Beta-lactamase inhibitor (penicillanic acid sulfone) |
1978 |
Approved by FDA in 1986 |
1872 |
Tazobactam
|
Beta-lactamase inhibitor (penicillanic acid sulfone) |
1982 |
Approved by FDA in 1993 |
1873 |
Enmetazobactam
|
Beta-lactamase inhibitor (penicillanic acid sulfone) |
1998 |
Approved by FDA in 2024 |
1874 |
Avibactam (Avycaz, Zavicefta)
|
Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2002 |
Approved by FDA in 2015 |
1875 |
Relebactam
|
Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2009 |
Approved by FDA in 2019 |
1876 |
Vaborbactam
|
Beta-lactamase inhibitor (heterocyclic boron) |
2013 |
Approved by FDA in 2017 |
1877 |
Cefadroxil
|
Beta-lactam (cephalosporin, first generation) |
1967 |
Approved by FDA in 1987 |
1878 |
Cefazolin
|
Beta-lactam (cephalosporin, first generation) |
1967 |
Approved by FDA in 1987 |
1879 |
Cephalexin
|
Beta-lactam (cephalosporin, first generation) |
1967 |
Approved by FDA in 1978 |
1880 |
Cephaloridine
|
Beta-lactam (cephalosporin, first generation) |
1962 |
Approved |
1881 |
Cephalotin
|
Beta-lactam (cephalosporin, first generation) |
1962 |
Approved |
1882 |
Cephapirin
|
Beta-lactam (cephalosporin, first generation) |
1971 |
Approved by FDA in 1974 |
1883 |
Cephradine
|
Beta-lactam (cephalosporin, first generation) |
1972 |
Approved by FDA in 1974 |
1885 |
Cephaloglycin
|
Beta-lactam (cephalosporin, first generation) |
1965 |
Approved by FDA in 1970 |
1886 |
Cefazedone
|
Beta-lactam (cephalosporin, first generation) |
1979 |
|
1887 |
Cefatrizine
|
Beta-lactam (cephalosporin, first generation) |
1974 |
|
1888 |
Ceftezole
|
Beta-lactam (cephalosporin, first generation) |
1976 |
|
1889 |
Cefaclor
|
Beta-lactam (cephalosporin, second generation) |
1973 |
Approved by FDA in 1979 |
1890 |
Cefamandole
|
Beta-lactam (cephalosporin, second generation) |
1974 |
|
1891 |
Cefmetazole
|
Beta-lactam (cephalosporin, second generation) |
1979 |
Approved by FDA in 1989 |
1892 |
Cefonicid
|
Beta-lactam (cephalosporin, second generation) |
1981 |
Approved by FDA in 1984 |
1893 |
Ceforanide
|
Beta-lactam (cephalosporin, second generation) |
1979 |
Approved by FDA in 1984 |
1894 |
Cefotetan
|
Beta-lactam (cephalosporin, second generation) |
1981 |
|
1895 |
Cefoxitin
|
Beta-lactam (cephalosporin, second generation) |
1972 |
|
1896 |
Cefprozil
|
Beta-lactam (cephalosporin, second generation) |
1983 |
|
1897 |
Cefuroxime
|
Beta-lactam (cephalosporin, second generation) |
1971 |
|
1898 |
Loracarbef
|
Beta-lactam (cephalosporin, second generation) |
1991 |
Approved by FDA in 1991 |
1899 |
Flomoxef
|
Beta-lactam (cephalosporin, second generation) |
1980 |
|
1900 |
Cefbuperazone
|
Beta-lactam (cephalosporin, second generation) |
1982 |
|
1901 |
Cefotiam
|
Beta-lactam (cephalosporin, second generation) |
1979 |
Approved by FDA in 1988 |
1902 |
Cefminox
|
Beta-lactam (cephalosporin, second generation) |
1983 |
|
1903 |
Ceftazidime
|
Beta-lactam (cephalosporin, third generation) |
1978 |
|
1904 |
Cefdinir
|
Beta-lactam (cephalosporin, third generation) |
1979 |
|
1905 |
Cefditoren
|
Beta-lactam (cephalosporin, third generation) |
1984 |
|
1906 |
Cefetamet
|
Beta-lactam (cephalosporin, third generation) |
1985 |
|
1907 |
Cefixime
|
Beta-lactam (cephalosporin, third generation) |
1984 |
|
1908 |
Cefmenoxime
|
Beta-lactam (cephalosporin, third generation) |
1980 |
Approved by FDA in 1987 |
1909 |
Cefoperazone
|
Beta-lactam (cephalosporin, third generation) |
1974 |
Approved by FDA in 1982 |
1910 |
Cefotaxime
|
Beta-lactam (cephalosporin, third generation) |
1979 |
|
1911 |
Cefpiramide
|
Beta-lactam (cephalosporin, third generation) |
1982 |
Approved by FDA in 1989 |
1912 |
Cefpodoxime
|
Beta-lactam (cephalosporin, third generation) |
1980 |
Approved by FDA in 1992 |
1913 |
Ceftibuten
|
Beta-lactam (cephalosporin, third generation) |
1987 |
Approved by FDA in 1995 |
1914 |
Ceftriaxone
|
Beta-lactam (cephalosporin, third generation) |
1980 |
Approved by FDA in 1984 |
1915 |
Latamoxef
|
Beta-lactam (cephalosporin, third generation) |
1982 |
Approved |
1916 |
Cefcapene
|
Beta-lactam (cephalosporin, third generation) |
1997 |
Approved in Japan |
1917 |
Cefodizime
|
Beta-lactam (cephalosporin, third generation) |
1978 |
|
1919 |
Cefepime
|
Beta-lactam (cephalosporin, fourth generation) |
1982 |
Approved by FDA in 1996 |
1920 |
Cefoselis
|
Beta-lactam (cephalosporin, fourth generation) |
1993 |
Approved in Japan |
1921 |
Cefozopran
|
Beta-lactam (cephalosporin, fourth generation) |
1991 |
Approved in Japan |
1922 |
Penicillin V
|
Beta-lactam (penicillin) |
1948 |
Approved by FDA |
1923 |
Penicillin G
|
Beta-lactam (penicillin) |
1938 |
Approved by FDA in 1951 |
1924 |
Amoxicillin
|
Beta-lactam (aminopenicillin) |
1958 |
Approved by FDA in 1974 |
1925 |
Ampicillin
|
Beta-lactam (aminopenicillin) |
1953 |
Approved by FDA in 1971 |
1926 |
Azlocillin
|
Beta-lactam (ureidopenicillin) |
1975 |
Approved |
1927 |
Carbenicillin
|
Beta-lactam (carboxypenicillin) |
1967 |
Approved by FDA |
1928 |
Cloxacillin
|
Beta-lactam (isoxazolylpenicillin) |
1963 |
Approved by FDA in 1971 |
1929 |
Dicloxacillin
|
Beta-lactam (isoxazolylpenicillin) |
1964 |
|
1930 |
Epicillin
|
Beta-lactam (aminopenicillin) |
1971 |
|
1931 |
Flucloxacillin
|
Beta-lactam (isoxazolylpenicillin) |
1970 |
Approved |
1932 |
Hetacillin
|
Beta-lactam (aminopenicillin) |
1965 |
Approved by FDA in 1971 |
1933 |
Methicillin
|
Beta-lactam (penicillin) |
1960 |
Approved by FDA in 1971 |
1934 |
Mezlocillin
|
Beta-lactam (ureidopenicillin) |
1976 |
Approved by FDA in 1981 |
1935 |
Nafcillin
|
Beta-lactam (penicillin, naphthalen) |
1961 |
Approved by FDA in 1970 |
1936 |
Oxacillin
|
Beta-lactam (isoxazolylpenicillin) |
1960 |
Approved by FDA in 1989 |
1937 |
Piperacillin
|
Beta-lactam (ureidopenicillin) |
1974 |
Approved by FDA in 1981 |
1938 |
Sulbenicillin
|
Beta-lactam (penicillin with increased spectrum) |
1970 |
Approved |
1939 |
Ticarcillin
|
Beta-lactam (carboxypenicillin) |
1963 |
Approved by FDA in 1976 |
1940 |
Metampicillin
|
Beta-lactam (aminopenicillin) |
1969 |
Approved |
1941 |
Penamecillin
|
Beta-lactam (penicillin) |
1966 |
Approved |
1943 |
Pheneticillin
|
Beta-lactam (penicillin) |
1961 |
Approved for veterinary use in EU |
1944 |
Carindacillin
|
Beta-lactam (carboxypenicillin) |
1972 |
Approved by FDA in 1972 |
1945 |
Carfecillin
|
Beta-lactam (carboxypenicillin) |
1974 |
|
1946 |
Cyclacillin
|
Beta-lactam (aminopenicillin) |
1970 |
Approved by FDA in 1979 |
1947 |
Talampicillin
|
Beta-lactam (aminopenicillin) |
1974 |
|
1948 |
Sultamicillin
|
Beta-lactam (Aminopenicillin) |
1982 |
Approved by FDA in 1986 |
1949 |
Azidocillin
|
Beta-lactam (aminopenicillin) |
1968 |
|
1950 |
Propicillin
|
Beta-lactam (penicillin) |
1961 |
|
1951 |
Bacampicillin
|
Beta-lactam (aminopenicillin) |
1975 |
Approved by FDA in 1980 |
1952 |
Aspoxicillin
|
Beta-lactam (penicillin) |
1983 |
Approved in Japan |
1953 |
Clometocillin
|
Beta-lactam (penicillin) |
1964 |
|
1954 |
Sulbactam plus durlobactam (Xacduro)
|
Beta-lactamase inhibitor (penicillanic acid sulfone) |
2017 |
Approved by FDA in 2023 |
1955 |
Nacubactam
|
Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2015 |
Phase 3 (NCT05905055) |
1956 |
Imipenem/funobactam
|
Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2021 |
Phase 3 |
1957 |
Ledaborbactam
|
Beta-lactamase inhibitor (boron-based) |
2017 |
Phase 1 (as of 2022) |
1958 |
Durlobactam
|
Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2017 |
Phase 3 (NCT03894046) |
1959 |
ETX-0282
|
Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO]) |
2019 |
Phase 1 (as of 2022) |
1960 |
Aztreonam
|
Beta-lactam (monobactam) |
1979 |
|
1961 |
Nocardicin A
|
Beta-lactam (monobactam) |
1975 |
|
1962 |
Carumonam
|
Beta-lactam (monobactam) |
1984 |
|
1963 |
Gloximonam
|
Beta-lactam (monobactam, oxymazins) |
1985 |
|
1964 |
Oximonam
|
Beta-lactam (monobactam, oxymazins) |
1985 |
|
1965 |
Trimethoprim
|
Diaminopyrimidine |
1962 |
|
1966 |
Iclaprim
|
Diaminopyrimidine |
2003 |
|
1967 |
Brodimoprim
|
Diaminopyrimidine |
1984 |
|
1968 |
Epiroprim
|
Diaminopyrimidine |
1993 |
|
1969 |
Tetroxoprim
|
Diaminopyrimidine |
1979 |
|
1970 |
Helvolic acid
|
Fusidane |
1943 |
|
1971 |
Cephalosporin P1
|
Fusidane |
1951 |
|
1972 |
Telavancin
|
Lipoglycopeptide |
2002 |
|
1973 |
Lincomycin
|
Lincosamide |
1958 |
|
1974 |
Clindamycin
|
Lincosamide |
1964 |
|
1975 |
Daptomycin (Cubicin)
|
Lipopeptide |
1986 |
|
1976 |
Tinidazole
|
Nitroimidazole |
1969 |
|
1977 |
Pretomanid (Dovprela)
|
Nitroimidazole |
2000 |
Approved by FDA in 2019 |
1978 |
Nitrofurantoin
|
Nitrofuran |
1952 |
|
1979 |
Furazolidone
|
Nitrofuran |
1953 |
|
1980 |
Nifurquinazol
|
Nitrofuran |
|
|
1981 |
Nifurtoinol
|
Nitrofuran |
1973 |
|
1982 |
Nifuratel
|
Nitrofuran |
1960 |
|
1983 |
Nifuroxazide
|
Nitrofuran |
1966 |
|
1984 |
Nifurtimox
|
Nitrofuran |
1965 |
|
1985 |
Nifurzide
|
Nitrofuran |
1981 |
|
1986 |
Nitrofurazone
|
Nitrofuran |
1946 |
|
1987 |
Furagin
|
Nitrofuran |
1984 |
|
1988 |
Azidamfenicol
|
Phenicol |
1978 |
|
1989 |
Chloramphenicol
|
Phenicol |
1947 |
|
1990 |
Florfenicol
|
Phenicol |
1981 |
|
1991 |
Tevenel
|
Phenicol |
1975 |
|
1992 |
Thiamphenicol
|
Phenicol |
1959 |
|
1993 |
Pleuromutilin
|
Pleuromutilin |
1951 |
|
1994 |
Retapamulin
|
Pleuromutilin |
2005 |
|
1995 |
Erythromycin
|
Macrolide (14-membered macrolide) |
1952 |
|
1996 |
Telithromycin
|
Macrolide (14-membered macrolide, ketolide) |
1994 |
|
1997 |
Modithromycin
|
Macrolide (14-membered macrolide, ketolide) |
1981 |
Phase 1 |
1998 |
Roxithromycin
|
Macrolide (14-membered macrolide) |
1986 |
|
1999 |
Spiramycin
|
Macrolide (16-membered macrolide) |
1954 |
|
2000 |
Midecamycin
|
Macrolide (16-membered macrolide) |
1975 |
|
2001 |
Rokitamycin
|
Macrolide (16-membered macrolide) |
1981 |
|
2002 |
Flurithromycin
|
Macrolide (14-membered macrolide) |
1985 |
|
2003 |
Dirithromycin
|
Macrolide (14-membered macrolide) |
1987 |
Approved by FDA in 1995 |
2004 |
Oleandomycin
|
Macrolide (14-membered macrolide) |
1945 |
|
2005 |
Troleandomycin
|
Macrolide (14-membered macrolide) |
1964 |
|
2006 |
Josamycin
|
Macrolide (16-membered macrolide) |
1964 |
|
2007 |
Fidaxomicin
|
Macrolide (18-membered macrolide, tiacumicin) |
1980 |
|
2008 |
Tetracycline
|
Tetracycline |
1953 |
|
2009 |
Chlortetracycline
|
Tetracycline |
1945 |
|
2010 |
Oxytetracycline (terramycin)
|
Tetracycline |
1952 |
|
2011 |
Doxycycline
|
Tetracycline |
1957 |
|
2012 |
Tigecycline
|
Tetracycline |
1999 |
|
2013 |
Demeclocycline
|
Tetracycline |
1962 |
|
2014 |
Meclocycline
|
Tetracycline |
1964 |
|
2015 |
Rolitetracycline
|
Tetracycline |
1958 |
|
2016 |
Lymecycline
|
Tetracycline |
1961 |
|
2017 |
Clomocycline
|
Tetracycline |
1966 |
|
2018 |
Bacitracin
|
Polypeptide |
1943 |
|
2019 |
Colistin
|
Polymyxin |
1947 |
|
2020 |
Polymyxin B
|
Polymyxin |
1947 |
|
2021 |
Tyrothricin
|
Polypeptide |
1940 |
|
2022 |
Gramicidin
|
Polypeptide |
1939 |
|
2023 |
Nalidixic acid
|
Quinolone |
1962 |
|
2024 |
Ciprofloxacin
|
Fluoroquinolone |
1980 |
|
2025 |
Moxifloxacin
|
Fluoroquinolone |
1989 |
Approved by FDA in 2001 |
2026 |
Levofloxacin
|
Fluoroquinolone |
1985 |
|
2027 |
Sitafloxacin
|
Fluoroquinolone |
1992 |
|
2028 |
Cinoxacin
|
Quinolone |
1972 |
Approved by FDA in 1980 |
2029 |
Prulifloxacin
|
Fluoroquinolone |
1987 |
|
2030 |
Enoxacin
|
Fluoroquinolone |
1983 |
Approved by FDA in 1991 |
2031 |
Garenoxacin
|
Fluoroquinolone |
2000 |
|
2032 |
Gemifloxacin
|
Fluoroquinolone |
1997 |
|
2033 |
Lomefloxacin
|
Fluoroquinolone |
1987 |
Approved by FDA in 1992 |
2034 |
Nadifloxacin
|
Fluoroquinolone |
1989 |
|
2035 |
Pipemidic acid
|
Quinolone |
1974 |
|
2036 |
Norfloxacin
|
Fluoroquinolone |
1978 |
|
2037 |
Ofloxacin
|
Fluoroquinolone |
1980 |
|
2038 |
Pazufloxacin
|
Fluoroquinolone |
1986 |
|
2039 |
Pefloxacin
|
Fluoroquinolone |
1979 |
|
2040 |
Rufloxacin
|
Fluoroquinolone |
1987 |
Approved |
2041 |
Sparfloxacin
|
Fluoroquinolone |
1985 |
Approved by FDA in 1996 |
2042 |
Temafloxacin
|
Fluoroquinolone |
1984 |
Approved by FDA in 1992 |
2043 |
Trovafloxacin
|
Fluoroquinolone |
1993 |
Approved by FDA in 1997 |
2045 |
Piromidic acid
|
Quinolone |
1967 |
|
2046 |
Fleroxacin
|
Fluoroquinolone |
1986 |
|
2048 |
Finafloxacin
|
Fluoroquinolone |
2000 |
|
2049 |
Tosufloxacin
|
Fluoroquinolone |
1985 |
|
2050 |
Besifloxacin
|
Fluoroquinolone |
2000 |
|
2051 |
Levonadifloxacin
|
Fluoroquinolone |
2001 |
Approved 2014 |
2052 |
Flumequine
|
Fluoroquinolone |
1973 |
|
2053 |
Pristinamycin
|
Streptogramin |
1962 |
|
2054 |
Quinupristin/dalfopristin (Synercid)
|
Streptogramin |
1989 |
Approved by FDA in 1999 |
2055 |
Dalfopristin
|
Streptogramin |
1989 |
|
2056 |
Quinupristin
|
Streptogramin |
1989 |
Approved |
2057 |
Prontosil
|
Sulfa drug / Sulphonamide |
1935 |
|
2058 |
Sulfanilamide
|
Sulfa drug / Sulphonamide |
1940 |
|
2059 |
Sulfabenzamide
|
Sulfa drug / Sulphonamide |
1943 |
|
2060 |
Sulfacetamide
|
Sulfa drug / Sulphonamide |
1941 |
|
2061 |
Sulfachlorpyridazine
|
Sulfa drug / Sulphonamide |
1957 |
|
2062 |
Sulfadiazine
|
Sulfa drug / Sulphonamide |
1941 |
|
2063 |
Sulfadimethoxine
|
Sulfa drug / Sulphonamide |
1958 |
|
2064 |
Sulfaguanidine
|
Sulfa drug / Sulphonamide |
1941 |
|
2065 |
Sulfamerazine
|
Sulfa drug / Sulphonamide |
1944 |
|
2067 |
Sulfamethazine
|
Sulfa drug / Sulphonamide |
1945 |
|
2068 |
Sulfamethizole
|
Sulfa drug / Sulphonamide |
1953 |
|
2069 |
Sulfamethoxazole
|
Sulfa drug / Sulphonamide |
1950 |
|
2070 |
Sulfamethoxypyridazine
|
Sulfa drug / Sulphonamide |
1956 |
|
2071 |
Sulfamonomethoxine
|
Sulfa drug / Sulphonamide |
1962 |
|
2072 |
Sulfaphenazole
|
Sulfa drug / Sulphonamide |
1958 |
|
2073 |
Sulfapyridine
|
Sulfa drug / Sulphonamide |
1937 |
|
2074 |
Sulfathiazole
|
Sulfa drug / Sulphonamide |
1942 |
|
2075 |
Sulfisoxazole
|
Sulfa drug / Sulphonamide |
1949 |
|
2076 |
Sulfametomidine
|
Sulfa drug / Sulphonamide |
1961 |
|
2077 |
Sulfamethoxypyrazine
|
Sulfa drug / Sulphonamide |
1953 |
|
2078 |
Sulfadoxine
|
Sulfa drug / Sulphonamide |
1962 |
|
2079 |
Sulfametrole
|
Sulfa drug / Sulphonamide |
1975 |
|
2080 |
Sulfaperine
|
Sulfa drug / Sulphonamide |
1946 |
|
2081 |
Sulfamoxole
|
Sulfa drug / Sulphonamide |
1961 |
|
2082 |
Sulfasalazine
|
Sulfa drug / Sulphonamide |
1959 |
|
2083 |
Sulfathiourea
|
Sulfa drug / Sulphonamide |
1946 |
|
2084 |
Mafenide
|
Sulfa drug / Sulphonamide |
1948 |
|
2085 |
Sulfamethoxazole+trimethoprim
|
Drug combination |
1959 |
|
2086 |
Thiolutin
|
RNA polymerase inhibitor (dithiolopyrrolone) |
1950 |
|
2087 |
Holomycin
|
RNA polymerase inhibitor (dithiolopyrrolone) |
1959 |
|
2088 |
Aureothricin
|
RNA polymerase inhibitor (dithiolopyrrolone) |
1948 |
|
2089 |
Actinorhodin
|
Polyketide |
1947 |
|
2090 |
Batumin
|
Fatty acid synthesis inhibitor (FabI inhibitor, polyketide) |
1996 |
|
2091 |
Ripostatin
|
RNA polymerase inhibitor |
1995 |
|
2092 |
Murgocil
|
MurG inhibitor |
2013 |
|
2093 |
Friulimicin
|
Lipopeptide |
2000 |
Phase 1 |
2094 |
Copsin
|
Antimicrobial peptide (defensin) |
2014 |
|
2095 |
Fosfonochlorin
|
Phosphonic acid |
1982 |
|
2096 |
Tiamulin
|
Pleuromutilin |
1951 |
|
2097 |
Valnemulin
|
Pleuromutilin |
1997 |
|
2098 |
Cycloserine
|
Isoxazoline |
1955 |
Approved by FDA in 1964 |
2099 |
Streptolydigin
|
RNA polymerase inhibitor |
1955 |
|
2100 |
Streptomycin
|
Aminoglycoside |
1944 |
Approved by FDA in 1946 |
2101 |
Ceftetrame (Ro15-8074)
|
Beta-lactam |
1984 |
Preclinical |
2102 |
Tunicamycin
|
Natural product antibiotic |
1971 |
|
2103 |
Amphomycin
|
Lipopeptide |
1953 |
|
2104 |
MX-2401
|
Small molecule antibacterial agent |
2006 |
Preclinical |
2105 |
Muraymycin
|
Natural product antibiotic |
2002 |
|
2106 |
Liposidomycin
|
Natural product antibiotic |
1985 |
|
2107 |
Capuramycin
|
Natural product antibiotic |
1986 |
|
2108 |
Muraminomicin
|
Natural product antibiotic |
2012 |
|
2109 |
CPZEN-45
|
Small molecule antibacterial agent |
2008 |
Preclinical |
2110 |
Pacidamycin
|
Natural product antibiotic |
1988 |
|
2111 |
Sansanmycin
|
Natural product antibiotic |
2007 |
|
2113 |
Malioxamycin
|
Natural product antibiotic |
1980 |
|
2114 |
Luminamicin
|
Macrolide |
1985 |
|
2115 |
Thiotetromycin
|
Natural product antibiotic |
1983 |
|
2116 |
Thiolactomycin
|
Natural product antibiotic |
1981 |
|
2117 |
Thiotetroamide
|
Natural product antibiotic |
1988 |
|
2118 |
Fumaramidimycin
|
Natural product antibiotic |
1975 |
|
2119 |
Nodusmicin
|
Macrolide |
1980 |
|
2120 |
Nargenicin
|
Macrolide |
1980 |
|
2121 |
IMB-H4
|
Small molecule antibacterial agent |
2020 |
|
2122 |
Swalpamycin
|
Macrolide |
1987 |
|
2123 |
Gargantulide A, B, C
|
Macrolide |
2015 |
|
2124 |
Monazomycin
|
Natural product antibiotic |
1963 |
|
2125 |
Desertomycin A, B, G, H
|
Natural product antibiotic |
1958 |
|
2126 |
Moiramide A, B, C
|
Natural product antibiotic |
1994 |
|
2127 |
Corytuberine
|
Natural product antibiotic |
2006 |
|
2128 |
CG 3401
|
Small molecule antibacterial agent |
1975 |
|
2129 |
IMB-0042
|
Small molecule antibacterial agent |
2022 |
|
2130 |
Relacidine and analogues
|
Lipopeptide |
2018 |
|
2131 |
Brevicidine
|
Lipopeptide |
2018 |
|
2132 |
Laterocidine
|
Lipopeptide |
2018 |
|
2133 |
Paenibacterin and analogues
|
Lipopeptide |
2012 |
|
2134 |
Bogorol and analogues
|
Lipopeptide |
2001 |
|
2135 |
Brevibacillin and analogues
|
Lipopeptide |
2016 |
|
2136 |
Succilin and analogues
|
Lipopeptide |
2020 |
|
2137 |
Cerexin and analogues
|
Lipopeptide |
1975 |
|
2138 |
Laterosporulin and analogues
|
Lipopeptide |
2012 |
|
2139 |
GSK945237
|
Small molecule antibacterial agent |
2016 |
Phase 1 |
2140 |
AM-8722
|
Small molecule antibacterial agent |
2014 |
Phase 1 |
2141 |
AM-8085
|
Small molecule antibacterial agent |
2014 |
|
2142 |
DS-2969b
|
Small molecule antibacterial agent |
2017 |
Phase 1 |
2143 |
JSF-2414
|
Small molecule antibacterial agent |
2022 |
|
2144 |
Fascaplysin and derivatives
|
Natural product antibiotic |
1988 |
|
2145 |
DS01750413
|
Small molecule antibacterial agent |
2021 |
|
2146 |
GE23077
|
Natural product antibiotic |
2004 |
|
2147 |
Macolacin and analogues
|
Polymyxin |
2022 |
|
2148 |
Heteroaryl isothiazolones
|
Small molecule antibacterial agent |
2006 |
|
2149 |
Streptavidin
|
Antimicrobial peptide |
1964 |
|
2150 |
Amiclenomycin
|
Antimicrobial peptide |
1974 |
|
2152 |
Tomaymycin
|
Natural product antibiotic |
1972 |
|
2153 |
Fumaquinone
|
Natural product antibiotic |
2005 |
|
2154 |
CMB001
|
Antimicrobial peptide |
2020 |
|
2155 |
Pa-MAP 2
|
Antimicrobial peptide |
2012 |
|
2156 |
SLAP-S25
|
Antimicrobial peptide |
2020 |
|
2157 |
Paeoniflorin
|
Drug efflux pump inhibitor |
2020 |
|
2158 |
Compound 137
|
Small molecule antibacterial agent |
2022 |
|
2159 |
SC5005
|
Small molecule antibacterial agent |
2015 |
|
2160 |
PLP-3
|
Antimicrobial peptide |
2022 |
|
2161 |
S-MGB-364
|
Small molecule antibacterial agent |
2017 |
|
2162 |
Econazole
|
Small molecule antibacterial agent |
2021 |
|
2163 |
CF-296
|
Bacteriophage and/or bacteriophage-derived product |
2021 |
Preclinical |
2164 |
WAM-1
|
Antimicrobial peptide |
2018 |
|
2165 |
Pyocin S5 and pyocin AP41
|
Antimicrobial peptide |
2021 |
|
2166 |
PIM1
|
Antimicrobial peptide |
2020 |
|
2167 |
BTZ-043
|
Small molecule antibacterial agent |
2009 |
Phase 2 (NCT04044001) |
2168 |
GSK2556286
|
Small molecule antibacterial agent |
2022 |
Phase 1 (NCT04472897) |
2169 |
T405
|
Beta-lactam |
2020 |
|
2170 |
Kanglemycin A
|
Rifamycin |
2018 |
|
2171 |
EC/11716
|
DNA synthesis inhibitor |
2021 |
|
2172 |
Punicalagin
|
Antivirulence agent |
2022 |
|
2173 |
MRX-6038
|
Small molecule antibacterial agent |
2022 |
|
2174 |
CDBN-YGXZ
|
Small molecule antibacterial agent |
2023 |
|
2175 |
Negamycin
|
Antimicrobial peptide |
1970 |
|
2176 |
Hinokiflavone
|
Antivirulence agent |
2014 |
|
2177 |
AN11527
|
Small molecule antibacterial agent |
2017 |
|
2178 |
Telacebec
|
Small molecule antibacterial agent |
2013 |
Phase 2 (NCT06481163) |
2179 |
TBAJ-587
|
Small molecule antibacterial agent |
2019 |
Phase 1 (NCT04890535) |
2180 |
PBT2
|
Small molecule antibacterial agent |
2005 |
|
2181 |
S02030 and MB_076
|
Beta-lactamase inhibitor |
2016 |
|
2182 |
TBI-166
|
Small molecule antibacterial agent |
2012 |
Phase 2 (NCT04670120) |
2183 |
TPP8
|
Small molecule antibacterial agent |
2022 |
|
2184 |
EC/11770
|
Small molecule antibacterial agent |
2015 |
|
2185 |
CUO246
|
Small molecule antibacterial agent |
2022 |
|
2186 |
TBI-223
|
Oxazolidinone |
2019 |
Phase 1 (NCT04865536) |
2187 |
Febuxostat
|
Small molecule antibacterial agent |
2022 |
|
2188 |
Cyclohexyl-griselimycin
|
Antimicrobial peptide |
2015 |
|
2189 |
GaMF1
|
Small molecule antibacterial agent |
2020 |
|
2190 |
TPN-0006239
|
Small molecule antibacterial agent |
2017 |
|
2191 |
Vancapticin
|
Lipoglycopeptide |
2023 |
|
2192 |
Gp105
|
Bacteriophage and/or bacteriophage-derived product |
2022 |
|
2193 |
Sulfoxanthicillin
|
Natural product antibiotic |
2023 |
|
2194 |
Chrysomycin A
|
Natural product antibiotic |
1955 |
|
2195 |
PE-2C-C8-DH
|
Polymyxin |
2023 |
|
2196 |
IMB-XMA0038
|
Small molecule antibacterial agent |
2021 |
|
2197 |
Tumebacin
|
Natural product antibiotic |
2023 |
|
2198 |
Mollicellin S
|
Natural product antibiotic |
2021 |
|
2199 |
Avidumicin
|
Antimicrobial peptide |
2023 |
|
2200 |
TP0586532
|
Small molecule antibacterial agent |
2021 |
|
2201 |
Pulvomycin
|
Aminoglycoside |
1957 |
|
2202 |
GT-1
|
Beta-lactam |
2017 |
Phase 1 (Australia ACTRN12618001980224) |
2203 |
GT-055
|
Beta-lactamase inhibitor |
2020 |
|
2204 |
ZIF-67
|
Small molecule antibacterial agent |
2021 |
|
2205 |
Pestalotinone A, pestalotinone B, and pestalotinone C
|
Natural product antibiotic |
2022 |
|
2206 |
Kimidinomycin
|
Macrolide |
2022 |
|
2207 |
Rausuquinone
|
Natural product antibiotic |
2022 |
|
2208 |
Wychimicin
|
Natural product antibiotic |
2022 |
|
2209 |
Thiosemicarbazone
|
Beta-lactamase inhibitor |
2020 |
|
2210 |
TXA6101
|
Small molecule antibacterial agent |
2022 |
|
2211 |
GA003
|
Natural product antibiotic |
2021 |
|
2212 |
Suertide
|
Antimicrobial peptide |
2022 |
|
2213 |
2-(2-amino-3-chloro-benzoylamino)-benzoic acid
|
Antivirulence agent |
2022 |
|
2214 |
Mycomethoxin B
|
Natural product antibiotic |
1972 |
|
2215 |
CSA-13
|
Antimicrobial peptide |
2005 |
|
2216 |
Longicatenamide
|
Antimicrobial peptide |
2021 |
|
2217 |
Aldsulfin
|
Natural product antibiotic |
2021 |
|
2218 |
Tetrahydropiperic acid
|
Antimicrobial peptide |
2021 |
|
2219 |
H2-60, H2-81
|
Small molecule antibacterial agent |
2021 |
|
2220 |
C20-epi-salinomycin derivative
|
Small molecule antibacterial agent |
2022 |
|
2221 |
5-O-mycaminosyltylonolide
|
Macrolide |
2006 |
|
2222 |
Iboxamycin
|
Small molecule antibacterial agent |
2021 |
|
2223 |
Abaucin
|
Small molecule antibacterial agent |
2023 |
|
2224 |
Thermorubin
|
Natural product antibiotic |
1964 |
|
2225 |
GP6738
|
Glycopeptide |
2020 |
|
2226 |
Dynobactin
|
Antimicrobial peptide |
2022 |
|
2227 |
Rifaphenzine
|
Rifampicin |
2021 |
|
2228 |
3′,4′-difluoroquercetin
|
Small molecule antibacterial agent |
2012 |
|
2229 |
BDM73185
|
Drug efflux pump inhibitor |
2022 |
|
2230 |
Picolinamycin
|
Natural product antibiotic |
2020 |
|
2231 |
PIS-A-1
|
Antimicrobial peptide |
2022 |
|
2232 |
Tatiomicin
|
Natural product antibiotic |
2022 |
|
2233 |
Menaquinone Binding Antibiotic (MBA)
|
Small molecule antibacterial agent |
2022 |
|
2234 |
Lawsone derivative 6c
|
Small molecule antibacterial agent |
2020 |
|
2235 |
Venturicidin A
|
Natural product antibiotic |
1989 |
|
2236 |
Evybactin
|
Antimicrobial peptide |
2022 |
|
2237 |
Mithramycin A
|
Natural product antibiotic |
2004 |
|
2238 |
Pyrimidomycin
|
Natural product antibiotic |
2022 |
|
2239 |
F365
|
Lipopeptide |
2022 |
Phase 1 (NCT04808414) |
2240 |
Plantaricin NC8 β derivative
|
Lipopeptide |
2023 |
|
2241 |
6-thioguanine
|
Natural product antibiotic |
2021 |
|
2242 |
MAD1
|
Antimicrobial peptide |
2021 |
|
2243 |
g-D50
|
Membrane-active agent |
2023 |
|
2244 |
PA-13
|
Antimicrobial peptide |
2020 |
|
2245 |
BING
|
Antimicrobial peptide |
2021 |
|
2246 |
Ticagrelor
|
Nucleoside analogue |
2019 |
|
2247 |
D-AP19
|
Antimicrobial peptide |
2022 |
|
2248 |
Homicorcin
|
Antimicrobial peptide |
2021 |
|
2249 |
Angicin
|
Antimicrobial peptide |
2021 |
|
2250 |
NAT13-338148
|
Small molecule antibacterial agent |
2021 |
|
2251 |
Sphaerimicin analogue
|
Small molecule antibacterial agent |
2022 |
|
2252 |
Myricetin
|
Small molecule antibacterial agent |
2023 |
|
2253 |
Ruminococcin C1
|
Antimicrobial peptide |
2019 |
|
2254 |
Oxadiazole 1
|
Small molecule antibacterial agent |
2023 |
|
2255 |
DSM186
|
Small molecule antibacterial agent |
2022 |
|
2256 |
PS757
|
Small molecule antibacterial agent |
2022 |
|
2257 |
Compound 10 HD5 analogue
|
Antimicrobial peptide |
2022 |
|
2258 |
Kasugamycin
|
Aminoglycoside |
1965 |
|
2259 |
1-amino substituted tetrahydrocarbazole (THCz)
|
Cell wall synthesis inhibitor |
2021 |
|
2260 |
AB569
|
Small molecule antibacterial agent |
2020 |
|
2261 |
Amycomicin
|
Natural product antibiotic |
2018 |
|
2262 |
L-CS319
|
Beta-lactamase inhibitor |
2015 |
|
2263 |
Clomiphene
|
Cell wall synthesis inhibitor |
2015 |
|
2264 |
Auranofin
|
Small molecule antibacterial agent |
2015 |
|
2265 |
Micasin
|
Antimicrobial peptide |
2012 |
|
2266 |
Bithionol
|
Membrane-active agent |
2019 |
|
2267 |
Tridecaptin A1
|
Lipopeptide |
2016 |
|
2268 |
4,6-diaryl-5,7-dimethyl coumarin
|
Small molecule antibacterial agent |
2013 |
|
2269 |
Planosporicin
|
Antimicrobial peptide |
2007 |
|
2270 |
Geobacillin I
|
Antimicrobial peptide |
2012 |
|
2271 |
Geobacillin II
|
Antimicrobial peptide |
2012 |
|
2272 |
Thuricin CD
|
Antimicrobial peptide |
2010 |
|
2273 |
Hybrimycin A
|
Aminoglycoside |
1969 |
|
2274 |
Hybrimycin B
|
Aminoglycoside |
1969 |
|
2275 |
ZY4
|
Antimicrobial peptide |
2019 |
|
2276 |
Arylfluorosulfate derivative compound 3 (Ar-O-SO2-F)
|
Small molecule antibacterial agent |
2021 |
|
2277 |
Arylfluorosulfate derivative compound 81 (Ar-O-SO2-F)
|
Small molecule antibacterial agent |
2021 |
|
2278 |
Arylfluorosulfate derivative compound 101 (Ar-O-SO2-F)
|
Small molecule antibacterial agent |
2021 |
|
2279 |
Horine
|
Antimicrobial peptide |
2020 |
|
2280 |
Verine
|
Antimicrobial peptide |
2020 |
|
2281 |
Peptide K6
|
Antimicrobial peptide |
2023 |
|
2282 |
Shapeshifting vancomycin dimer (SVD 6d)
|
Glycopeptide |
2023 |
|
2283 |
Mitoxantrone
|
Small molecule antibacterial agent |
2023 |
|
2284 |
Omega 76
|
Antimicrobial peptide |
2019 |
|
2285 |
Cutimycin
|
Antimicrobial peptide (thiopeptide) |
2020 |
|
2286 |
Small Molecule Aborting Resistance (SMARt-420)
|
Small molecule antibacterial agent |
2017 |
|
2287 |
DCH
|
Antibiofilm agent |
2020 |
|
2288 |
N-benzyl–substituted 3′-(R)-3′-aminomethyl-3′-hydroxy spectinomycin 1
|
Aminoglycoside |
2015 |
|
2289 |
N-benzyl–substituted 3′-(R)-3′-aminomethyl-3′-hydroxy spectinomycin 2
|
Aminoglycoside |
2015 |
|
2290 |
N-benzyl–substituted 3′-(R)-3′-aminomethyl-3′-hydroxy spectinomycin 3
|
Aminoglycoside |
2015 |
|
2291 |
N-benzyl–substituted 3′-(R)-3′-aminomethyl-3′-hydroxy spectinomycin 4
|
Aminoglycoside |
2015 |
|
2292 |
Cilagicin
|
Lipopeptide |
2022 |
|
2293 |
Cilagicin BP
|
Lipopeptide |
2022 |
|
2294 |
Mast-MO
|
Antimicrobial peptide |
2020 |
|
2295 |
3,5- dimethoxy-2-(methylthio)cyclohexa-2,5-diene-1,4-dione
|
Small molecule antibacterial agent |
2019 |
|
2296 |
5-methoxy-2,3- bis(methylthio)cyclohexa-2,5-diene-1,4-dione
|
Small molecule antibacterial agent |
2019 |
|
2297 |
Cholestenone
|
Small molecule antibacterial agent |
2021 |
|
2298 |
AZ1
|
Small molecule antibacterial agent |
2015 |
|
2299 |
JH-LPH-28
|
Small molecule antibacterial agent |
2020 |
|
2300 |
JH-LPH-33
|
Small molecule antibacterial agent |
2020 |
|
2301 |
NL1
|
Small molecule antibacterial agent |
2021 |
|
2302 |
NL2
|
Small molecule antibacterial agent |
2021 |
|
2303 |
NL3
|
Small molecule antibacterial agent |
2021 |
|
2304 |
Oligoamidine 3
|
Membrane-active agent |
2021 |
|
2305 |
SAAP-148
|
Antimicrobial peptide |
2018 |
|
2306 |
LPC-233
|
Lipopolysaccharide synthesis inhibitor |
2023 |
|
2307 |
Phenelfamycin B
|
Natural product antibiotic |
1988 |
|
2308 |
Equisetin
|
Natural product antibiotic |
2013 |
|
2309 |
Demethoxytetronasin
|
Natural product antibiotic |
2023 |
|
2310 |
Tetronasin
|
Natural product antibiotic |
1988 |
|
2311 |
Van-QC14
|
Glycopeptide |
2016 |
|
2312 |
BAY 11-7082
|
Small molecule antibacterial agent |
2022 |
|
2313 |
Feleucin-K59 (K59)
|
Antimicrobial peptide |
2021 |
|
2314 |
Plantazolicin
|
Antimicrobial peptide |
2011 |
|
2315 |
Phocoenamicin
|
Macrolide |
2018 |
|
2316 |
AMINOPIP2-ceftazidime 12
|
Beta-lactam |
2020 |
|
2317 |
Ionized NonClassical Antifolate (INCA) compound 14
|
Small molecule antibacterial agent |
2019 |
|
2318 |
TBL-140
|
Small molecule antibacterial agent |
2016 |
|
2319 |
ETX1317
|
Beta-lactamase inhibitor |
2020 |
|
2320 |
1,2,3-Triazolylmethaneboronate compound 6q
|
Beta-lactamase inhibitor |
2020 |
|
2321 |
MAC-0547630
|
Small molecule antibacterial agent |
2016 |
|
2322 |
QDP-1
|
Beta-lactamase inhibitor |
2022 |
|
2323 |
Pt@ZIF8
|
Membrane-active agent |
2023 |
|
2324 |
Peptide 73
|
Antimicrobial peptide |
2019 |
|
2325 |
Clovibactin
|
Natural product antibiotic |
2023 |
|
2326 |
SCH-79797
|
Membrane-active agent |
2018 |
|
2327 |
Irresistin-16
|
Small molecule antibacterial agent |
2020 |
|
2328 |
TAM16
|
Small molecule antibacterial agent |
2017 |
|
2329 |
Pseudouridimycin
|
Natural product antibiotic |
2017 |
|
2330 |
Bacillimidazole G
|
Natural product antibiotic |
2023 |
|
2331 |
Artocarpin
|
Membrane-active agent |
2017 |
|
2332 |
Micrococcin P2
|
Antimicrobial peptide |
2022 |
|
2333 |
Mindapyrrole B
|
Natural product antibiotic |
2019 |
|
2334 |
Berberine
|
Drug efflux pump inhibitor |
2010 |
|
2335 |
Krisynomycin B
|
Antimicrobial peptide |
2020 |
|
2336 |
Krisynomycin C
|
Antimicrobial peptide |
2020 |
|
2337 |
8-deacetylcyclocalopin B
|
Natural product antibiotic |
2018 |
|
2338 |
Somuncurin-1
|
Antimicrobial peptide |
2020 |
|
2339 |
Arsinothricin
|
Natural product antibiotic |
2018 |
|
2340 |
Chuangxinmycin
|
Natural product antibiotic |
1976 |
|
2341 |
Enduracyclinone A
|
Natural product antibiotic |
2019 |
|
2342 |
Fucomycin V
|
Natural product antibiotic |
2023 |
|
2343 |
Tamarixetin
|
Natural product antibiotic |
2018 |
|
2344 |
Acidonemycin
|
Antivirulence agent |
2023 |
|
2345 |
Cudraflavone C
|
Natural product antibiotic |
2021 |
|
2346 |
Triculamin
|
Antimicrobial peptide |
1958 |
|
2347 |
Metamarin
|
Antivirulence agent |
2021 |
|
2348 |
Albomycin δ2
|
Natural product antibiotic |
1947 |
|
2349 |
Salvarsan
|
Small molecule antibacterial agent |
1907 |
|
2350 |
Aspergillomarasmine A
|
Beta-lactamase inhibitor |
2021 |
|
2351 |
Beta-chloro-D-alanine
|
Small molecule antibacterial agent |
1974 |
|
2352 |
Cadaside A
|
Lipopeptide |
2019 |
|
2353 |
Cerulenin
|
Natural product antibiotic |
1960 |
|
2354 |
Thiomarinol A
|
Natural product antibiotic |
1993 |
|
2355 |
Ribocil C-PA
|
Small molecule antibacterial agent |
2020 |
|
2356 |
Vancomycin GR-MoTr conjugate
|
Glycopeptide |
2018 |
|
2357 |
Myxovalargin
|
Antimicrobial peptide |
1983 |
|
2358 |
Everninomicin P
|
Natural product antibiotic |
2020 |
|
2359 |
GE81112 B1
|
Antimicrobial peptide |
2021 |
|
2360 |
Apralog 57β
|
Aminoglycoside |
2020 |
|
2361 |
Concolactam
|
Antivirulence agent |
2023 |
|
2362 |
Albofungin
|
Natural product antibiotic |
1973 |
|
2363 |
TAN1532B
|
Natural product antibiotic |
2018 |
|
2364 |
Bequinostatin E
|
Natural product antibiotic |
2018 |
|
2365 |
Benastatin B
|
Natural product antibiotic |
1992 |
|
2366 |
qDP-1
|
Small molecule antibacterial agent |
2022 |
|
2367 |
Promysalin
|
Natural product antibiotic |
2011 |
|
2368 |
Streptosactin
|
Antimicrobial peptide |
2020 |
|
2369 |
AM10SL018
|
Polymyxin |
2023 |
|
2370 |
L-linker daptomycin conjugate 7
|
Small molecule antibacterial agent |
2020 |
|
2371 |
Mannopeptimycin
|
Glycopeptide |
1970 |
|
2372 |
Maxamycin 20
|
Glycopeptide |
2023 |
|
2373 |
Maxamycin 21
|
Glycopeptide |
2023 |
|
2374 |
Maxamycin 22
|
Glycopeptide |
2023 |
|
2375 |
Dialkylamine 1
|
Natural product antibiotic |
2021 |
|
2376 |
Chrysophaentin A
|
Natural product antibiotic |
2010 |
|
2377 |
Beta-peptide polymer P4
|
Antimicrobial peptide |
2022 |
|
2378 |
Isopedopeptin B
|
Antimicrobial peptide |
2020 |
|
2379 |
V30-SP-8
|
Antimicrobial peptide |
2020 |
|
2380 |
Liproxstatin-1
|
Small molecule antibacterial agent |
2021 |
|
2381 |
MAC-0568743
|
Small molecule antibacterial agent |
2021 |
|
2382 |
Harundomycin A
|
Natural product antibiotic |
2022 |
|
2383 |
Siamycin I
|
Antimicrobial peptide |
2017 |
|
2384 |
Oxa 1
|
Small molecule antibacterial agent |
2020 |
|
2385 |
Oxa 2
|
Small molecule antibacterial agent |
2020 |
|
2386 |
Obafluorin
|
Natural product antibiotic |
2019 |
|
2387 |
TXH9179
|
Small molecule antibacterial agent |
2023 |
|
2388 |
GW3965 HCl
|
Small molecule antibacterial agent |
2019 |
|
2389 |
Cyclic temporin L peptide 12
|
Antimicrobial peptide |
2021 |
|
2390 |
5-amino-4-quinolone 111
|
Quinolone |
2022 |
|
2391 |
Neolignan-AMP mimic conjugate III5
|
Antimicrobial peptide |
2022 |
|
2392 |
Neolignan-AMP mimic conjugate III15
|
Antimicrobial peptide |
2022 |
|
2393 |
Apidaecin 137
|
Antimicrobial peptide |
2013 |
|
2394 |
Anoplin A-21
|
Antimicrobial peptide |
2021 |
|
2395 |
6-arylmethylidene penicillin-based sulfone
|
Beta-lactamase inhibitor |
2020 |
|
2396 |
d,l-K6L9 Amp1D
|
Antimicrobial peptide |
2022 |
|
2397 |
F(RI)2R
|
Antimicrobial peptide |
2022 |
|
2398 |
F(KW)2K
|
Antimicrobial peptide |
2022 |
|
2399 |
YU253434
|
Small molecule antibacterial agent |
2020 |
|
2400 |
Dipicolylamine-containing carbazole derivatives combined with Zn2+
|
Antimicrobial peptide |
2021 |
|
2401 |
Kaempferol-derived compound 52
|
Small molecule antibacterial agent |
2020 |
|
2402 |
Bakuchiol derivative compound 28
|
Antimicrobial peptide |
2021 |
|
2403 |
Aromatic-linked diamino acid AMP mimic 8j
|
Antimicrobial peptide |
2023 |
|
2404 |
AAV-qC10
|
Glycopeptide |
2021 |
|
2405 |
PrAMP Bac7 (1–16)
|
Antimicrobial peptide |
2020 |
|
2406 |
6-pyrenyl PTM 6t
|
Small molecule antibacterial agent |
2018 |
|
2407 |
Imidazolidine-4-one derivative 3
|
Antimicrobial peptide |
2020 |
|
2408 |
Rimomycin derivative 17
|
Glycopeptide |
2023 |
|
2409 |
Honokiol/ Magnolol amphiphile 5i
|
Antimicrobial peptide |
2021 |
|
2410 |
Dimeric lysine alkylamide 3d
|
Antimicrobial peptide |
2018 |
|
2411 |
Nonivamide derivative 51
|
Small molecule antibacterial agent |
2022 |
|
2412 |
Kynomycin
|
Lipopeptide |
2020 |
|
2413 |
3-(4-(cyclopentyloxy)phenyl)-5-(4-nitro-1H-imidazol-2-yl)-1,2,4-oxadiazole
|
Small molecule antibacterial agent |
2023 |
|
2414 |
4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic acid derivative 44
|
Small molecule antibacterial agent |
2023 |
|
2415 |
1,3-Diamino-7H-pyrrol[3,2-f]quinazoline derivative
|
Small molecule antibacterial agent |
2023 |
|
2416 |
Isoxazole (−)17j
|
Small molecule antibacterial agent |
2023 |
|
2417 |
Vancomycin-arginine conjugate
|
Glycopeptide |
2023 |
|
2418 |
MB076
|
Beta-lactamase inhibitor |
2023 |
|
2419 |
Linear brevicidine
|
Antimicrobial peptide |
2023 |
|
2420 |
Linear laterocidine
|
Antimicrobial peptide |
2023 |
|
2421 |
Triazolylpyrimidinediol (triazolyl PD) 7a
|
Small molecule antibacterial agent |
2023 |
|
2422 |
Pyridine-Thiazole-Pleuromutilin 10b
|
Pleuromutilin |
2023 |
|
2423 |
Octapeptin C-02
|
Lipopeptide |
2023 |
|
2424 |
2-substituted 3-hydroxy-1,6-dimethylpyridin-4(1H)-one–ciprofloxacin conjugate 5e
|
Antivirulence agent |
2023 |
|
2425 |
JMV7061
|
Beta-lactamase inhibitor |
2022 |
|
2426 |
Halofuginone derivative 3
|
Small molecule antibacterial agent |
2022 |
|
2427 |
Phenyl sulphide-based cationic amphiphile 17
|
Antimicrobial peptide |
2022 |
|
2428 |
5-Amino-4-quinolone 111, antibacterial agent 123
|
Quinolone |
2022 |
|
2429 |
Spiropyrimidinetrione 42
|
Small molecule antibacterial agent |
2022 |
|
2430 |
N-Aryl mercaptopropionamide 29
|
Beta-lactamase inhibitor |
2022 |
|
2431 |
Rifasutenizol
|
Small molecule antibacterial agent |
2022 |
Phase 3 (NCT05857163) |
2432 |
Sansanmycin analogue 9
|
Antimicrobial peptide |
2017 |
|
2433 |
Sansanmycin analogue 17
|
Antimicrobial peptide |
2017 |
|
2434 |
5-Amino-1,3-dioxane-linked Novel Bacterial Topoisomerase Inhibitor (NBTI) 79
|
Small molecule antibacterial agent |
2021 |
|
2435 |
Pyrimido[4,5-b]indole 18r
|
Small molecule antibacterial agent |
2021 |
|
2436 |
Tricyclic-2-quinolone 25
|
Small molecule antibacterial agent |
2021 |
|
2437 |
6-Halopyridylmethylidene bromopyridyl 2
|
Beta-lactamase inhibitor |
2021 |
|
2438 |
2,4-Dibromo-3-chloro-1-hydroxyphenazine 29
|
Small molecule antibacterial agent |
2021 |
|
2439 |
Adenine–benzyltriazolo–pleuromutilin conjugate 35
|
Small molecule antibacterial agent |
2020 |
|
2440 |
KL-L9P
|
Antimicrobial peptide |
2020 |
|
2441 |
Polyaminoisoprenyl derivative 5r/doxycycline combination
|
Small molecule antibacterial agent |
2020 |
|
2442 |
StRRL
|
Antimicrobial peptide |
2023 |
|
2443 |
Xanthohumol derivative IV15
|
Antimicrobial peptide |
2023 |
|
2444 |
12-mer α-helical peptide 8b
|
Antimicrobial peptide |
2023 |
|
2445 |
Peptide 5a
|
Antimicrobial peptide |
2022 |
|
2446 |
Feleucin-K3 derived peptide K122
|
Antimicrobial peptide |
2023 |
|
2447 |
Carbazole-oxadiazole 5g
|
Membrane-active agent |
2022 |
|
2448 |
Nitroimidazole derivative 4d
|
Nitroimidazole |
2022 |
|
2449 |
Benzothiazole-2-thiol compound 18b
|
Membrane-active agent |
2022 |
|
2450 |
Dioxonaphthoimidazolium 32
|
Small molecule antibacterial agent |
2021 |
|
2451 |
N-Aryl-3-mercaptosuccinimide
|
Antivirulence agent |
2020 |
|
2452 |
Heteroaryl phosphonate compound 16
|
Beta-lactamase inhibitor |
2019 |
|
2453 |
Pyridopyrimidine 14e
|
Small molecule antibacterial agent |
2019 |
|
2454 |
Trp-rich dodecapeptide 6
|
Antimicrobial peptide |
2019 |
|
2455 |
7-nitrobenzoxadiazole IV-related compounds
|
Small molecule antibacterial agent |
2013 |
|
2456 |
Cephalosporin–fluoroquinolone prodrug 35
|
Beta-lactam |
2019 |
|
2457 |
Cinchona alkaloid 48
|
Small molecule antibacterial agent |
2019 |
|
2458 |
Pyrrolo-imidazolone 18d
|
Small molecule antibacterial agent |
2020 |
|
2459 |
(E)-3-(5-carboxy-2-fluorophenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one 73
|
Small molecule antibacterial agent |
2020 |
|
2460 |
C8-linked pyrrolobenzodiazepine (PBD) 7, C8-linked pyrrolobenzodiazepine (PBD) 8
|
Small molecule antibacterial agent |
2020 |
|
2461 |
Tideglusib and its analogues
|
Antivirulence agent |
2020 |
|
2462 |
Cyclic IDR-1018
|
Antimicrobial peptide |
2020 |
|
2463 |
N-((1,3,6-trimethyl-4-oxo-1,4-dihydropyridin-2-yl)methyl)hexanamide 10d
|
Antibiofilm agent |
2020 |
|
2464 |
HSGN-218
|
Small molecule antibacterial agent |
2020 |
|
2465 |
2,4-diamino-6-(4-tert-butylphenyl)-1,3,5-trazine (DATPT)
|
Small molecule antibacterial agent |
2022 |
|
2466 |
MsbA-IN-6
|
Drug efflux pump inhibitor |
2022 |
|
2467 |
HSGN-94
|
Small molecule antibacterial agent |
2022 |
|
2468 |
Linker-evolved-group-optimized LEGO-LPPO (lipophosphonoxin) 25
|
Antimicrobial peptide |
2022 |
|
2469 |
Auranofin analogue
|
Small molecule antibacterial agent |
2019 |
|
2470 |
Mastoparan-R1
|
Antimicrobial peptide |
2019 |
|
2471 |
Mastoparan-R4
|
Antimicrobial peptide |
2019 |
|
2472 |
Thienopyrimidinone derivative
|
Small molecule antibacterial agent |
2019 |
|
2473 |
Pyrido[2,3-b]indole 17r
|
Small molecule antibacterial agent |
2020 |
|
2474 |
Chimeric macrocyclic peptide 3a
|
Antimicrobial peptide |
2021 |
|
2475 |
Corallopyronin A
|
RNA polymerase inhibitor |
1985 |
Preclinical |
2476 |
Decatromicins (decatromicin A, decatromicin B)
|
Antimicrobial peptide |
1999 |
|
2477 |
Deoxyactagardine B
|
Antimicrobial peptide |
2010 |
|
2478 |
NVB302
|
Antimicrobial peptide |
2009 |
|
2479 |
Desotamide A
|
Antimicrobial peptide |
2014 |
|
2480 |
Ethambutol
|
Small molecule antibacterial agent |
1961 |
Approved by FDA in 1967 |
2481 |
Flavomycin
|
Natural product antibiotic |
1980 |
Approved for veterinary use only in 1993 |
2482 |
Antibiotic FR900109
|
Natural product antibiotic |
1983 |
|
2483 |
Griseolutin A
|
Natural product antibiotic |
1958 |
|
2484 |
Kirromycin
|
Natural product antibiotic |
1972 |
|
2485 |
Lassomycin
|
Antimicrobial peptide |
2014 |
|
2486 |
Lysobactin
|
Antimicrobial peptide |
1988 |
|
2487 |
Malacidin A
|
Lipopeptide |
2018 |
|
2488 |
Monensin
|
Natural product antibiotic |
1967 |
Approved for veterinary use only in 1975 |
2489 |
Mupirocin
|
Natural product antibiotic |
1971 |
Approved for topical use by FDA in 1997 |
2490 |
Hygromycin A
|
Natural product antibiotic |
1997 |
|
2491 |
Tur1A
|
Antimicrobial peptide |
2018 |
|
2492 |
Tur1B
|
Antimicrobial peptide |
2018 |
|
2493 |
Cacaoidin
|
Antimicrobial peptide |
2020 |
|
2494 |
Symbah-1
|
Antimicrobial peptide |
2021 |
|
2495 |
Daunorubicin
|
Natural product antibiotic |
2023 |
|
2496 |
Ostruthin
|
Natural product antibiotic |
2023 |
|
2497 |
Benzamide 1j
|
Small molecule antibacterial agent |
2018 |
|
2498 |
Tun-X,X
|
Small molecule antibacterial agent |
2018 |
|
2499 |
Ruthenium red
|
Small molecule antibacterial agent |
2020 |
|
2500 |
Armeniaspirol A
|
Antivirulence agent |
2012 |
|
2501 |
Plantacyclin B21AG
|
Antimicrobial peptide |
2020 |
|
2502 |
Dephostatin
|
Antivirulence agent |
2020 |
|
2503 |
BacPROTAC
|
Antivirulence agent |
2023 |
|
2504 |
Chlorotonil A
|
Macrolide |
2007 |
|
2505 |
Suramin
|
Small molecule antibacterial agent |
2014 |
|
2506 |
Quinazolinone 34
|
Antivirulence agent |
2022 |
|
2507 |
4-(4,7-DiMethyl-1,2,3,4-tetrahydroNaphthalene-1-yl)Pentanoic acid (DMNP)
|
Antibiofilm agent |
2021 |
|
2508 |
Enterocin A, Enterocin B
|
Antimicrobial peptide |
2023 |
|
2509 |
JCP276
|
Small molecule antibacterial agent |
2022 |
|
2510 |
Loratadine
|
Antivirulence agent |
2022 |
|
2511 |
Imidazolium bromide salt NIM-Br 1a
|
Small molecule antibacterial agent |
2019 |
|
2512 |
Imidazolium bromide salt NIM-Br 1b
|
Small molecule antibacterial agent |
2019 |
|
2513 |
Imidazolium bromide salt NIM-Br 1c
|
Small molecule antibacterial agent |
2019 |
|
2514 |
Hydroquinone
|
Natural product antibiotic |
2021 |
|
2515 |
Bionectin F
|
Natural product antibiotic |
2022 |
|
2516 |
Imidazoquinoline 5f
|
Small molecule antibacterial agent |
2021 |
|
2517 |
Titanium/Hydroxyapatite
|
Small molecule antibacterial agent |
2023 |
|
2518 |
BRGP-001
|
Antimicrobial peptide |
2023 |
|
2519 |
BRGP-005
|
Antimicrobial peptide |
2023 |
|
2520 |
BRGP-006
|
Antimicrobial peptide |
2023 |
|
2521 |
Caerin 1.1
|
Antimicrobial peptide |
2023 |
|
2522 |
Benzofuran-triazine derivative 8e (2-benzothiazole)
|
Small molecule antibacterial agent |
2023 |
|
2523 |
1,2,3-triazole-thymol derivative 9
|
Small molecule antibacterial agent |
2022 |
|
2524 |
Halicin
|
Small molecule antibacterial agent |
2019 |
|
2525 |
Amoxapine
|
Small molecule antibacterial agent |
2018 |
|
2526 |
Peptide P3
|
Antimicrobial peptide |
2020 |
|
2527 |
Pept-in P2, Pept-in P33, and Pept-in P5
|
Antimicrobial peptide |
2021 |
|
2528 |
Epithienamycin E
|
Beta-lactam |
1978 |
|
2529 |
Drosocin
|
Antimicrobial peptide |
1996 |
|
2530 |
Abierixin
|
Natural product antibiotic |
1985 |
|
2531 |
Albonoursin
|
Antimicrobial peptide |
2002 |
|
2532 |
Amicetin A
|
Natural product antibiotic |
1953 |
Preclinical |
2533 |
Blasticidin S
|
Natural product antibiotic |
1957 |
|
2534 |
Bottromycin A2
|
Antimicrobial peptide |
1955 |
Preclinical |
2535 |
Bottromycin B2
|
Antimicrobial peptide |
1955 |
Preclinical |
2536 |
Brevimycin
|
Natural product antibiotic |
1970 |
|
2537 |
Brevistin
|
Antimicrobial peptide |
1975 |
|
2538 |
Carbomycin A
|
Macrolide |
1977 |
Preclinical |
2539 |
Cepacin A
|
Natural product antibiotic |
1984 |
|
2540 |
Cepacin B
|
Natural product antibiotic |
1984 |
|
2541 |
Cephamycin C
|
Beta-lactam |
1973 |
Preclinical |
2543 |
Cirratiomycin B
|
Antimicrobial peptide |
1982 |
|
2544 |
Colicin Z
|
Natural product antibiotic |
2019 |
|
2545 |
Deltamycin A1
|
Macrolide |
1978 |
|
2546 |
Deltamycin A2
|
Macrolide |
1978 |
|
2547 |
Denamycin
|
Natural product antibiotic |
1969 |
|
2548 |
Derinamycin
|
Natural product antibiotic |
1975 |
|
2549 |
Diazoquinomycin H
|
Natural product antibiotic |
1982 |
|
2550 |
Diumycin A
|
Natural product antibiotic |
1972 |
|
2551 |
Edeine A
|
Natural product antibiotic |
1970 |
|
2552 |
Ericamycin
|
Natural product antibiotic |
1966 |
|
2553 |
Erythronolide
|
Macrolide |
2005 |
|
2554 |
Ferensimycin
|
Natural product antibiotic |
1982 |
|
2555 |
Fomecin A
|
Natural product antibiotic |
1982 |
|
2556 |
Fortimicin A
|
Aminoglycoside |
1981 |
|
2557 |
Fridamycin
|
Natural product antibiotic |
2003 |
|
2558 |
Fucothricin
|
Aminoglycoside |
1974 |
|
2559 |
Furanomycin
|
Natural product antibiotic |
1998 |
|
2560 |
Fuscin
|
Natural product antibiotic |
1948 |
|
2561 |
Gallidermin
|
Antimicrobial peptide |
1988 |
|
2562 |
Geodin derivative 37
|
Natural product antibiotic |
2022 |
|
2563 |
Griseomycin
|
Macrolide |
1953 |
|
2564 |
Grividomycin
|
Streptogramin |
1987 |
|
2565 |
Gunacin
|
Natural product antibiotic |
1979 |
|
2566 |
Hapalindole T
|
Natural product antibiotic |
2009 |
|
2567 |
Heliomycin
|
Natural product antibiotic |
1984 |
|
2568 |
Hexa-N-benzylneomycin
|
Aminoglycoside |
1973 |
|
2569 |
Hikizimycin
|
Nucleoside analogue |
1979 |
|
2570 |
Hodydamycin
|
Antimicrobial peptide |
1970 |
|
2571 |
Hormaomycin
|
Natural product antibiotic |
1990 |
|
2572 |
Hydroxynybomycin
|
Natural product antibiotic |
1977 |
|
2573 |
Ingramycin
|
Natural product antibiotic |
1971 |
|
2574 |
Inolomin
|
Natural product antibiotic |
1941 |
|
2575 |
Iodinin
|
Natural product antibiotic |
1945 |
|
2576 |
Juglomycin
|
Natural product antibiotic |
1971 |
|
2577 |
Juvenimicin A2
|
Macrolide |
1976 |
|
2578 |
Juvenimicin A3
|
Macrolide |
1973 |
|
2579 |
Kalafungin
|
Natural product antibiotic |
1968 |
|
2580 |
Kinamycin A
|
Natural product antibiotic |
1971 |
|
2581 |
Kinamycin B
|
Natural product antibiotic |
1971 |
|
2582 |
Lactaroviolin
|
Natural product antibiotic |
1947 |
|
2583 |
Lactoquinomycin A
|
Natural product antibiotic |
1976 |
|
2584 |
Lankamycin
|
Macrolide |
1994 |
|
2585 |
Lankacidin C
|
Macrocycle |
1971 |
|
2586 |
Lasalocid
|
Natural product antibiotic |
1979 |
|
2587 |
Lateriomycin
|
Natural product antibiotic |
1969 |
|
2588 |
Lateritiin
|
Natural product antibiotic |
1947 |
|
2589 |
Laterosporin
|
Natural product antibiotic |
1949 |
|
2590 |
Lavendulin
|
Natural product antibiotic |
1953 |
|
2591 |
Leucomycin A7
|
Macrolide |
2010 |
|
2592 |
Leuseramycin
|
Natural product antibiotic |
1979 |
|
2593 |
Libramycin
|
Natural product antibiotic |
1974 |
|
2594 |
Licheniformin
|
Natural product antibiotic |
1947 |
|
2595 |
Lienomycin
|
Macrolide |
1980 |
|
2596 |
Lividomycin A
|
Aminoglycoside |
1972 |
|
2597 |
Longicatenamycin
|
Antimicrobial peptide |
1970 |
|
2598 |
Lonomycin
|
Natural product antibiotic |
1976 |
|
2599 |
Lysocellin
|
Natural product antibiotic |
1969 |
|
2600 |
Macarbomycin
|
Natural product antibiotic |
1973 |
|
2601 |
Macromomycin
|
Antimicrobial peptide |
1968 |
|
2602 |
Manumycin
|
Natural product antibiotic |
1994 |
|
2603 |
Balofloxacin
|
Fluoroquinolone |
2005 |
Approved in Korea |
2604 |
AGXX
|
Small molecule antibacterial agent |
2023 |
|
2605 |
9-propionylmaridomycin
|
Macrolide |
1972 |
|
2606 |
Chimedermycin
|
Natural product antibiotic |
2022 |
|
2607 |
Megalomicin A
|
Macrolide |
1969 |
|
2608 |
Megovalicin D, megovalicin G, megovalicin H
|
Natural product antibiotic |
1988 |
|
2609 |
Chilaphylin
|
Natural product antibiotic |
1973 |
|
2610 |
Mepicycline
|
Tetracycline |
1962 |
|
2611 |
Metacycline (Rondomycin)
|
Tetracycline |
1961 |
Approved |
2612 |
Sch 33256
|
Tetracycline |
1987 |
|
2613 |
8-Methoxychlortetracycline
|
Tetracycline |
1987 |
|
2614 |
2-Methyl-L-arginine
|
Natural product antibiotic |
1976 |
|
2615 |
α-methylbiotin
|
Natural product antibiotic |
1972 |
|
2616 |
α-methyldethiobiotin
|
Natural product antibiotic |
1972 |
|
2617 |
Methylenomycin
|
Natural product antibiotic |
1974 |
|
2618 |
Methymycin
|
Macrolide |
1968 |
|
2619 |
Pikromycin
|
Macrolide |
1968 |
|
2620 |
Microcin proximity-dependent-inhibition (PDI)
|
Antimicrobial peptide |
2012 |
|
2621 |
Micromonosporin
|
Macrolide |
1947 |
|
2622 |
Mimosamycin
|
Natural product antibiotic |
1976 |
|
2623 |
Minimycin
|
Natural product antibiotic |
1972 |
|
2624 |
Minosaminomycin
|
Aminoglycoside |
1974 |
|
2625 |
Moracin C
|
Natural product antibiotic |
2012 |
|
2626 |
Chalcomoracin
|
Natural product antibiotic |
2012 |
|
2627 |
Olemorphocycline
|
Tetracycline |
1968 |
Approved in 1968 (Russia) |
2628 |
Multhiomycin
|
Antimicrobial peptide |
1970 |
|
2629 |
Musettamycin
|
Natural product antibiotic |
1977 |
|
2630 |
Marcellomycin
|
Natural product antibiotic |
1977 |
|
2631 |
Mutalomycin
|
Natural product antibiotic |
1977 |
|
2632 |
Mutamicin
|
Aminoglycoside |
1974 |
|
2633 |
Mycelianamide
|
Small molecule antibacterial agent |
1948 |
|
2634 |
Mycinamicin
|
Macrolide |
1980 |
|
2635 |
Mycobacidin
|
Natural product antibiotic |
1952 |
|
2636 |
Mycocidin
|
Natural product antibiotic |
1945 |
|
2637 |
Myxopyronin
|
Natural product antibiotic |
1983 |
|
2638 |
Nannochelin
|
Natural product antibiotic |
1992 |
|
2639 |
Naphthyridinomycin
|
Natural product antibiotic |
1975 |
|
2640 |
Napyradiomycin
|
Natural product antibiotic |
1986 |
|
2641 |
Narbomycin
|
Macrolide |
2005 |
|
2642 |
Neomycin A
|
Natural product antibiotic |
1951 |
|
2643 |
Neonocardin
|
Natural product antibiotic |
1951 |
|
2644 |
Neoviridogrisein
|
Natural product antibiotic |
1979 |
|
2645 |
Netropsin
|
Natural product antibiotic |
1951 |
|
2646 |
Nigericin
|
Natural product antibiotic |
1951 |
|
2647 |
Nitrosporin
|
Natural product antibiotic |
1952 |
|
2648 |
Nocardamin
|
Natural product antibiotic |
1982 |
|
2649 |
Nogalamycin
|
Natural product antibiotic |
1965 |
|
2650 |
Norplicacetin
|
Natural product antibiotic |
1977 |
|
2651 |
Novenamine
|
Aminocoumarin |
1972 |
|
2652 |
Nybomycin
|
Natural product antibiotic |
1955 |
|
2653 |
Erythronolide A oxime
|
Macrolide |
1974 |
|
2654 |
Oleficin
|
Natural product antibiotic |
1971 |
|
2655 |
Oxamicetin
|
Natural product antibiotic |
1973 |
|
2656 |
Pactamycin
|
Natural product antibiotic |
1962 |
|
2657 |
Paromamine
|
Aminoglycoside |
1964 |
|
2658 |
Parvodicin
|
Glycopeptide |
1987 |
|
2659 |
U-77,802 and U-77,803
|
Natural product antibiotic |
1988 |
|
2660 |
Notatin
|
Beta-lactam |
1942 |
|
2661 |
Penicillin N
|
Beta-lactam |
1953 |
|
2662 |
Penimepicycline
|
Beta-lactam |
1962 |
|
2663 |
Pentenomycin
|
Natural product antibiotic |
1973 |
|
2664 |
Pentenomycin analogues
|
Natural product antibiotic |
2019 |
|
2665 |
AVS-03d
|
Natural product antibiotic |
2008 |
|
2666 |
Pepthiomycin
|
Antimicrobial peptide |
1968 |
|
2667 |
Pholipomycin
|
Natural product antibiotic |
1977 |
|
2668 |
Phthiocol
|
Natural product antibiotic |
1946 |
|
2669 |
Violacein
|
Natural product antibiotic |
1946 |
|
2670 |
Prodigiosin
|
Natural product antibiotic |
1946 |
|
2671 |
Platenomycin A1
|
Macrolide |
1974 |
|
2672 |
Pleocidin
|
Aminoglycoside |
1952 |
|
2673 |
Pleurotin
|
Natural product antibiotic |
1947 |
|
2674 |
Plumbagin
|
Natural product antibiotic |
2016 |
|
2675 |
Polymyxin A
|
Lipopeptide |
1949 |
|
2676 |
Polymyxin D
|
Lipopeptide |
1947 |
|
2677 |
Polymyxin F
|
Lipopeptide |
1977 |
|
2678 |
Polymyxin M
|
Antimicrobial peptide |
2003 |
|
2679 |
Polymyxin P
|
Antimicrobial peptide |
1969 |
|
2680 |
Polymyxin S1
|
Antimicrobial peptide |
1977 |
|
2681 |
Polymyxin T1
|
Antimicrobial peptide |
1977 |
|
2682 |
Polypeptin
|
Antimicrobial peptide |
1948 |
|
2683 |
Polyporin
|
Natural product antibiotic |
1944 |
|
2684 |
Porothramycin
|
Natural product antibiotic |
1988 |
|
2685 |
Portmicin
|
Natural product antibiotic |
1987 |
|
2686 |
Prasinomycin
|
Natural product antibiotic |
1968 |
|
2687 |
Prenomycin
|
Natural product antibiotic |
1974 |
|
2688 |
Proactinomycin
|
Natural product antibiotic |
1949 |
|
2689 |
Platenolide
|
Macrolide |
1978 |
|
2690 |
Proticin
|
Natural product antibiotic |
1972 |
|
2691 |
Protoanemonin
|
Antivirulence agent |
1945 |
|
2692 |
Angustmycin A
|
Natural product antibiotic (adenosine analogues) |
1958 |
|
2693 |
Pterygospermin
|
Natural product antibiotic |
1946 |
|
2694 |
Puberulic acid
|
Natural product antibiotic |
1947 |
|
2695 |
Puromycin
|
Aminoglycoside |
1979 |
|
2696 |
Purpuromycin
|
Protein synthesis inhibitor |
1974 |
|
2697 |
Pyo
|
Quinolone |
1945 |
|
2698 |
Pyoverdin
|
Natural product antibiotic |
2024 |
|
2699 |
Pyracrimycin
|
Natural product antibiotic |
1971 |
|
2700 |
Quinacillin
|
Beta-lactam |
1963 |
|
2701 |
Azalomycin F
|
Macrolide |
1995 |
|
2702 |
CP-84,657
|
Natural product antibiotic |
1990 |
|
2703 |
Salivabactin
|
Antimicrobial peptide |
2024 |
|
2704 |
Compound with N-[2-(2-chlorophenoxy)ethyl]aniline core
|
Small molecule antibacterial agent |
2023 |
|
2705 |
Zosurabalpin
|
Antimicrobial peptide |
2024 |
Phase 1 (NCT05614895) |
2706 |
Quinaldopeptin
|
Natural product antibiotic |
1990 |
|
2707 |
Rabelomycin
|
Natural product antibiotic |
1970 |
|
2708 |
Racemomycin
|
Streptothricin |
1990 |
|
2709 |
Ractinomycin
|
Natural product antibiotic |
1957 |
|
2710 |
Raphanin
|
Natural product antibiotic |
1947 |
|
2711 |
Requinomycin
|
Natural product antibiotic |
1972 |
|
2712 |
Resistaphylin
|
Natural product antibiotic |
1971 |
|
2713 |
Rhodirubin
|
Natural product antibiotic |
1977 |
|
2714 |
Rhodocidin
|
Natural product antibiotic |
1952 |
|
2715 |
Cyanomycin
|
Natural product antibiotic |
1958 |
|
2716 |
Rhodomycetin
|
Natural product antibiotic |
1951 |
|
2717 |
Rhodomycin
|
Natural product antibiotic |
1953 |
|
2718 |
Rifamazine
|
Rifamycin |
1975 |
|
2719 |
Rinamycin
|
Natural product antibiotic |
1975 |
|
2720 |
Ristocetin
|
Glycopeptide |
1956 |
|
2721 |
Rubradirin
|
Natural product antibiotic |
1965 |
|
2722 |
Rubromycin
|
Natural product antibiotic |
1953 |
|
2723 |
Rufomycin
|
Antimicrobial peptide |
1962 |
|
2724 |
Saframycin Mx1
|
Natural product antibiotic |
1987 |
|
2725 |
Sakyomicin
|
Natural product antibiotic |
1984 |
|
2726 |
Salinomycin
|
Natural product antibiotic (polyether antibiotic, ionophore) |
1974 |
|
2727 |
Sancycline
|
Tetracycline |
1962 |
|
2728 |
Sannamycin
|
Aminoglycoside |
1980 |
|
2729 |
Scopafungin
|
Natural product antibiotic |
1971 |
|
2730 |
Schlerothricin
|
Streptothricin |
1969 |
|
2731 |
Selenomycin
|
Natural product antibiotic |
1972 |
|
2732 |
Septamycin
|
Natural product antibiotic |
1975 |
|
2733 |
Shincomycin
|
Macrolide |
1965 |
|
2734 |
Showdomycin
|
Nucleoside analogue |
1964 |
|
2735 |
Sibanomicin
|
Natural product antibiotic |
1988 |
|
2736 |
Siomycin
|
Antimicrobial peptide |
1961 |
|
2737 |
Sorbistin
|
Aminoglycoside |
1976 |
|
2738 |
Sparsomycin
|
Natural product antibiotic |
1962 |
|
2739 |
Spirocardin
|
Natural product antibiotic |
1989 |
|
2740 |
Sporaviridin
|
Natural product antibiotic |
1989 |
|
2741 |
Staphylococcin
|
Antimicrobial peptide |
1975 |
|
2742 |
Staphylomycin S
|
Streptogramin |
1954 |
|
2743 |
Stilbellin
|
Antimicrobial peptide |
1971 |
|
2744 |
Streptocin
|
Natural product antibiotic |
1949 |
|
2745 |
Streptogramin
|
Streptogramin |
1953 |
|
2746 |
Streptolin
|
Streptothricin |
1947 |
|
2747 |
Streptothricin
|
Streptothricin |
1942 |
|
2748 |
Streptovaricin
|
Natural product antibiotic |
1957 |
|
2749 |
Steptovirudin
|
Natural product antibiotic |
1975 |
|
2750 |
Striatin
|
Natural product antibiotic |
1976 |
|
2751 |
Subtenolin
|
Natural product antibiotic |
1945 |
|
2752 |
Subtilin
|
Antimicrobial peptide |
1945 |
|
2753 |
Sulfactin
|
Natural product antibiotic |
1947 |
|
2754 |
Sulfocillin
|
Beta-lactam |
1971 |
|
2755 |
Sulfurmycin
|
Natural product antibiotic |
1982 |
|
2756 |
Suncillin
|
Beta-lactam |
1968 |
|
2757 |
Suzukacillin
|
Antimicrobial peptide |
1965 |
|
2758 |
Teichomycin A1
|
Glycopeptide |
1978 |
|
2759 |
Teichomycin A2
|
Glycopeptide |
1978 |
|
2760 |
Telomycin
|
Antimicrobial peptide |
1957 |
|
2761 |
Tenebrimycin
|
Aminoglycoside |
1972 |
|
2762 |
Tetranactin
|
Natural product antibiotic |
1971 |
|
2763 |
Thermomycin
|
Natural product antibiotic |
1951 |
|
2764 |
Thianosine
|
Polymyxin |
1971 |
|
2765 |
Thienamycin
|
Beta-lactam |
1979 |
|
2766 |
Thiopeptin
|
Antimicrobial peptide |
1972 |
|
2767 |
Tirandamycin
|
Natural product antibiotic |
1971 |
|
2768 |
Tolypomycin
|
Rifamycin |
1971 |
|
2769 |
Triostin
|
Natural product antibiotic |
1968 |
|
2770 |
Tuberactin
|
Antimicrobial peptide |
1968 |
|
2771 |
Tubercidin
|
Natural product antibiotic |
1957 |
Preclinical |
2772 |
Tumimycin
|
Natural product antibiotic |
1972 |
|
2773 |
Umbrinomycin
|
Naphthoquinone |
1970 |
|
2774 |
Unphenelfamycin
|
Natural product antibiotic |
1989 |
|
2775 |
Ustin
|
Natural product antibiotic |
1953 |
|
2776 |
Valinomycin
|
Antimicrobial peptide |
1955 |
|
2777 |
Variamycin
|
Natural product antibiotic |
1971 |
|
2778 |
Variapeptin
|
Antimicrobial peptide |
1990 |
|
2779 |
Viomycin
|
Natural product antibiotic |
1951 |
Approved in 1953 |
2780 |
Viridogrisein
|
Streptogramin |
1958 |
|
2781 |
Xanthocillin X
|
Natural product antibiotic |
1954 |
|
2782 |
Xanthomycin A
|
Tetracycline |
1981 |
|
2783 |
Yemenimycin
|
Antimicrobial peptide |
1971 |
|
2784 |
Zervamicin
|
Antimicrobial peptide |
1974 |
|
2785 |
Zorbamycin
|
Glycopeptide |
1971 |
|
2786 |
Zorbonomycin
|
Glycopeptide |
1971 |
|
2787 |
VanQAmC10
|
Glycopeptide |
2020 |
|
2788 |
RO7196472
|
Antimicrobial peptide |
2024 |
|
2789 |
RO7075573
|
Antimicrobial peptide |
2024 |
Preclinical |
2790 |
Fusidic acid prodrug
|
Fusidane |
2023 |
|
2791 |
Mycoplanecin
|
Natural product antibiotic |
1983 |
|
2792 |
Amycobactin
|
Natural product antibiotic |
2020 |
|
2793 |
Kitamycobactin
|
Natural product antibiotic |
2020 |
|
2794 |
Streptomycobactin
|
Antimicrobial peptide |
2020 |
|
2795 |
MEndoB
|
Bacteriophage and/or bacteriophage-derived product |
2024 |
|
2796 |
NCR094
|
Antimicrobial peptide |
2024 |
|
2797 |
NCR992
|
Antimicrobial peptide |
2024 |
|
2798 |
Hypochlorous acid producing electrochemical bandage (HOCl e-bandage)
|
DNA synthesis inhibitor |
2007 |
|
2799 |
Prodrug methyl tris diazeniumdiolate (prodrug MD3)
|
Membrane-active agent |
2024 |
|
2800 |
φPaP11-13
|
Bacteriophage and/or bacteriophage-derived product |
2024 |
|
2801 |
Z-Ethylthio enynone
|
Antivirulence agent |
2024 |
|
2802 |
Maleimide-diselenide hybrid compound (YH7), YH7
|
Small molecule antibacterial agent |
2024 |
|
2803 |
Ethylenediaminetetraacetic acid (EDTA)/polymyxin B
|
Small molecule antibacterial agent |
2024 |
|
2804 |
Secretion Modification Region (SMRwt) peptide
|
Antimicrobial peptide |
2024 |
|
2805 |
Compound IV (4-[(4-methoxyphenyl)methylsulfanyl]−7-nitro-2,1,3-benzoxadiazole)
|
Small molecule antibacterial agent |
2023 |
|
2806 |
Fisetin
|
Antivirulence agent |
2023 |
|
2807 |
MSU-43085
|
Small molecule antibacterial agent |
2023 |
|
2808 |
Tafenoquine
|
Membrane-active agent |
2021 |
|
2809 |
Amidochelocardin, 2-carboxamido-2-deacetyl-chelocardin
|
Tetracycline |
2015 |
|
2810 |
Stattic
|
Small molecule antibacterial agent |
2023 |
|
2811 |
8-O-methyltetrangomycin (MTN) and 8-O-methyltetrangulol (MTL)
|
Natural product antibiotic |
2023 |
|
2812 |
CU032
|
Drug efflux pump inhibitor |
2023 |
|
2813 |
CU232
|
Drug efflux pump inhibitor |
2023 |
|
2814 |
CU244
|
Drug efflux pump inhibitor |
2023 |
|
2815 |
EPM35
|
Drug efflux pump inhibitor |
2018 |
|
2816 |
(Z)-13-methyltetra-4-decenoic acid ((Z)-4C-14:1)
|
Membrane-active agent |
2023 |
|
2817 |
Romsacin
|
Antimicrobial peptide |
2023 |
|
2818 |
Bactobolin
|
Folate synthesis inhibitor |
2023 |
|
2819 |
NSC367428
|
Folate synthesis inhibitor |
2023 |
|
2820 |
B59
|
Small molecule antibacterial agent |
2023 |
|
2821 |
QingXiaoWuWei (QXWWD)
|
Natural product antibiotic |
2023 |
|
2822 |
Ultra-short palmitoylated 5-mer phenylalanine:lysine (FK5P)
|
Antimicrobial peptide |
2020 |
|
2823 |
S-342-3
|
Antibiofilm agent |
2023 |
|
2824 |
Thiolato-bridged dinuclear ruthenium(II)-arene compound 5
|
Small molecule antibacterial agent |
2023 |
|
2825 |
Thiolato-bridged dinuclear ruthenium(II)-arene compound 6
|
Small molecule antibacterial agent |
2023 |
|
2826 |
Sophorolipid-capped gold nanoparticles (AuNPs-SL)
|
Small molecule antibacterial agent |
2023 |
|
2827 |
Cecropin HC1 (Hill-Cec1)
|
Antimicrobial peptide |
2022 |
|
2828 |
Cecropin HC10 (Hill-Cec10)
|
Antimicrobial peptide |
2022 |
|
2829 |
Shikonin
|
Natural product antibiotic |
2015 |
|
2830 |
WQ-3154
|
Fluoroquinolone |
2023 |
|
2831 |
WQ-3810, KPI-10, WQ-3813
|
Fluoroquinolone |
2014 |
Phase 1 |
2832 |
MMV676501 (Pbc 1)
|
Small molecule antibacterial agent |
2023 |
|
2833 |
MMV676388 (Pbc 2)
|
Small molecule antibacterial agent |
2023 |
|
2834 |
MMV002817 (Pbc 3)
|
Small molecule antibacterial agent |
2023 |
|
2835 |
MMV688508 (Pbc 5)
|
Oxazolidinone |
2023 |
|
2836 |
MMV024937 (Pbc 6)
|
Small molecule antibacterial agent |
2023 |
|
2837 |
MMV272144 (Pbc 8)
|
Small molecule antibacterial agent |
2023 |
|
2838 |
MMV021013 (Pbc 9)
|
Small molecule antibacterial agent |
2023 |
|
2839 |
SMJ-5
|
Drug efflux pump inhibitor |
2023 |
|
2840 |
Cesin A
|
Antimicrobial peptide |
2022 |
|
2841 |
Coli myophage (Killian)
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
|
2842 |
Tricyclic amide NBTI (N-(2-((9-fluoro-4-oxo-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)methyl)- trans -1,3-dioxan-5-yl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-carboxamide)
|
DNA synthesis inhibitor |
2023 |
|
2843 |
Eugenol
|
Small molecule antibacterial agent |
2023 |
|
2844 |
NCL195
|
Small molecule antibacterial agent |
2017 |
|
2845 |
KKL-55
|
Small molecule antibacterial agent |
2013 |
|
2846 |
HC2210
|
Nitroimidazole |
2023 |
|
2847 |
AJ-037, AJ-039, and AJ-206
|
Antimicrobial peptide |
2023 |
|
2848 |
RP557
|
Antimicrobial peptide |
2019 |
|
2849 |
Famotidine
|
Membrane-active agent |
2023 |
|
2850 |
Silver-tellurite combination
|
Small molecule antibacterial agent |
2022 |
|
2851 |
MJ-22
|
Small molecule antibacterial agent |
2023 |
|
2852 |
B6
|
Small molecule antibacterial agent |
2012 |
|
2853 |
Ceftazidime-decorated gold nanoparticles (CAZ_Au NPs)
|
Membrane-active agent |
2023 |
|
2854 |
Artificial-Bp7e6 endolysin (Art-Bp7e6)
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
|
2855 |
Wollamide B
|
Antimicrobial peptide |
2014 |
|
2856 |
Acidicin P
|
Antimicrobial peptide |
2022 |
|
2857 |
Phosphonoalamide F
|
Natural product antibiotic |
2023 |
|
2858 |
NH125, 1-benzyl-3-cetyl-2-methylimidazolium iodide
|
Small molecule antibacterial agent |
2000 |
|
2859 |
CY-158-11
|
Antibiofilm agent |
2023 |
|
2860 |
GE81112 A
|
Antimicrobial peptide |
2006 |
|
2861 |
ClyQ
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
|
2862 |
PlyKp104
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
|
2863 |
Antibiotic 2B5
|
Antibiofilm agent |
2023 |
|
2864 |
Baicalein
|
Membrane-active agent |
2005 |
|
2865 |
Thymol-decorated gold nanoparticle (Thymol_Au NPs)
|
Membrane-active agent |
2023 |
|
2866 |
Secreted antigen A (SagA)
|
Cell wall synthesis inhibitor |
2023 |
|
2867 |
Heterocyclic iodonium salt analogue 3a
|
Small molecule antibacterial agent |
2023 |
|
2868 |
Flufenamic acid
|
Membrane-active agent |
2023 |
|
2869 |
NITD-916
|
Small molecule antibacterial agent |
2015 |
|
2870 |
APC148
|
Beta-lactamase inhibitor |
2020 |
Phase 1 (NCT06360640) |
2871 |
APL-2301
|
Membrane-active agent |
2024 |
Phase 1 (to begin in Australia in 2024) |
2872 |
PF-07612577 (avibactam tomilopil [ARX-1796] + ceftibuten)
|
Beta-lactam + beta-lactamase inhibitor |
2023 |
Phase 1 (NCT05554237) |
2873 |
KSP-1007+meropenem
|
Beta-lactam + beta-lactamase inhibitor |
2023 |
Phase 1 (NCT05226923) |
2874 |
R327 (RECCE 327)
|
Membrane-active agent |
2023 |
Phase 1/Phase 2 (ACTRN12623000056695; ACTRN12623000448640; ACTRN12621001313820) |
2875 |
RG6319, GDC-5780
|
Small molecule antibacterial agent |
2022 |
Phase 1 (ISRCTN16073754) |
2876 |
BV100 (Mycobutin)
|
Rifamycin |
2022 |
Phase 1 (NCT05685615) |
2877 |
FL058/meropenem
|
Beta-lactam + beta-lactamase inhibitor |
2023 |
Phase 2 (NCT05060419) |
2878 |
Gallium citrate (AR-501)
|
Small molecule antibacterial agent |
2011 |
Phase 2 (NCT0366614) |
2879 |
Nacubactam/Aztreonam (OP0595/Aztreonam)
|
Beta-lactam + beta-lactamase inhibitor |
2015 |
Phase 3 (NCT05887908) |
2880 |
Cefepime + Tazobactam
|
Beta-lactam + beta-lactamase inhibitor |
2018 |
Phase 3 (NCT03630081) |
2881 |
APT-CF phage (WRAIR-PAM-CF1)
|
Bacteriophage and/or bacteriophage-derived product |
2022 |
Phase 2 (NCT05453578) |
2882 |
AP-PA02
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
Phase 2 (NCT05616221) |
2883 |
CF-370
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
Preclinical |
2884 |
CMTX101
|
Antibody |
2023 |
Phase 1 (NCT06159725) |
2885 |
SER-155
|
Natural product antibiotic |
2022 |
Phase 1 (NCT04995653) |
2886 |
SNIPR001
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
Phase 1 (NCT05277350) |
2887 |
TP-102
|
Bacteriophage and/or bacteriophage-derived product |
2022 |
Phase 2 (NCT05948592) |
2888 |
BX004
|
Bacteriophage and/or bacteriophage-derived product |
2023 |
Phase 2 (NCT05010577) |
2889 |
F598
|
Antibody |
2013 |
Phase 2 (NCT03222401) |
2890 |
LBP-EC01
|
Bacteriophage and/or bacteriophage-derived product |
2022 |
Phase 2 (NCT05488340) |
2891 |
Macozinone (MCZ; PBTZ169)
|
Small molecule antibacterial agent |
2014 |
Phase 2 (NCT03334734) |
2892 |
SPR720 (phosphate prodrug of SPR719)
|
Small molecule antibacterial agent |
2018 |
Phase 2 (NCT05496374) |
2893 |
BB2-50F
|
Antivirulence agent |
2021 |
|
2894 |
TBA-7371
|
Small molecule antibacterial agent |
2014 |
Phase 2 (NCT04176250) |
2895 |
Salifungin
|
Membrane-active agent |
2024 |
|
2896 |
Conjugate 16 (22-[4-(6-((6-(Piperazin-1-yl)-9H-purin-9-yl)methyl)pyridin-3-yl)-1H-1,2,3-triazol-1-yl]-22-deoxypleuromutilin)
|
Pleuromutilin |
2024 |
|
2897 |
Meropenem/ANT3310
|
Beta-lactam + beta-lactamase inhibitor |
2024 |
Phase 1 (NCT05905913) |
2898 |
Mavintramycin A
|
Protein synthesis inhibitor |
2024 |
|
2899 |
Cresomycin
|
Protein synthesis inhibitor |
2024 |
|
2900 |
Autoinducing peptide (AIP II, AIP IV, and AIP V)
|
Antivirulence agent |
2024 |
|
2901 |
Compound 23 (4-(4-(Hydroxymethyl)phenyl)-3-(1H-tetrazol-5-yl)pyridine-2-sulfonamide)
|
Beta-lactamase inhibitor |
2022 |
|
2902 |
Epifadin
|
Membrane-active agent |
2024 |
|
2903 |
Reutericyclin A
|
Membrane-active agent |
2000 |
|
2904 |
Lugdunin
|
Antimicrobial peptide |
2016 |
|
2905 |
Metamycin C
|
Small molecule antibacterial agent |
2019 |
|
2906 |
Metamycin D
|
Small molecule antibacterial agent |
2019 |
|
2907 |
Epilancin 15X
|
Antimicrobial peptide |
2005 |
|
2908 |
PQQ16P
|
Drug efflux pump inhibitor |
2018 |
|
2909 |
NSC 33353
|
Drug efflux pump inhibitor |
2017 |
|
2910 |
NSC 305798
|
Drug efflux pump inhibitor |
2017 |
|
2911 |
BDM91288
|
Drug efflux pump inhibitor |
2023 |
|
2912 |
BDM91270
|
Drug efflux pump inhibitor |
2023 |
|
2913 |
Pyridomycin
|
Natural product antibiotic |
2012 |
|
2914 |
Vancomycin-templated DEL-derived vancomycin analogue
|
Glycopeptide |
2024 |
|
2915 |
Lusutrombopag
|
Membrane-active agent |
2024 |
|
2916 |
Silver N-heterocyclic carbene halido complex
|
Small molecule antibacterial agent |
2024 |
|
2917 |
Oct-TriA5 (tridecaptin A5 derivative)
|
Antimicrobial peptide |
2024 |
|
2918 |
Bosutinib
|
Small molecule antibacterial agent |
2024 |
|
2919 |
Compound 162
|
Small molecule antibacterial agent |
2024 |
|
2920 |
YFJ-36 (compound 86b)
|
Beta-lactam |
2024 |
|
2921 |
Compound 681
|
Small molecule antibacterial agent |
2024 |
|
2922 |
2-Phenoxyalkylhydrazide benzoxazole derivative 26c (N′-(Benzo[d]oxazo-2-yl)-2-(4-fluorophenoxy)acetylhydrazine)
|
Antivirulence agent |
2024 |
|
2923 |
Cloacaenodin
|
Antimicrobial peptide |
2023 |
|
2924 |
Compound III13 (2-phenyl-1H-phenanthro[9,10-d]imidazole-antimicrobial peptide (AMP) mimic conjugate III13)
|
Membrane-active agent |
2024 |
|
2925 |
Compound j9 (AF-353 derivative), 5-(4-(Cyclopropylmethoxy)-5-iodo-2-isopropylphenoxy)pyrimidine-2,4-diamine
|
Small molecule antibacterial agent |
2024 |
|
2926 |
SG-B-52
|
Small molecule antibacterial agent |
2024 |
|
2927 |
SG-B-22
|
Small molecule antibacterial agent |
2024 |
|
2928 |
BGAz 002 (azetidine derivative)
|
Mycolic acid synthesis inhibitor |
2024 |
|
2929 |
Neomycin-X8 combination
|
Small molecule antibacterial agent |
2024 |
|
2930 |
Compound 4t (1,2,4-oxadiazole substituent derivative 4t)
|
Membrane-active agent |
2024 |
|
2931 |
V-triguan (Vancomycin-polyguanidino dendrimer conjugate)
|
Glycopeptide |
2024 |
|
2932 |
DDC18–8A
|
Membrane-active agent |
2022 |
|
2933 |
JSF-3269 (benzothiophene derivative)
|
Nitrofuran |
2024 |
|
2934 |
Compound 6f (2-(4-(3-((6-chloro-1-isopropyl-1H-benzo[d]imidazol-2-yl)amino)-2-hydroxypropoxy)phenyl)acetonitrile)
|
Antivirulence agent |
2024 |
|
2935 |
CGS19 (LARVARRVIRFIRRAW-NH2)
|
Antimicrobial peptide |
2024 |
|
2936 |
CGS20 (RRRLARRLIFFIRRAW-NH2)
|
Antimicrobial peptide |
2024 |
|
2937 |
Y40 (ML346 analogue)
|
Antivirulence agent |
2024 |
|
2938 |
ML346
|
Antivirulence agent |
2022 |
|
2939 |
BDM88855
|
Drug efflux pump inhibitor |
2022 |
|
2940 |
MBX-3132
|
Drug efflux pump inhibitor |
2016 |
|
2941 |
Ubonodin
|
RNA synthesis inhibitor |
2020 |
|
2942 |
Citrocin
|
RNA synthesis inhibitor |
2019 |
|
2943 |
JSF-4088
|
Nitrofuran |
2019 |
|
2944 |
Amylocyclicin
|
Antimicrobial peptide |
2014 |
|
2945 |
Chicken cathelicidin-2 (CATH-2)
|
Antimicrobial peptide |
2009 |
|
2946 |
Antibiotic 1717
|
Small molecule antibacterial agent |
2017 |
|
2947 |
Antibiotic 2093
|
Small molecule antibacterial agent |
2017 |
|
2948 |
Antibiotic 2144
|
Small molecule antibacterial agent |
2017 |
|
2949 |
MPC-1
|
Beta-lactamase inhibitor |
2017 |
|
2950 |
Lactolisterin BU
|
Antimicrobial peptide |
2017 |
|
2951 |
NP108 (Luminaderm)
|
Antimicrobial peptide |
2017 |
Preclinical |
2952 |
SPI009 (1-((2,4-dichlorophenethyl)amino)-3-phenoxypropan-2-ol)
|
Small molecule antibacterial agent |
2017 |
|
2953 |
Cyclic lipopeptide 4 (CLP-4)
|
Lipopeptide |
2017 |
|
2954 |
LPC-069
|
Lipopolysaccharide synthesis inhibitor |
2017 |
|
2955 |
LPC-058
|
Lipopolysaccharide synthesis inhibitor |
2016 |
|
2956 |
WCK-5153
|
Cell wall synthesis inhibitor |
2017 |
|
2957 |
INP0341
|
Antivirulence agent |
2017 |
|
2958 |
INP1750
|
Antivirulence agent |
2017 |
|
2959 |
INP1855
|
Antivirulence agent |
2017 |
|
2960 |
Blasticidin P10
|
Nucleoside analogue |
2017 |
|
2961 |
Blasticidin derivative 16
|
Nucleoside analogue |
2024 |
|
2962 |
Blasticidin derivative 20
|
Nucleoside analogue |
2024 |
|
2963 |
REDX06213
|
DNA synthesis inhibitor |
2017 |
|
2964 |
REDX07623
|
DNA synthesis inhibitor |
2017 |
|
2965 |
Toremifene
|
Membrane-active agent |
2017 |
|
2966 |
Arenicin-3 derivative N4 (N4)
|
Antimicrobial peptide |
2016 |
Preclinical |
2967 |
RBx 11760
|
Oxazolidinone |
2016 |
|
2968 |
ND-10885 (Compound 2)
|
Small molecule antibacterial agent |
2016 |
|
2969 |
CMA3
|
Antimicrobial peptide |
2015 |
|
2970 |
Campynexin A
|
Small molecule antibacterial agent |
2015 |
|
2971 |
Campynexin B
|
Small molecule antibacterial agent |
2015 |
|
2972 |
Campynexin C
|
Small molecule antibacterial agent |
2015 |
|
2973 |
Campynexin D
|
Small molecule antibacterial agent |
2015 |
|
2974 |
Campynexin E
|
Small molecule antibacterial agent |
2015 |
|
2975 |
T9W
|
Antimicrobial peptide |
2015 |
|
2976 |
Pyridineimidazole compound 1
|
Small molecule antibacterial agent |
2015 |
|
2977 |
Pyridineimidazole compound 2
|
Small molecule antibacterial agent |
2015 |
|
2978 |
VXc-486 (prodrug pVXc-486)
|
DNA synthesis inhibitor |
2015 |
|
2979 |
PVP-SE1gp146
|
Bacteriophage and/or bacteriophage-derived product |
2012 |
|
2980 |
LoGT-008
|
Bacteriophage and/or bacteriophage-derived product |
2014 |
|
2981 |
Cerecidin A7
|
Antimicrobial peptide |
2014 |
|
2982 |
AmiBA2446
|
Bacteriophage and/or bacteriophage-derived product |
2013 |
|
2983 |
Maculatin 1.1
|
Antimicrobial peptide |
2013 |
|
2984 |
Rattusin
|
Antimicrobial peptide |
2013 |
|
2985 |
Pep19-2.5
|
Antimicrobial peptide |
2013 |
Preclinical |
2986 |
SM-295291
|
Beta-lactam |
2013 |
Preclinical |
2987 |
SM-369926
|
Beta-lactam |
2013 |
Preclinical |
2988 |
NVC-422 (Aganocide®, Auriclosene)
|
Antivirulence agent |
2011 |
Phase 2 (NCT01367314; NCT00781339; NCT01532336; NCT01877694; NCT01243125) |
2989 |
18-β-Glycyrrhetinic Acid (GRA)
|
Antivirulence agent |
2013 |
|
2990 |
NK-18
|
Antimicrobial peptide |
2013 |
|
2991 |
MC-1
|
Beta-lactam |
2010 |
|
2992 |
Aminododecanoyl-lysyl-[aminodecanoyl-lysyl]5 (α12-5α10)
|
Antimicrobial peptide |
2012 |
|
2993 |
Compound 1
|
Small molecule antibacterial agent |
2012 |
|
2994 |
Compound 2
|
Small molecule antibacterial agent |
2012 |
|
2995 |
Signermycin B
|
Antivirulence agent |
2012 |
|
2996 |
Polybia-CP
|
Antimicrobial peptide |
2012 |
|
2997 |
Loureirin A
|
Natural product antibiotic |
2024 |
|
2998 |
Usnic acid
|
Natural product antibiotic |
1948 |
|
2999 |
Croconazole
|
Small molecule antibacterial agent |
2012 |
|
3000 |
Diffocin
|
Antimicrobial peptide |
2012 |
|
3001 |
Lactococcin 972
|
Antimicrobial peptide |
2012 |
|
3002 |
JEDI-1444
|
Small molecule antibacterial agent |
2024 |
|
3003 |
EBL-3647
|
Small molecule antibacterial agent |
2024 |
|
3004 |
EBL-3599
|
Small molecule antibacterial agent |
2024 |
|
3005 |
eAmSPC 2593
|
Aminoglycoside |
2024 |
|
3006 |
eAmSPC 2694
|
Aminoglycoside |
2024 |
|
3007 |
Argyrin B
|
Antimicrobial peptide |
1996 |
|
3008 |
NDM1i-1F and NDM1i-1G
|
Beta-lactamase inhibitor |
2021 |
|
3009 |
Burkfloxacin
|
Fluoroquinolone |
1980 |
|
3010 |
Flucytosine (prodrug)
|
Antivirulence agent |
2019 |
|
3011 |
M21
|
Small molecule antibacterial agent |
2018 |
|
3012 |
Fusaricidin
|
Antimicrobial peptide |
1996 |
|
3013 |
Streptothricin BI and Streptothricin BII
|
Streptothricin |
1948 |
|
3014 |
Exfoliatin
|
Natural product antibiotic |
1952 |
|
3015 |
Roseomycin
|
Streptothricin |
1953 |
|
3016 |
Basic antibiotic from strain No. 24
|
Streptothricin |
1953 |
|
3017 |
3-N-Nonylpyrazole
|
Natural product antibiotic |
1954 |
|
3018 |
Actinoleukin
|
Natural product antibiotic |
1956 |
|
3019 |
Griseolutein B
|
Natural product antibiotic |
1953 |
|
3020 |
Mycospocidin
|
Natural product antibiotic |
1957 |
|
3021 |
Elaiomycin
|
Natural product antibiotic |
1957 |
|
3022 |
Aburamycin
|
Natural product antibiotic |
1957 |
|
3023 |
Althiomycin
|
Natural product antibiotic |
1957 |
|
3024 |
Cellocidin
|
Natural product antibiotic |
1958 |
|
3025 |
Latumcidin
|
Natural product antibiotic |
1958 |
|
3026 |
Alboverticillin
|
Antimicrobial peptide |
1958 |
Preclinical (1967) |
3027 |
Dextromycin
|
Aminoglycoside |
1958 |
|
3028 |
Virocidin
|
Natural product antibiotic |
1958 |
|
3029 |
Neocidin
|
Natural product antibiotic |
1959 |
|
3030 |
Esperin
|
Antimicrobial peptide |
1959 |
|
3031 |
Taitomycin
|
Antimicrobial peptide |
1959 |
|
3032 |
δ-Hydroxy-γ-oxo-L-norvaline (HON)
|
Natural product antibiotic |
1960 |
|
3033 |
Bovinocidin
|
Natural product antibiotic |
1960 |
|
3034 |
Tubermycin A and Tubermycin B
|
Natural product antibiotic |
1958 |
|
3035 |
Zygomycin B
|
Aminoglycoside |
1961 |
|
3036 |
Bandamycin
|
Natural product antibiotic |
1961 |
|
3037 |
Antibiotic A-59
|
Natural product antibiotic |
1961 |
|
3038 |
Bacimethrin
|
Natural product antibiotic |
1961 |
|
3039 |
Antibiotic K-288
|
Natural product antibiotic |
1961 |
|
3040 |
Gougerotin
|
Natural product antibiotic |
1962 |
|
3041 |
A-418-Z4
|
Natural product antibiotic |
1962 |
|
3042 |
Tuberin
|
Antimicrobial peptide |
1962 |
|
3043 |
Griseococcin
|
Natural product antibiotic |
1962 |
|
3045 |
Succinimycin
|
Natural product antibiotic |
1963 |
|
3046 |
Cirramycin
|
Macrolide |
1963 |
|
3047 |
Emimycin
|
Nucleoside analogue |
1963 |
|
3048 |
Pillaromycin
|
Natural product antibiotic |
1964 |
|
3049 |
Pyrrolnitrin
|
Natural product antibiotic |
1964 |
|
3050 |
Danomycin
|
Antimicrobial peptide |
1964 |
Preclinical |
3051 |
Cranomycin
|
Natural product antibiotic |
1964 |
|
3052 |
Lancovutide
|
Antimicrobial peptide |
1964 |
|
3053 |
Proceomycin
|
Natural product antibiotic |
1964 |
|
3054 |
Macrocin
|
Macrolide |
1964 |
|
3055 |
Laurusin
|
Natural product antibiotic |
1965 |
|
3056 |
Polychlorosubtilin
|
Natural product antibiotic |
1965 |
|
3057 |
Antibiotic R-468
|
Natural product antibiotic |
1965 |
|
3058 |
Aztreonam lysine (Cayston)
|
Beta-lactam |
2010 |
Approved by FDA in 2010 |
3059 |
Lolamicin
|
Small molecule antibacterial agent |
2024 |
|
3060 |
Ceftibuten + VNRX-7145
|
Beta-lactam + beta-lactamase inhibitor |
2022 |
Phase 1 (NCT04243863) |
3061 |
Ertapenem + Zidebactam
|
Beta-lactam + beta-lactamase inhibitor |
2022 |
Phase 1 (NCT05645757) |
3062 |
Coumermycin A2
|
DNA synthesis inhibitor |
1965 |
|
3063 |
Aquayamycin
|
Natural product antibiotic |
1968 |
|
3064 |
SF-701
|
Streptothricin |
1968 |
|
3065 |
Tetra-N-4-chlorobenzyl kanamycin
|
Aminoglycoside |
1968 |
|
3066 |
E-749-C
|
Streptothricin |
1968 |
|
3067 |
MC21-A (C58)
|
Natural product antibiotic |
2003 |
|
3068 |
Cervimycin C
|
Natural product antibiotic |
2024 |
|
3069 |
Ursoricin
|
Antimicrobial peptide |
2024 |
|
3070 |
LEI-800
|
DNA synthesis inhibitor |
2024 |
|
3071 |
SM-5
|
Cell wall synthesis inhibitor |
2024 |
|
3072 |
Prolixicin
|
Antimicrobial peptide |
2024 |
|
3073 |
Kobenomycin
|
Antimicrobial peptide |
1968 |
|
3074 |
Citromycin
|
Streptothricin |
1969 |
|
3075 |
Coriolin
|
Natural product antibiotic |
1969 |
|
3076 |
Matchamycin
|
Natural product antibiotic |
1970 |
|
3077 |
S-520
|
Natural product antibiotic |
1970 |
|
3078 |
Janiemycin
|
Antimicrobial peptide |
1970 |
|
3079 |
Boseimycin
|
Streptothricin |
1970 |
|
3080 |
Neopluramycin
|
Natural product antibiotic |
1970 |
|
3081 |
Leucylnegamycin
|
Protein synthesis inhibitor |
1971 |
|
3082 |
YA 56
|
Natural product antibiotic |
1971 |
|
3083 |
Fumarylcarboxyamido-L-2,3-diaminopropionyl-L-alanine
|
Antimicrobial peptide |
1972 |
|
3084 |
Antibiotic No. 5879
|
Natural product antibiotic |
1972 |
|
3085 |
Antibiotic 24010 B-1
|
Streptothricin |
1972 |
|
3086 |
Jolipeptin
|
Antimicrobial peptide |
1972 |
|
3087 |
Cephacetrile
|
Beta-lactam |
1972 |
|
3088 |
Cryomycin
|
Antimicrobial peptide |
1972 |
|
3089 |
Actinotiocin
|
Antimicrobial peptide |
1973 |
|
3090 |
SP-351
|
Natural product antibiotic |
1973 |
|
3091 |
Myomycin
|
Aminoglycoside |
1973 |
|
3092 |
XK-19-2
|
Antimicrobial peptide |
1973 |
|
3093 |
Kuwaitimycin
|
Antimicrobial peptide |
1973 |
|
3094 |
Magnesidin
|
Natural product antibiotic |
1973 |
|
3095 |
Aminodeoxybutirosin
|
Aminoglycoside |
1973 |
|
3096 |
Butirosin
|
Aminoglycoside |
1972 |
Preliminary human studies (1975) |
3097 |
Acidolin
|
Antimicrobial peptide |
1974 |
|
3098 |
Antibiotic R4H
|
Streptothricin |
1974 |
|
3099 |
XK-46
|
Natural product antibiotic |
1974 |
|
3100 |
NRCS-15
|
Antimicrobial peptide |
1974 |
|
3101 |
ASK-753
|
Protein synthesis inhibitor |
1969 |
|
3102 |
Baciphelacin
|
Natural product antibiotic |
1975 |
|
3103 |
Mannopeptin
|
Glycopeptide |
1975 |
|
3104 |
AB-65
|
Glycopeptide |
1975 |
|
3105 |
Antibiotic SS-228 Y
|
Natural product antibiotic |
1975 |
|
3106 |
Destomycin C
|
Aminoglycoside |
1975 |
|
3107 |
Antibiotic complex 61-26
|
Antimicrobial peptide |
1975 |
|
3108 |
Antibiotic TL-119
|
Antimicrobial peptide |
1975 |
|
3109 |
Asukamycin
|
Natural product antibiotic |
1976 |
|
3110 |
Antibiotic B-43
|
Antimicrobial peptide |
1976 |
|
3111 |
Aplasmomycin
|
Macrolide |
1976 |
|
3112 |
Efrotomycin
|
Protein synthesis inhibitor |
1976 |
|
3113 |
Octapeptin C1
|
Lipopeptide |
1976 |
|
3114 |
Gardimycin
|
Antimicrobial peptide |
1976 |
|
3115 |
Antibiotic G-52
|
Aminoglycoside |
1976 |
|
3116 |
Aurantinin
|
Membrane-active agent |
1976 |
|
3117 |
Laterosporamine
|
Natural product antibiotic |
1976 |
|
3118 |
C-2801X
|
Beta-lactam |
1976 |
|
3119 |
Lenoremycin
|
Natural product antibiotic |
1975 |
|
3120 |
XK-90
|
Natural product antibiotic |
1976 |
|
3121 |
K-52 A
|
Natural product antibiotic |
1976 |
|
3122 |
Cinodine
|
Natural product antibiotic |
1977 |
|
3123 |
A26771B
|
Macrolide |
1977 |
|
3124 |
Glycinothricin
|
Streptothricin |
1977 |
|
3125 |
OS-1804
|
Natural product antibiotic |
1977 |
|
3126 |
Ribosylparomamine
|
Aminoglycoside |
1977 |
|
3127 |
Dityromycin
|
Antimicrobial peptide |
1977 |
|
3128 |
KT-151
|
Natural product antibiotic |
1977 |
|
3129 |
K-52 B
|
Natural product antibiotic |
1977 |
|
3130 |
Sequanamycin 9
|
Macrolide |
2023 |
|
3131 |
Sequanamycin A
|
Macrolide |
1969 |
|
3132 |
QPX7831 (Prodrug of QPX7728)
|
Beta-lactamase inhibitor |
2021 |
Phase 1 (NCT04578873, NCT06157242, NCT06079775) |
3133 |
GE82832
|
Antimicrobial peptide |
2006 |
|
3134 |
Ionomycin
|
Natural product antibiotic |
1978 |
|
3135 |
AA-57
|
Natural product antibiotic |
1978 |
|
3136 |
PS-5
|
Beta-lactam |
1978 |
|
3137 |
G2201-C
|
Natural product antibiotic |
1978 |
|
3138 |
Tolypomycin Y
|
RNA synthesis inhibitor |
1978 |
|
3139 |
Setomimycin
|
Natural product antibiotic |
1978 |
|
3140 |
A-10947
|
Antimicrobial peptide |
1979 |
|
3141 |
2-Hydroxy-5-iminoazacyclopent-3-ene hydrochloride
|
Natural product antibiotic |
1979 |
|
3142 |
Heneicomycin
|
Protein synthesis inhibitor |
1979 |
|
3143 |
MM 19290
|
Natural product antibiotic |
1979 |
|
3144 |
Permetin
|
Antimicrobial peptide |
1979 |
|
3145 |
Dactimycin
|
Aminoglycoside |
1979 |
|
3146 |
Staphcoccomycin
|
Macrolide |
1979 |
|
3147 |
Tf-26Vx
|
Natural product antibiotic |
1979 |
|
3148 |
Azureomycin B
|
Natural product antibiotic |
1979 |
|
3149 |
Pisiferic acid
|
Natural product antibiotic |
1978 |
|
3150 |
Sporaricin A
|
Aminoglycoside |
1979 |
|
3151 |
Antibiotic U-58,431
|
Natural product antibiotic |
1980 |
|
3152 |
1-Deamino-1-hydroxyxylostasin
|
Aminoglycoside |
1980 |
|
3153 |
B-1008
|
Natural product antibiotic |
1980 |
|
3154 |
Bu-2545
|
Lincosamide |
1980 |
|
3155 |
3-Amino-3-deoxy-α-D-glucopyranosyl-α-D-glucopyranoside
|
Natural product antibiotic |
1980 |
|
3156 |
Heptelidic acid
|
Natural product antibiotic |
1980 |
|
3157 |
FR-900137
|
Cell wall synthesis inhibitor |
1980 |
|
3158 |
Antlermicin A
|
Natural product antibiotic |
1980 |
|
3159 |
Bu-2313
|
Aminoglycoside |
1980 |
|
3160 |
FR-900130
|
Natural product antibiotic |
1980 |
|
3161 |
Clazamycin B
|
Membrane-active agent |
1979 |
|
3162 |
Repromicin
|
Macrolide |
1977 |
|
3163 |
Dnacin B1
|
Natural product antibiotic |
1980 |
|
3164 |
Antibiotic 6016
|
Membrane-active agent |
1980 |
|
3165 |
U-60,394
|
Natural product antibiotic |
1980 |
|
3166 |
4-N-Glycyl sannamycin C
|
Aminoglycoside |
1980 |
|
3167 |
SF-1961
|
Natural product antibiotic |
1980 |
|
3168 |
SF-1771
|
Natural product antibiotic |
1980 |
|
3169 |
K-82
|
Natural product antibiotic |
1980 |
|
3170 |
Funicin
|
Natural product antibiotic |
1980 |
|
3171 |
Toromycin
|
Natural product antibiotic |
1980 |
|
3172 |
Imidazo [4,5b] [1,8] naphthyridine derivative
|
Small synthetic molecule |
1980 |
|
3173 |
Kijanimicin
|
Natural product antibiotic |
1981 |
|
3174 |
Isosulfazecin
|
Beta-lactam |
1981 |
|
3175 |
Rubeomycin
|
Natural product antibiotic (anthracycline) |
1981 |
|
3176 |
Asparenomycin
|
Beta-lactam (carbapenem) |
1981 |
|
3177 |
Sulfazecin
|
Beta-lactam (monobactam) |
1981 |
|
3178 |
9-Epi-leucomycin A5
|
Macrolide |
1981 |
|
3179 |
Haloquinone
|
Natural product antibiotic |
1981 |
|
3180 |
Oganomycin A
|
Beta-lactam (cephamycin) |
1981 |
|
3181 |
Pyrrolomycin B
|
Natural product antibiotic (protonophore) |
1981 |
|
3182 |
Antibiotic 6643-X
|
Beta-lactam (carbapenem) |
1982 |
|
3183 |
C-19393 E5
|
Beta-lactam (carbapenem) |
1982 |
|
3184 |
AT-265
|
Protein synthesis inhibitor |
1982 |
|
3185 |
Cyanocycline A
|
DNA synthesis inhibitor |
1982 |
|
3186 |
PS-8
|
Beta-lactam (carbapenem) |
1982 |
|
3187 |
Oxanosine
|
Natural product antibiotic (nucleoside) |
1982 |
|
3188 |
Isopenicillin N
|
Beta-lactam (penicillin) |
1982 |
|
3189 |
Antibiotic U-62162
|
Protein synthesis inhibitor |
1982 |
|
3190 |
Antibiotic 8006-I
|
RNA synthesis inhibitor |
1982 |
|
3191 |
FA-2097
|
Natural product antibiotic |
1982 |
|
3192 |
Sarubicin B
|
Natural product antibiotic |
1982 |
|
3193 |
Ceftriaxone-sulbactam
|
Beta-lactamase (cephalosporin) + beta-lactamase inhibitor |
2007 |
Phase 4 (NCT04066621) |
3194 |
Nitroxoline
|
RNA synthesis inhibitor |
1947 |
|
3195 |
Aldesulfone sodium
|
Sulfone |
1937 |
Clinical Trial (1944-1945) |
3196 |
Aminosalicylate calcium
|
Mycolic acid synthesis inhibitor |
1950 |
Clinical Trial (1952) |
3197 |
Delamanid
|
Nitroimidazole |
2006 |
Phase 3 (NCT01424670) |
3198 |
Ethionamide
|
Mycolic acid synthesis inhibitor |
1960 |
Approved by FDA in 1965 |
3199 |
Morinamide
|
Mycolic acid synthesis inhibitor |
1962 |
|
3200 |
Para-aminosalicylic acid (Rezipas)
|
Mycolic acid synthesis inhibitor |
1946 |
Clinical Trial (1950; with streptomycin or isoniazid from 1950-1964) |
3201 |
Protionamide
|
Mycolic acid synthesis inhibitor |
1950 |
Phase 3 (NCT06081361) |
3202 |
Terizidone
|
Oxazolidinone |
1965 |
Phase 2/3 (NCT02454205) |
3203 |
Tiocarlide
|
Small molecule antibiotic |
1966 |
|
3204 |
VA-2
|
DNA synthesis inhibitor |
1982 |
|
3205 |
BA-4
|
Natural product antibiotic |
1982 |
|
3206 |
BN-1
|
Natural product antibiotic |
1982 |
|
3207 |
Diazaquinomycin A
|
Folate synthesis inhibitor |
1982 |
|
3208 |
Saphenamycin
|
Natural product antibiotic (phenazine) |
1982 |
|
3209 |
Precezomycin
|
Natural product antibiotic |
2024 |
|
3211 |
OA-7653
|
Glycopeptide |
1983 |
|
3212 |
U-56,407
|
Natural product antibiotic (asukamycin) |
1983 |
|
3213 |
Y-T0678H
|
Natural product antibiotic |
1983 |
|
3214 |
Clerocidin
|
DNA synthesis inhibitor |
1983 |
|
3215 |
KA-5685
|
Aminoglycoside |
1983 |
|
3216 |
Saccharocin
|
Aminoglycoside |
1983 |
|
3217 |
Decilorubicin
|
Natural product antibiotic (anthracycline) |
1983 |
|
3218 |
Ravidomycin
|
DNA synthesis inhibitor |
1983 |
|
3219 |
Microcin 15n
|
Antimicrobial peptide |
1983 |
|
3220 |
Bu-2470
|
Antimicrobial peptide |
1983 |
|
3221 |
Clavalanine
|
Natural product antibiotic |
1983 |
|
3222 |
Safracin B
|
Natural product antibiotic (quinone) |
1983 |
|
3223 |
G-367 S1
|
Aminoglycoside |
1983 |
|
3224 |
Tylosin
|
Macrolide |
1983 |
|
3225 |
Antibiotic X-14885A
|
Natural product antibiotic (pyrrolether) |
1983 |
|
3226 |
Curvulic Acid
|
Cell wall synthesis inhibitor |
1984 |
|
3227 |
Empedopeptin
|
Lipodepsipeptide |
1984 |
|
3228 |
Cefpirome
|
Beta-lactam (cephalosporin, fourth-generation) |
1983 |
Approved (not in US) |
3229 |
Griseochelin
|
Natural product antibiotic (carboxylic acid) |
1984 |
|
3230 |
Penitricin
|
Cyclopropenone |
1984 |
|
3231 |
Antibiotic U-64846
|
Natural product antibiotic |
1984 |
|
3232 |
Myxovirescin B
|
Macrocyclic antibiotic |
1984 |
|
3233 |
ε-Poly-L-lysine
|
Antimicrobial peptide |
1984 |
|
3234 |
3-methyl-7-oxo-2,3-dihydro-7H-furo [2, 3-h] pyrido [1, 2, 3-de] [1, 4] benzoxazine-6-carboxylic acid
|
Small molecule antibiotic |
1984 |
|
3235 |
Defucogilvocarcin V
|
Natural product antibiotic |
1985 |
|
3236 |
Glycocinnasperimicin D
|
Natural product antibiotic (glycocinnamolyspermidine) |
1985 |
|
3237 |
Sohbumycin
|
Natural product antibiotic (peptide lactone) |
1985 |
|
3238 |
Lavendomycin
|
Antimicrobial peptide |
1985 |
|
3239 |
Nourseimycin
|
Antimicrobial peptide |
1983 |
|
3240 |
SN-07
|
DNA synthesis inhibitor |
1985 |
|
3241 |
Angiolam A
|
Protein synthesis inhibitor |
1985 |
|
3242 |
SF-2370
|
Natural product antibiotic |
1985 |
|
3243 |
Lustromycin
|
Natural product antibiotic (lactone) |
1986 |
|
3244 |
SQ 30,957
|
Natural product antibiotic |
1986 |
|
3245 |
3,3'-Neotrehalosadiamine
|
Aminoglycoside |
1986 |
|
3246 |
SF-2330
|
Natural product antibiotic |
1986 |
|
3247 |
AC4437
|
Aminoglycoside |
1986 |
|
3248 |
YN-0165J-A
|
Natural product antibiotic (enteromycin) |
1986 |
|
3249 |
Crisamicin A
|
Natural product antibiotic (dimeric pyranonaphthoquinone) |
1986 |
|
3250 |
Dopsisamine
|
Natural product antibiotic |
1986 |
|
3251 |
U-68,204
|
Natural product antibiotic (thiolactone-containing antibiotic) |
1986 |
|
3252 |
Aldgamycin G
|
Macrolide |
1986 |
|
3253 |
Cefovecin
|
Beta-lactam (cephalosporin) |
2006 |
|
3254 |
Cefquinome
|
Beta-lactam (cephalosporin) |
1990 |
|
3255 |
Ceftiofur
|
Beta-lactam (cephalosporin) |
1987 |
Approved for veterinary use |
3256 |
Danofloxacin
|
Fluoroquinolone |
1990 |
|
3257 |
Enrofloxacin
|
Fluoroquinolone |
1983 |
|
3258 |
Marbofloxacin
|
Fluoroquinolone |
1993 |
|
3259 |
Orbifloxacin
|
Fluoroquinolone |
1995 |
|
3260 |
Oxolinic acid
|
Quinolone |
1993 |
|
3261 |
Pradofloxacin
|
Fluoroquinolone |
2005 |
Approved for veterinary use |
3262 |
Gamithromycin
|
Macrolide |
2010 |
Approved for veterinary use |
3263 |
Tildipirosin
|
Macrolide |
2012 |
Approved for veterinary use |
3264 |
Tilmicosin
|
Macrolide |
1987 |
Approved for veterinary use in 1990 |
3265 |
Tulathromycin
|
Macrolide |
2004 |
|
3266 |
Tylvalosin
|
Macrolide |
2008 |
Approved for veterinary use |
3267 |
Cefroxadine
|
Beta-lactam (cephalosporin) |
1980 |
|
3268 |
Cefalonium
|
Beta-lactam (cephalosporin) |
1977 |
|
3269 |
Pirlimycin
|
Lincosamide |
1982 |
|
3270 |
Amoxicillin + clavulanic acid
|
Beta-lactam (penicillin) + beta-lactamase inhibitor |
1978 |
Approved by FDA in 2002 |
3271 |
Phthalylsulfathiazole
|
Sulfa drug / Sulphonamide |
1945 |
Clinical trial in 1945 |
3272 |
Sulfaisodimidine
|
Sulfa drug / Sulphonamide |
1946 |
Clinical trial in 1952 |
3273 |
Sulfamazone
|
Sulfa drug / Sulphonamide |
1972 |
|
3274 |
Sulfametoxydiazine
|
Sulfa drug / Sulphonamide |
1962 |
|
3275 |
Furaltadone
|
Nitrofuran |
1959 |
Clinical trial in 1959-1960 |
3276 |
Chlorhydroxyquinoline
|
Synthetic small molecule |
1953 |
|
3277 |
Laidlomycin
|
Natural product antibiotic (ionophore or polyether) |
1974 |
|
3278 |
Semduramicin
|
Synthetic small molecule (ionophore or polyether) |
1992 |
|
3279 |
Avilamycin
|
Orthosomycin |
1968 |
|
3280 |
Carbadox
|
Quinoxaline |
1972 |
|
3281 |
Azinothricin
|
Antimicrobial peptide (hexadepsipeptide) |
1986 |
|
3282 |
9-O-propionyl-9-dihydrotylosin
|
Macrolide |
1986 |
|
3283 |
Cervinomycin A1 triacetate
|
Aminoglycoside (anthracycline) |
1986 |
|
3284 |
Cervinomycin A2 monoacetate
|
Aminoglycoside (anthracycline) |
1986 |
|
3285 |
Avibactam tomilopil (prodrug)
|
Beta-lactamase inhibitor |
2018 |
|
3286 |
Sudapyridine
|
Diarylquinoline |
2022 |
Phase 3 (NCT05824871) |
3287 |
Taurolidine
|
Synthetic small molecule |
1977 |
Approved by FDA in 2023 |
3288 |
Pralurbactam
|
Beta-lactamase inhibitor |
2017 |
|
3289 |
XF-73 (exeporfinium chloride)
|
Membrane-active agent |
2023 |
Phase 2 (NCT03915470) |
3290 |
JEDI-852
|
Lipopolysaccharide synthesis inhibitor (LpxH inhibitor) |
2023 |
|
3291 |
MK-7762 (TBD09)
|
Oxazolidinone |
2023 |
Phase 1 (NCT05824091) |
3292 |
FNDR-20081
|
Synthetic small molecule |
2021 |
Preclinical |
3293 |
TBA-354
|
Nitroimidazole |
2010 |
Phase 1 (NCT02606214) |
3294 |
OTB-658
|
Oxazolidinone |
2020 |
Preclinical (approved Phase 1 clinical trial in China) |
3295 |
3-Hydroxycezomycin
|
Natural product antibiotic (ionophore; pyrroloether) |
1987 |
|
3296 |
IIIM-019
|
Nitroimidazole |
2016 |
Preclinical |
3297 |
Cefepime + nacubactam
|
Beta-lactam (cephalosporin) + beta-lactamase inhibitor |
2015 |
Phase 3 (NCT05905055) |
3298 |
Ceftibuten + ledaborbactam
|
Beta-lactam (cephalosporin) + beta-lactamase inhibitor |
2022 |
Phase 1 |
3299 |
Meropenem + pralurbactam
|
Beta-lactam + beta-lactamase |
2023 |
Phase 3 (NCT06633718) |
3300 |
FNDR-20364
|
Antimicrobial peptide |
2021 |
Preclinical |
3301 |
Abbeymycin
|
Natural product antibiotic (pyrrolobenzodiazepine) |
1987 |
|
3302 |
Deepoxycirramycin A1
|
Macrolide |
1987 |
|
3303 |
CV-1
|
Lipopolysaccharide synthesis inhibitor |
1987 |
|
3304 |
Indisocin
|
Natural product antibiotic |
1987 |
|
3305 |
N-Methylindisocin
|
Natural product antibiotic |
1987 |
|
3306 |
Sch 34164
|
Tetracycline |
1987 |
|
3307 |
CP-54,883
|
Natural product antibiotic (polyether) |
1987 |
|
3308 |
Okilactomycin
|
Natural product antibiotic |
1987 |
|
3309 |
Aerocyanidin
|
Natural product antibiotic (isonitrile containing) |
1988 |
|
3310 |
Aerocavin
|
Natural product antibiotic |
1988 |
|
3311 |
Neoberninamycin
|
Protein synthesis inhibitor |
1988 |
|
3312 |
DOB-41
|
Natural product antibiotic (phenazine) |
1988 |
|
3313 |
ABAC-39877
|
Small molecule antibacterial agent |
2018 |
Preclinical |
3314 |
MF 5137
|
Quinolone |
1995 |
|
3315 |
ABAC-40244
|
Small molecule antibacterial agent |
2024 |
Preclinical |
3316 |
ABAC-40411
|
Small molecule antibacterial agent |
2024 |
Preclinical |
3317 |
ABX-605
|
Aminoglycoside |
2019 |
Preclinical |
3318 |
Andrimid
|
Fatty acid synthesis inhibitor |
1988 |
|
3319 |
Diffusomycin
|
Membrane-active agent |
1988 |
|
3320 |
Actaplanin
|
Glycopeptide |
1984 |
|
3321 |
A83586C
|
Antimicrobial peptide (depsipeptide) |
1988 |
|
3322 |
Boholmycin
|
Aminoglycoside |
1988 |
|
3323 |
A21978C
|
Lipopeptide |
1988 |
|
3324 |
16-Deethylindanomycin
|
Membrane-active agent (ionophore) |
1988 |
|
3325 |
SN-706
|
Natural product antibiotic |
1988 |
|
3326 |
Aranorosin
|
Natural product antibiotic |
1988 |
|
3327 |
UK-63,052
|
Membrane-active agent |
1989 |
|
3328 |
A42867
|
Glycopeptide |
1989 |
|
3329 |
19-Deformyl-4'-deoxydesmycosin
|
Macrolide |
1989 |
|
3330 |
19-Deformyldesmycosin
|
Macrolide |
1988 |
|
3331 |
834-B1
|
Fatty acid synthesis inhibitor |
1989 |
|
3332 |
Hatomamicin
|
Natural product antibiotic |
1989 |
|
3333 |
RK-699A
|
Antimicrobial peptide |
1989 |
|
3334 |
CP-78,545
|
Natural product antibiotic |
1989 |
|
3335 |
Dynemicin A
|
Natural product antibiotic (esperamicin/ calicheamicin) |
1989 |
|
3336 |
Triacetyldynemicin A
|
Natural product antibiotic (esperamicin/ calicheamicin) |
1989 |
|
3337 |
Demycinosyltylosin
|
Macrolide |
1989 |
|
3338 |
AT2433 A2
|
Natural product antibiotic |
1989 |
|
3339 |
AT2433 B2
|
Natural product antibiotic |
1989 |
|
3340 |
SF2487
|
Natural product antibiotic (polyether) |
1990 |
|
3341 |
Kijimicin
|
Natural product antibiotic (polyether) |
1990 |
|
3342 |
Monazomycin B
|
Macrolide |
1990 |
|
3343 |
5-Formyloxymethyluridine
|
Nucleoside analogue |
1990 |
|
3344 |
MK4588
|
Natural product antibiotic (xanthocillin) |
1990 |
|
3345 |
FR112123
|
Antimicrobial peptide (oligopeptide) |
1990 |
|
3346 |
CP-80,219
|
Natural product antibiotic (polyether) |
1990 |
|
3347 |
A80915
|
Natural product antibiotic (naphthoquinone) |
1990 |
|
3348 |
Depsidomycin
|
Antimicrobial peptide (heptapeptide) |
1990 |
|
3349 |
Simaomicin
|
Natural product antibiotic (isoquinoline) |
1990 |
|
3350 |
Lydicamycin
|
Natural product antibiotic |
1991 |
|
3351 |
Hydroniddamycin derivative
|
Macrolide |
1991 |
|
3352 |
Tetrazomine
|
Natural product antibiotic |
1991 |
|
3353 |
Naphthomevalin
|
Natural product antibiotic (naphthoquinone) |
1991 |
|
3354 |
Methoxygriseorhodin
|
Natural product antibiotic (naphthoquinone) |
1991 |
|
3355 |
Aldecalmycin
|
Natural product antibiotic |
1992 |
|
3356 |
A83016A
|
Natural product antibiotic (kinamycin) |
1992 |
|
3357 |
Sporeamicin
|
Macrolide |
1992 |
|
3358 |
SF2457
|
Nucleoside analogue |
1992 |
|
3359 |
CP-120,509
|
Natural product antibiotic (polyether) |
1992 |
|
3360 |
Octacyclomycin
|
Natural product antibiotic (polyether) |
1992 |
|
3361 |
SO-075R1
|
Natural product antibiotic (anthracycline) |
1992 |
|
3362 |
Tachyplesin I
|
Antimicrobial peptide (cationic beta-hairpin) |
1993 |
|
3363 |
Jadomycin B
|
Natural product antibiotic (isoquinoline) |
1993 |
|
3364 |
3''-Epi-erythromycin A
|
Macrolide |
1993 |
|
3365 |
(9S)-11-dehydroxy-9-deoxo-9-hydroxy-11-oxoerythromycin A
|
Macrolide |
1993 |
|
3366 |
Sperabillin derivative 29
|
Membrane-active agent |
1993 |
|
3367 |
Sperabillin
|
Membrane-active agent |
1992 |
|
3368 |
PC-766B
|
Macrolide |
1993 |
|
3369 |
Azicemicin
|
Natural product antibiotic |
1993 |
|
3370 |
Nisamycin
|
Natural product antibiotic (manumycin) |
1993 |
|
3371 |
Amythiamicin
|
Protein synthesis inhibitor |
1994 |
|
3372 |
3,4'-Dideoxymycaminosyltylonolide derivative
|
Macrolide |
1994 |
|
3373 |
Cefuzonam
|
Beta-lactam (cephalosporin, second generation) |
1987 |
|
3374 |
N-Methylstreptothricin D
|
Streptothricin |
1994 |
|
3375 |
Martinomycin
|
Natural product antibiotic (polyether) |
1994 |
|
3376 |
Bactenecin 7, Bac7
|
Antimicrobial peptide |
1995 |
|
3377 |
Leucinostatin A3
|
Antimicrobial peptide |
1995 |
|
3378 |
Hexafluorotilmicosin
|
Macrolide |
1995 |
|
3379 |
Thiomarinol B
|
Aminoacyl-tRNA synthetase inhibitor (isoleucyl-tRNA synthetase [Ile-RS] inhibitor) |
1995 |
|
3380 |
Thiomarinol C
|
Aminoacyl-tRNA synthetase inhibitor (isoleucyl-tRNA synthetase [Ile-RS] inhibitor) |
1995 |
|
3381 |
Sorangiolid A
|
Natural product antibiotic |
1995 |
|
3382 |
AL072
|
Natural product antibiotic |
1995 |
|
3383 |
Tetrodecamycin
|
Natural product antibiotic (tetrodecamycin; tetronate) |
1995 |
|
3384 |
Dihydrotetrodecamycin
|
Natural product antibiotic (tetrodecamycin; tetronate) |
1995 |
|
3385 |
Trichorzin HA
|
Antimicrobial peptide |
1995 |
|
3386 |
Trichorzin MA
|
Antimicrobial peptide |
1995 |
|
3387 |
Cefiderocol (QPX2014, S-649228) + Xeruborbactam (QPX7728)
|
Beta-lactam (cephalosporin) + beta-lactamase inhibitor (boronic acid beta-lactamase inhibitor) |
2023 |
Phase 1 (NCT06547554) |
3388 |
9MW1411
|
Antibody (IgG1 mAb) |
2021 |
Phase 2 (NCTC04784312) |
3389 |
AP-SA02
|
Bacteriophage |
2021 |
Phase 2 (NCT05184764) |
3390 |
APT Phagebank
|
Bacteriophage |
2022 |
Phase 2 (NCT05269121) |
3391 |
EcoActive
|
Bacteriophage |
2019 |
Phase 2 (NCT03808103) |
3392 |
Cefepime + Ftortiazinon (fluorothyazinone)
|
Beta-lactam (cephalosporin) + antivirulence (T3SS inhibitor) |
2022 |
Phase 2 |
3393 |
LMN-101
|
Antibody |
2019 |
Phase 2 (NCT04182490) |
3394 |
OligoG
|
Biopolymer |
2011 |
Phase 2 (NCT01465529) |
3395 |
PP1493 and PP1815
|
Bacteriophage |
2022 |
Phase 2 (NCT05369104) |
3396 |
Reltecimod
|
Immunomodulator agent |
2011 |
Phase 3 (NCT03403751) |
3397 |
Rhu-pGSN
|
Immunomodulator agent |
2015 |
Phase 2 |
3398 |
ShigActive
|
Bacteriophage |
2015 |
Phase 2 (NCT05182749) |
3399 |
VRELysin
|
Bacteriophage |
2023 |
Phase 2 (NCT05715619) |
3400 |
YPT-01
|
Bacteriophage and phage-derived enzyme |
2020 |
Phase 2 (NCT04684641) |
3401 |
CC-11050
|
Immunomodulator agent |
2016 |
Phase 2 (NCT03807362) |
3402 |
SQ109
|
Ethylenediamine |
2005 |
Phase 2 |
3403 |
ADS024
|
Microbiome modulating agent |
2022 |
Phase 1 (NCT04891965) |
3404 |
IM-01
|
Antibody |
2017 |
Phase 2 (NCT04121169) |
3405 |
LMN-201
|
Bacteriophage and phage-derived enzyme |
2022 |
Phase 3 |
3406 |
MBK-01
|
Microbiome modulating agent |
2022 |
Phase 3 |
3407 |
NTCM-M3
|
Microbiome modulating agent |
2012 |
Phase 2 (NCT01259726) |
3408 |
RBX7455
|
Microbiome modulating agent |
2020 |
Phase 1 (NCT02981316) |
3409 |
Ribaxamase
|
Microbiome modulating agent |
2016 |
Phase 2 |
3410 |
VE303
|
Microbiome modulating agent |
2022 |
Phase 2 |
3411 |
SVT-1C469, SVT 1C469, SVT1C469
|
Microbiome modulating agent |
2020 |
Phase 1 (ACTRN12620000923965) |
3412 |
CRS0393
|
Mycolic acid synthesis inhibitor |
2018 |
Preclinical |
3413 |
CZ-02
|
Protein synthesis inhibitor |
2023 |
Preclinical |
3414 |
EB003
|
Microbiome modulating agent |
2021 |
Preclinical |
3415 |
LptA-OMPTA
|
Antimicrobial peptide |
2022 |
Preclinical |
3416 |
MBX-16
|
Small molecule antibacterial agent |
|
Preclinical |
3417 |
BE-24566B
|
Natural product antibiotic |
1995 |
|
3418 |
Sapecin B derivative
|
Antimicrobial peptide |
1996 |
|
3419 |
Carboxamide eremomycin
|
Glycopeptide |
1996 |
|
3420 |
YM-30059
|
Quinolone |
1996 |
|
3421 |
Nisin Z
|
Antimicrobial peptide |
1996 |
|
3422 |
Tobicillin
|
Beta-lactam |
1997 |
|
3423 |
250-144C
|
Macrolide |
1997 |
|
3424 |
Thiomarinol D
|
Aminoacyl-tRNA synthetase inhibitor (isoleucyl-tRNA synthetase [IleRS] inhibitor) |
1997 |
|
3425 |
Korormicin
|
Natural product antibiotic (lactone) |
1997 |
|
3426 |
YM-47515
|
Natural product antibiotic (isonitrile) |
1997 |
|
3427 |
1-Hydroxycrisamicin A
|
Natural product antibiotic (naphthoquinone) |
1998 |
|
3428 |
Polyketomycin
|
Natural product antibiotic |
1998 |
|
3429 |
Cremimycin
|
Natural product antibiotic (macrocyclic lactam) |
1998 |
|
3430 |
N-alkyl Demethylvancomycin
|
Glycopeptide |
1998 |
|
3431 |
LL-49F233 alpha
|
Membrane-active agent |
1998 |
|
3432 |
Diperamycin
|
Antimicrobial peptide |
1998 |
|
3433 |
BE-40665D
|
Natural product antibiotic |
1999 |
|
3434 |
Lactonamycin
|
Natural product antibiotic (naphthoquinone) |
1999 |
|
3435 |
Hinokitiol
|
Membrane-active agent |
1999 |
|
3436 |
Beta-dolabrin
|
Natural product antibiotic |
1999 |
|
3437 |
Vinylamycin
|
Antimicrobial peptide |
1999 |
|
3438 |
Tylopeptin
|
Antimicrobial peptide |
1999 |
|
3439 |
Streptopyrrole
|
Antivirulence agent |
1998 |
|
3440 |
UCS1025A
|
Natural product antibiotic (polyketide) |
2000 |
|
3441 |
Piptamine
|
Natural product antibiotic |
2000 |
|
3442 |
Xanthoepocin
|
Natural product antibiotic |
2000 |
|
3443 |
Tubelactomicin A
|
Natural product antibiotic (lactone) |
2000 |
|
3444 |
Micacocidin
|
Natural product antibiotic (thiazoline) |
2001 |
|
3445 |
CJ-17,665
|
Natural product antibiotic |
2001 |
|
3446 |
CJ-15,801
|
CoA synthesis inhibitor |
2001 |
|
3447 |
Apolipoprotein
|
Antimicrobial peptide |
2002 |
|
3448 |
YM-181741
|
Natural product antibiotic |
2002 |
|
3449 |
CJ-17,572
|
Natural product antibiotic (tetramic acid) |
2002 |
|
3450 |
Pseudopyronine B
|
Natural product antibiotic |
2002 |
|
3451 |
3-Keto tylosin derivative
|
Macrolide |
2002 |
|
3452 |
Chalcomycin B
|
Macrolide |
2002 |
|
3453 |
Altersetin
|
Natural product antibiotic |
2002 |
|
3454 |
Chloroquinocin
|
Natural product antibiotic (naphthoquinone) |
2002 |
|
3455 |
Coniosetin
|
Natural product antibiotic |
2003 |
|
3456 |
Erythromycin G
|
Macrolide |
2003 |
|
3457 |
Seitomycin
|
Natural product antibiotic (angucycline) |
2003 |
|
3458 |
Helquinoline
|
Natural product antibiotic (quinoline) |
2004 |
|
3459 |
Mutactimycin PR
|
Natural product antibiotic (anthracycline) |
2004 |
|
3460 |
Carnosol
|
Membrane-active agent |
2007 |
|
3461 |
CW-270033
|
Beta-lactam (carbapenem) |
2007 |
|
3462 |
Oleanolic Acid
|
Natural product antibiotic |
2007 |
|
3463 |
D-9-mer peptides (diastereomer)
|
Antimicrobial peptide |
2007 |
|
3464 |
Glioperazine B
|
Antimicrobial peptide (diketopiperazine) |
2007 |
|
3465 |
Rhodomyrtone
|
Natural product antibiotic (acylphloroglucinol) |
2008 |
|
3466 |
Morinol
|
Natural product antibiotic |
2009 |
|
3467 |
Des-fatty acyl-polymyxin B decapeptide derivative
|
Antimicrobial peptide |
2009 |
|
3468 |
12α-Hydroxyfriedelane-3,15-dione
|
Natural product antibiotic |
2009 |
|
3469 |
Cycloundecapeptide
|
Antimicrobial peptide |
2011 |
|
3470 |
Triclosan
|
Synthetic small molecule antibacterial agent |
1964 |
Approved by FDA in 1997 |
3471 |
Sy142
|
Oxazolidinone |
2014 |
|
3472 |
E-4502
|
Fluoroquinolone |
1990 |
|
3473 |
E-4501, E4501, E 4501
|
Fluoroquinolone |
1990 |
|
3474 |
E-4500, E4500, E 4500
|
Fluoroquinolone |
1990 |
|
3475 |
E-4480, E4480, E 4480
|
Fluoroquinolone |
1990 |
|
3476 |
E-4474, E4474, E 4474
|
Fluoroquinolone |
1990 |
|
3477 |
E-4441, E4441, E 4441
|
Fluoroquinolone |
1990 |
|
3478 |
Bactenecin 5
|
Antimicrobial peptide |
1989 |
|
3479 |
Irloxacin
|
Fluoroquinolone |
1987 |
|
3480 |
Bay v 3522
|
Beta-lactam (cephalosporin) |
1990 |
|
3481 |
Cefcanel
|
Beta-lactam |
1989 |
|
3482 |
Plantamajoside
|
Antivirulence agent (sortase inhibitor) |
2024 |
|
3483 |
Safencin E
|
Antimicrobial peptide (bacteriocin) |
2024 |
|
3484 |
Carbonyl cyanide 3-chlorophenylhydrazone (CCCP)
|
Efflux pump inhibitor |
2021 |
|
3485 |
MGC-10
|
Protein synthesis inhibitor (elongation factor [EF-Tu] inhibitor) |
2024 |
|
3486 |
Hs02
|
Antimicrobial peptide |
2024 |
|
3487 |
LC-AMP-I1
|
Antimicrobial peptide |
2024 |
|
3488 |
Doxifluridine
|
Small molecule antibacterial agent |
2017 |
|
3489 |
α-Mangostin derivative 4
|
Membrane-active agent |
2024 |
|
3490 |
P-92
|
Antimicrobial peptide |
2024 |
|
3491 |
MRS-2541
|
Aminoacyl-tRNA synthetase inhibitor (methionyl tRNA synthetase [MetRS] inhibitor) |
2024 |
|
3492 |
Arcanocin
|
Antimicrobial peptide |
2024 |
|
3493 |
Arachnicin
|
Antimicrobial peptide |
2024 |
|
3494 |
AMP-W5
|
Antimicrobial peptide |
2024 |
|
3495 |
Benzo[c]phenanthridine derivative 6
|
Small molecule antibacterial agent |
2024 |
|
3496 |
Benzo[c]phenanthridine derivative 9
|
Small molecule antibacterial agent |
2024 |
|
3497 |
MBX-4888A
|
Aminoglycoside |
2016 |
Preclinical |
3498 |
GuaBi G1
|
Nucleotide synthesis inhibitor |
2024 |
|
3499 |
GuaBi G2
|
Nucleotide synthesis inhibitor |
2024 |
|
3500 |
Dihydromycoplanecin
|
Antimicrobial peptide |
1985 |
|
3501 |
Merafloxacin
|
Fluoroquinolone |
1984 |
|
3502 |
RU-985
|
Macrolide |
1986 |
|
3503 |
Mederrhodin A
|
Natural product antibiotic (medermycin) |
1986 |
|
3504 |
3-de-O-methylsporaricin A sulfate
|
Aminoglycoside |
1982 |
|
3505 |
Zidovudine
|
DNA synthesis inhibitor |
1990 |
|
3506 |
Isorhapontigenin
|
Antivirulence agent |
2024 |
|
3507 |
A20L
|
Antimicrobial peptide |
2015 |
|
3508 |
Serrawettin W2-FL10
|
Lipopeptide |
2022 |
|
3509 |
Demethoxycurcumin, Amb2698241
|
Small molecule antibacterial agent |
2024 |
|
3510 |
(+)-Brazilin
|
Antibiofilm agent |
2018 |
|
3511 |
EC1
|
Bacteriophage lysin |
2024 |
|
3512 |
D66
|
Membrane-active agent |
2022 |
|
3513 |
Thiazolidinone derivative
|
Small molecule antibiotic |
2024 |
|
3514 |
Cd-IF1
|
Antimicrobial peptide |
2024 |
|
3515 |
Phenylimidazole analogue 296
|
Fatty acid synthesis inhibitor (FabK inhibitor) |
2019 |
|
3516 |
VesiX CPC
|
Membrane-active agent |
2022 |
Limited clinical trial |
3517 |
1D10
|
Lysin |
1999 |
|
3518 |
Turnercyclamycin
|
Lipopeptide |
2021 |
|
3519 |
Microcin Y
|
Antimicrobial peptide (lasso peptide) |
2021 |
|
3520 |
Bilothiazole E
|
Natural product antibiotic (thiazole) |
2025 |
|
3521 |
Bilothiazole F
|
Natural product antibiotic (thiazole) |
2025 |
|
3522 |
AD101
|
Protein synthesis inhibitor |
|
Preclinical |
3523 |
Disperazol
|
Antibiofilm agent |
2024 |
|
3524 |
CVH-88
|
Pleuromutilin |
2020 |
|
3525 |
CVH-174
|
Pleuromutilin |
2024 |
|
3526 |
Lysocin E
|
Lipopeptide |
2014 |
|
3527 |
Nosokomycin
|
Natural product antibiotic |
2010 |
|
3528 |
Xenorceptide A2
|
BamA inhibitor |
2025 |
|
3529 |
Vancomycin polycationic peptide conjugate (VN-R6C)
|
|
2020 |
|
3530 |
BT-33
|
Protein synthesis inhibitor |
2024 |
|
3531 |
SRI-12742
|
Small molecule antibiotic |
2018 |
|
3532 |
Ceftazidime-hexa-arginine conjugate (CTZ-R6)
|
Beta-lactam |
2024 |
|
3533 |
BioTryp small molecule inhibitor
|
Antibiofilm agent |
|
|
3534 |
5-Nitrofuran-2-carbohydrazide 21f
|
Sulfa drug / Sulphonamide |
2015 |
|
3535 |
Beetle-defensin derived AMP
|
Antimicrobial peptide |
1999 |
|
3536 |
Epigallocatechin gallate (EGCG)
|
Natural product antibiotic |
2016 |
|
3537 |
6-Phenylnicotinohydrazide derivative 8b
|
Small molecule antibacterial agent |
2017 |
|
3538 |
WFQ-228
|
Fluoroquinolone |
2018 |
|
3539 |
Bismuth lipophilic nanoparticle (BisBAL NP)
|
Nanoparticle |
2019 |
|
3540 |
Graphene oxide (GO) and the antimicrobial peptide (AMP) Nal-P-113
|
Antimicrobial peptide |
2022 |
|
3541 |
Antibiotic 1599
|
Spectinamide |
2015 |
|
3542 |
Amidino-urea 1-[(2,6-diethylphenyl)-3-N-ethylcarbamimodoyl]urea
|
PptT inhibitor |
2019 |
|
3543 |
Benzofuroxan derivative 8
|
Protein synthesis inhibitor |
2017 |
|
3544 |
Bortezomib derivative 58
|
Small molecule antibacterial agent |
2017 |
|
3545 |
SATB-082
|
DNA synthesis inhibitor (DnaN inhibitor) |
2015 |
|
3546 |
GSK 724A
|
Mycolic acid synthesis inhibitor |
2016 |
|
3547 |
GSK693
|
Fatty acid synthesis inhibitor (InhA inhibitor) |
2016 |
|
3548 |
GSK839
|
Tryptophan synthase inhibitor |
|
Preclinical |
3549 |
Imatinib
|
Small molecule antibacterial agent |
2012 |
|
3550 |
NITD-304
|
Mycolic acid synthesis inhibitor |
2013 |
Preclinical |
3551 |
NITD-349
|
Mycobacterial cell wall synthesis inhibitor |
2013 |
Preclinical |
3552 |
JSF-3285
|
Mycolic acid synthesis inhibitor |
2020 |
|
3553 |
NTB-3119
|
Mycolic acid synthesis inhibitor (DprE1 inhibitor) |
2018 |
|
3554 |
SQ609
|
Mycolic acid synthesis inhibitor |
2012 |
|
3555 |
Sulfolane
|
Tryptophan synthesis inhibitor |
2017 |
|
3556 |
TB47
|
QcrB inhibitor |
2015 |
Preclinical |
3557 |
Tryptanthrin analogue 5
|
Small molecule antibacterial agent |
2019 |
|
3558 |
NSC19723
|
Mycolic acid synthesis inhibitor |
2020 |
|
3559 |
11726172
|
Membrane-active agent |
2022 |
|
3560 |
24,25-Dihydrofusidic acid
|
Fusidane |
1966 |
|
3561 |
KW13
|
Antimicrobial peptide |
2025 |
|
3562 |
AI18
|
Antimicrobial peptide |
2025 |
|
3563 |
FI19
|
Antimicrobial peptide |
2025 |
|
3564 |
XT17
|
Membrane-active agent |
2025 |
|
3565 |
Erucamide
|
Antivirulence agent (T3SS) |
2025 |
|
3566 |
F3FT
|
Antimicrobial peptide (nanopeptide) |
2025 |
|
3567 |
N3FT
|
Antimicrobial peptide (nanopeptide) |
2025 |
|
3568 |
GmPcide PS757
|
Membrane-active agent |
2022 |
|
3569 |
ZnBq/Ce6@ZIF-8@OMV
|
Membrane-active agent |
2024 |
|
3570 |
COE-PNH2
|
Membrane-active agent |
2024 |
|
3571 |
Sviceucin
|
Antimicrobial peptide (lasso peptide) |
2025 |
|
3572 |
Macrosporusone A
|
Antivirulence agent |
2025 |
|
3573 |
NSC 18725
|
Small molecule antibacterial agent |
2020 |
|
3574 |
DCB001
|
Small molecule antibacterial agent |
|
|
3575 |
SPR113
|
|
|
Preclinical |
3576 |
Ligustroflavone
|
Antivirulence agent |
2025 |
|
3577 |
Microcin J25
|
Antimicrobial peptide (lasso peptide) |
1992 |
|
3578 |
Capistruin
|
Antimicrobial peptide (lasso peptide) |
2008 |
|
3579 |
Lariocidin B
|
Antimicrobial peptide (lasso peptide) |
2025 |
|
3580 |
CLB073
|
|
2023 |
Preclinical |
3581 |
S-004992
|
Small molecule antibacterial agent |
2018 |
Preclinical |
3582 |
TBK-613
|
Fluoroquinolone |
2009 |
Preclinical |
3583 |
Dapsone
|
Sulfa drug / Sulphonamide |
1937 |
Approved by FDA in 1979 |
3584 |
Isoxazole M1
|
Mycolic acid synthesis inhibitor |
2024 |
|
3585 |
Compound 42
|
Small molecule antibacterial agent |
2013 |
|
3586 |
V13KL
|
Antimicrobial peptide |
2005 |
|
3587 |
Rosoxacin
|
Quinolone |
1980 |
Approved |
3588 |
O-Demethylfortimicin A
|
Aminoglycoside |
1980 |
|
3589 |
R-type pyocin 611 131
|
Antimicrobial peptide (bacteriocin) |
1980 |
|
3590 |
Rhoifolin
|
Antivirulence agent |
2025 |
|
3591 |
Miloxacin
|
Quinolone |
1980 |
|
3592 |
Mycoidesin
|
Antimicrobial peptide (lantibiotic) |
2025 |
|
3593 |
Aridicin A
|
Glycopeptide |
1985 |
|
3594 |
Probenicid
|
Small molecule antibacterial agent |
1984 |
|
3595 |
2',3'-Dideoxyadenosin
|
DNA synthesis inhibitor |
1981 |
|
3596 |
YM-13115
|
Beta-lactam (cephalosporin) |
1985 |
|
3597 |
A47934
|
Glycopeptide |
1986 |
|
3598 |
UK-38,006
|
Beta-lactamase inhibitor |
1981 |
|
3599 |
Satranidazole
|
Nitroimidazole |
1986 |
|
3600 |
Microcin 7
|
Antimicrobial peptide |
1985 |
|
3601 |
Cecropin-4
|
Antimicrobial peptide |
2019 |
|
3602 |
Ro 13-9904
|
Beta-lactam (cephalosporin) |
1980 |
|
3603 |
Microcin 15m
|
Antimicrobial peptide |
1982 |
|
3604 |
N,N'-Dialkylpolymethylenediamine
|
Small molecule antibacterial agent |
1989 |
|
3605 |
Habekacin
|
Aminoglycoside |
1973 |
|
3606 |
Foramidocillin
|
Beta-lactam |
1986 |
|
3607 |
Antibiotic BB-K311
|
Aminoglycoside |
1981 |
|
3608 |
ICI 193428
|
Beta-lactam |
1987 |
|
3609 |
ICI 194008
|
Beta-lactam |
1987 |
|
3610 |
Grahamimycin A
|
Natural product antibiotic |
1981 |
|
3611 |
BK-218
|
Beta-lactam |
1990 |
|
3612 |
Microcin D93
|
Antimicrobial peptide |
1986 |
|
3613 |
Microcin B17
|
Antimicrobial peptide |
1987 |
|
3614 |
Helveticin J
|
Antimicrobial peptide |
1986 |
|
3615 |
Neodiosmin
|
Antivirulence agent |
2025 |
|
3616 |
Pentamidine isethionate
|
Small molecule antibacterial agent |
1990 |
|
3617 |
N-[4-(1-hydroxy-6-nitrobenzimidazol-2-yl)phenyl]-4-(1,3-oxazol-5-yl)benzamide
|
Antivirulence agent (T3SS inhibitor) |
2010 |
|
3618 |
2-Propenamide, 3-(4-fluorophenyl)-N-[4-(1-hydroxy-6-nitro-1H-benzimidazol-2-yl)phenyl]-, (2E)-
|
Antivirulence agent (T3SS inhibitor) |
2010 |
|
3619 |
ME1071
|
Beta-lactamase inhibitor (MBL inhibitor) |
2010 |
|
3620 |
Ceftolozane
|
Beta-lactam (cephalosporin) |
2007 |
Approved by FDA in 2014 |
3621 |
DiPGLa-H
|
Antimicrobial peptide |
2025 |
|
3622 |
Piperazinylsulfonylaryl compound
|
Small molecule antibacterial agent |
2021 |
|
3623 |
1,2,4-triazine-based compound
|
Small molecule antibacterial agent |
2010 |
|
3624 |
Aminoacyl adenylate mimic
|
Protein synthesis inhibitor |
1997 |
|
3625 |
ANASIA
|
Protein synthesis inhibitor |
2021 |
|
3626 |
MAC13243
|
Small molecule antibacterial agent |
2009 |
|
3627 |
(3S,4S)-4-((3-fluoro-4'-((S)-4-hydroxy-3-(2-((S)-1-hydroxyethyl-1H-imidazol-1-yl)but-1-yn-1-yl)-[1,1'-biphenyl]-4-4-yl)methoxy)tetrahydrofuran-3-ol
|
Lipopolysaccharide synthesis inhibitor |
2024 |
|
3628 |
Aromatic acetylene derivative 13
|
Lipopolysaccharide synthesis inhibitor |
2023 |
|
3629 |
Antibiotic TAN 1057
|
Natural product antibiotic |
1989 |
|
3630 |
JNJ-6640
|
Small molecule antibacterial agent |
2025 |
|
3631 |
Triazolopyrimidine compound 24
|
Small molecule antibacterial agent |
2025 |
|
3632 |
Triazolopyrimidine compound 33
|
Small molecule antibacterial agent |
2025 |
|
3633 |
N-(5-Benzyl-thiazol-2-yl)-2-[4-(4-methoxy-phenyl)-1H-tetrazol-5-ylsulfanyl]-acetamide
|
Small molecule antibacterial agent |
2025 |
|
3634 |
FG-2101
|
Small molecule antibacterial agent |
2025 |
Preclinical |